Babson Diagnostics (Austin, TX), a transformative medical technology company, announced it closed $13.7 million in cumulative Series A funding. Originally incubated at Siemens Healthineers and developed in partnership with Becton Dickinson, Babson’s disruptive technology is designed to analyze capillary blood samples using only one-tenth the volume typically collected with venipuncture without sacrificing quality, accuracy, or menu breadth, all from a simple finger stick. [company press release, Sep 24, 20]
ArcherDX (Boulder, CO; no SBIR, founded 2013) a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, is pleased to announce the acquisition of Baby Genes (Golden, CO; no SBIR) focused on empowering individuals to take charge of their health through genetic insights. [ArcherDX press release, Jan 30, 19] total funding $30M [crunchbase.com]
Tauriga Sciences (New York, NY; no SBIR, trading for a penny a share) micro-robot firm is acquiring startup Pilus Energy (Cincinnati, OH; no SBIR, a subsudiary of Bacterial Robotics (no SBIR) ) that uses tiny bacterial robots called BactoBots that metabolize wastewater and harvest direct current electricity to produce economically important gasses. [Andy Brownfield, Cincinnati Business Courier, Nov 26, 13]
Bacterioscan (St Louis. MO; one NIH grant, founded 2004) received [FDA] approval for its device that can quickly detect urinary tract infections, reducing lab time-to-results for a UTI from two days to three hours.. ... will now begin hiring more workers and moving into a new office space. [Samantha Liss, St. Louis Post-Dispatch, May 15, 2018] total funding $18M [crunchbase.com]
BacterioScan (St Louis, MO; no SBIR), an innovator in rapid in-vitro diagnostics (IVD), announced a National Institute of Health (NIH) contract award to fund accelerated development of the Company's technology for rapid detection of bloodstream infections (BSIs). [biospace.com, Jan 3, 18]
BacterioScan (St. Louis, MO; no SBIR, founded 2004 in Israel, 23 employees) biotech that uses laser technology to rapidly test for urinary tract infections, raised $1.7 million of a planned $4 million bridge round. ... will help wrap the company’s development of its UTI product and start development on its next device, which will help detect drug resistant infections ... in June signed a distribution agreement for the U.S. and Canada with Thermo Fisher [Brian Feldt, St. Louis Business Journal, Aug 13, 15]
Laser technology developed by startup BacterioScan (St. Louis, MO; no SBIR) has been named a finalist for the Medical Device Excellence Awards, which highlights the top four medtech trends to follow in the medical device industry. ... has developed laser technology to rapidly test for urinary tract infections. The device — called the 216R Laser Microbial Growth Monitor — can quickly detect urinary tract infections, which are one of the most common types of infections in the body. [Brian Feldt, St. Louis Business Journal, May 26, 15]
medical device startup BacterioScan (St. Louis, MO; no SBIR) was named the winner of the 2015 Prism Award for innovation in photonics for biomedical instrumentation by SPIE, the international photonics and optics society.
BacterioScan (St. Louis, MO; no SBIR) that uses laser technology to rapidly test for urinary tract infections, has raised the amount of its Series A financing by $1 million to $6 million. ... to help support commercial sales moving forward. BacterioScan's diagnostic tool is set to hit the market in early 2015, said Dana Marshall, the company's CEO [Brian Feldt, St. Louis Business Journal, Dec 10, 14]
BacterioScan (St. Louis MO, no SBIR, founded 2004), biotech company that uses laser technology to rapidly test for urinary tract infections, is set to close a $5 million Series A financing round ... device can quickly detect urinary tract infections, which are one of the most common types of infections in the body. [Brian Feldt, St. Louis Business Journal, Aug 26, 14]
Baebies (Durham, NC; no SBIR) raised $13 million to develop technologies to advance newborn screening worldwide. ... Pamula and CEO Richard West founded Baebies after the sale of Advanced Liquid Logic (Research Triangle Park, NC; $10M SBIR) to Illumina (in 2013 for undisclosed amount) and licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. [Jason deBruyn, Triangle Business Journal, Jul 28, 15]
Real seed investment. On average, every dollar N.C. Biotech loans to young life science companies is met with $118 in additional funding to those firms from disease philanthropy and government grants, angel and venture investment and other financial support, according to the center. Every grant dollar is met with an average $28 in additional funding. ... loans and grant made by the Biotech Center in the second fiscal quarter: $50,000 in a Company Inception Loan to Spyrix (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, developing a treatment for cystic fibrosis. The loan is intended to help position the company for outside investor and foundation funding and to help with preclinical development of its product. $75,000 to Eppin Pharma (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, to help in its development of a reversible, oral, non-hormonal male contraceptive pill. This money will help support toxicology and other testing of the company's lead drug candidate and help position Eppin to seek additional funding from investors, federal grants and foundations. $250,000 to Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees), developing a novel drug to help people with spinal injuries clear their bladders and bowels when they choose to do so. The loan will support studies of the drug's safety and help Dignify develop a final formulation of the remedy, for use in clinical trials. $458,000 to Bioptigen (Morrisville, NC; $2.9M SBIR), to support late-stage development and clinical testing needed for FDA approval of its intrasurgical optical coherence tomography device for real-time guidance of ophthalmic surgery. $500,000 to Baebies (Durham, NC; no SBIR), to help it develop its products to diagnose health risks in infants from a single dried blood spot, using a technology called digital microfluidics. This loan supports the company's newborn screening tests for three devastating disorders (Pompe, biotinidase deficiency and galactosemia). [Jason deBruyn,Triangle Business Journal, Feb 4, 15] SBIR has no chance of such rewarding results because about three-fourths of the money is spent by agencies that just want what they can use for their own purposes with no regard for whether there is any widespread economic payoff, nor any payoff to society. SBIR can hide these facts behind privacy of private business whihc is OK with Congress as long as the small biz get the prescribed handouts.
Money for science, again. Vestaron (Kalamazoo, MI; no SBIR, founded 2001) makes an eco-friendly pesticide derived from spider venom. Bagaveev (San Mateo, CA; no SBIR) uses 3-D printers to make rocket engines for nanosatellites. ... raised just $535,000 in seed funding in April from a group of investors to develop reusable launchers that can send a satellite weighing up to 22 pounds into space ... Transatomic Power (Cambridge, MA; no SBIR,founded in 2011 by [MIT] nuclear scientists ) is developing a next-generation [small-scale molten-salt reactors] that could generate reliable, clean energy without creating nuclear waste.reactor. [All] have one money from Silicon Valley [VCs]. .... After years of shying away from science, engineering and clean-technology start-ups, investors are beginning to take an interest in them again, [with] a sense that the field of consumer Internet companies has become impossibly crowded. [HIROKO TABUCHI , New York Times, OCT. 12, 2014]
Ballard Power up 25% [Sep 13,17]
Ballard Power up 19% [May 28, 14]
Ballard Power down 10% [Apr 29, 14]
Plug Power sold $124.3 million worth of stock in its biggest stock sale ever, capitalizing on its recent rebound from penny-stock territory. .... priced at a deep discount to Plug's recent stock price, suggesting some pushback among buyers .... Among other stocks in the fuel-cell sector, FuelCell Energy is up 73% this year. Canada's Ballard Power Systems is up 174%. But the industry participants' shares have given head fakes before. [Matt Jarzemsky, Wall Street Journal, Apr 24, 14] Meanwhile, workers at ClearEdge Power (headquartered in Oregon and founded in 2003; no SBIR) in South Windsor, CT were sent home, uncertain about what the future holds. ... Town Manager Matthew B. Gallagan said the fuel cell manufacturer will seek some form of bankruptcy protection. [Brian Dowling, Hartford Courant, Apr 24, 14]
Ballard Power down 23% [Mar 26, 14]
Ballard Power up 32% [Mar 25, 14]
Ballard Power up 12% [Mar 13, 14]
Ballard Power up 27% [Mar 4, 14]
Ballard Power up 14% [Mar 3, 14]
Fuel Cell Future Moves Further Off. Ballard Power Systems is chopping 400 employees, or nearly 30% of its work force, cutting development spending and seeking buyers for parts of its business. Even by Ballard's own reckoning, profitability is still five years off, which means it has to conserve cash, develop other revenue streams and persuade investors to stay the course until its engine technology becomes commercially viable. [TAMSIN CARLISLE, Wall Street Journal, Dec 27] SBIR hopefuls with a commercialization story, take note. Your projections of commercial success are probably fantasy. The good news for getting the government money is that the government neither knows nor cares whether you are right or wrong. They get the technology whatever happens to you.
Bandgap Technologies (Columbia, SC), a maker of SiC substrates, will be bought up by another private bandgap company INTRINSIC Semiconductor(Sterling VA). Bangap was founded in 2000 and has had at least three Phase 2 SBIRs all funded by BMDO. Intrinsic had one BMDO Phase 1 in 2003. Bangap materials was recently highlighted in a new MDA Technology Applications report Through Forbidden Band in which it was obvious that BMDO's only route to revolutionary technology is the SBIR program that existed before 2002.
Pfizer said it would acquire gene-therapy company Bamboo Therapeutics (Chapel Hill, NC; no SBIR) for $150 million, the latest sign of a resurgence of interest in the technology. will pay $150 million for the shares of Bamboo it doesn’t hold, with potential milestone payments of as much as $495 million. [Austen Hufford, Wall Street Journal, Aug 1, 16] UNC gene therapy spinout Bamboo Therapeutics raises $49.5M Series A advancing the work of Dr.Richard Jude Samulski, director of the gene therapy center at the University of North Carolina, into the clinic to treat rare neurologic diseases like Duchenne’s muscular dystrophy. Bamboo says that Samulski was the first person to use adeno-associated viruses to replace defective genes with healthy ones; as a result, the company holds more than 20 patents in using AAV for therapeutic applications. [MEGHANA KESHAVAN, medcitynews.com/, Feb 11, 16]
Banner Life Sciences LLC (High Point, NC; no SBIR, founded 1999) specialty pharmaceutical company, announced that [FDA] granted tentative approval on November 16, 2018 of the Company’s New Drug Application for BAFIERTAM, ™ a novel fumarate bioequivalent alternative to a prodrug of BAFIERTAM , Tecfidera ® (dimethyl fumarate) of Biogen, Inc. , as treatment for patients with relapsing forms of multiple sclerosis [company press release, Jan 2, 19]
Banyan Biomarkers (San Diego, CA; $2.3M SBIR, founded 2002) created the first-ever brain trauma blood test. On Feb. 14, the Food and Drug Administration (FDA) cleared marketing of the Banyan Biomarkers’ Brain Trauma Indicator, or BTI ™. [Military Health System Communications Office, Mar 15, 18]
Two companies have identified promising biomarkers and are devising and evaluating diagnostic tests to quickly diagnose concussions. A blood test that could quickly detect a brain injury and measure the damage it has done could help doctors provide better care for the millions of people suffering from such injuries. ... Quanterix (Cambrige, MA; $200K SBIR) claims its technology for detecting biomarkers in the blood requires only a single target molecule to generate a signal, whereas conventional systems need millions of molecules. ... Banyan Biomarkers (Alachua, FL; $1.1M SBIR) claims “we are in fact on the cusp of a revolution” in understanding how to noninvasively diagnose traumatic brain injury using both blood biomarkers as well as new imaging techniques. [Mike Orcutt, technology review.com, Aug 27, 15]
Banyan Biomarkers (Alachua, FL; $1.8M SBIR) developer of a test for traumatic brain injury, said it has raised $6 million from private investors. .... blood test detects signs of brain injury. ..... founded in Gainesville, Florida, but opened an office in Carlsbad to find the qualified employees it needs. [Bradley Fikes, utsandiego.com, Jun 20, 13]
Banyan Biomarkers ($1.7M SBIR) couldn’t find enough skilled employees to develop its disease diagnostic products in its Gainesville, Fla., headquarters. So it’s hiring them in Carlsbad [CA] .... conducting a pivotal clinical trial of a test to detect signs of traumatic brain injuries, Streeter said. It is also researching tests for stroke, Parkinson’s disease, depression and liver disease. .... [CEO] Streeter said that when Banyan moved beyond research into product development, San Diego’s highly developed “ecosystem for diagnostics” became attractive. Streeter knows the county from his years as a biomedical executive at PhotoThera (Carlsbad, CA; no SBIR). Other states, especially Texas, have long tried to lure biomedical companies from San Diego, but they don’t have the region’s advantages for innovation, Nordhoff said. The pool of qualified research and development specialists is deeper in San Diego. [Bradley Fikes, utsandiego.com, Feb 4, 13] Not in no-income-tax, petroleum-focused Texas.
Bardy Diagnostics (Seattle, WA; no SBIR, founded 2013), which is developing a cardiac monitor and arrhythmia detection device, raised $6 million in debt funding and other securities [Jeff Buchanan, xconomy.com, Jan 4, 19]
EnteroMedics (St Paul, MN; no SBIR), the developer of medical devices treating obesity, metabolic diseases and other gastrointestinal disorders, announced today that it has acquired the Gastric Vest System™ (the "Gastric Vest" or "Vest"), through its acquisition of BarioSurg (Lake Forest, CA; no SBIR, founded 2008) [for stock and $2M cash]. The Gastric Vest is an investigational, minimally-invasive, laparoscopically implanted medical device being studied for weight loss in morbidly obese patients. [Enteromedics press release, May 23, 17]
wind power developer Baryonyx (Austin, TX; no SBIR) will receive $4 million from the USDOE to design, develop and pursue permits for three new turbines off the Texas coast, the federal agency announced .... in its ongoing effort to build a wind farm with up to 300 turbines off the Texas coast, [Dan Zehr, Austin American Statesman, Dec 12, 12]
The purchase of a New Jersey-based pharmaceutical company that currently outsources all of its manufacturing could be good news for the Stiefel Laboratories (Coral Gables, FL) plant here in Greene County. Stiefel said Monday it is offering [$148 million] for Barrier Therapeutics (Princeton, NJ; no SBIR) [Eric Anderson, Albany Times-Union, Jun 24]
The Engine, a new VC fund in Cambridge, MA aims to bridge that [long lead time] gap by investing in breakthrough technologies that require extensive time and funding. Its [announced] first round of investments consists of seven startups (Analytical Space (Boston, MA, laser satellite data links w former Gen Pete Worden as advisor), Baseload Renewables (co-founded by Professor Yet-Ming Chiang who co-founded A123 Systems), C2Sense (Cambridge, MA; patented chemiresistive sensing C2Sense is able to selectively target gases unable to be sensed through other methods ), iSee (next generation of humanistic artificial intelligence technology for human and robotic collaborations), Kytopen (better genetically engineer cellsby developing technology that modifies microorganisms 10,000 times faster than current state-of-the-art methods ), Suono Bio (Cambridge, MA, ultrasonic therapeutics), and Via Separations (industrial separation processes, sonme SBIR) in sectors including aerospace, advanced materials, genetic engineering, and renewable energy. .... a for-profit, public-benefit corporation and a fund that’s separate from MIT ... MIT also contributed $25 million to your first investment fund of $200 million. [Elizabeth Woyke, technologyreview.com, Sep 19, 17]
Intel said it bought health-tracking wearable device maker Basis Science (San Francisco, CA; no SBIR). in a deal reported to be between $100 million and $150 million as it moves into the wearable computing market, according to VentureBeat...... developed a $199 wearable that goes beyond most fitness devices by tracking your heart rate, sweat, motion and sleep [Sarah Drake, Silicon Valley Business Journal, Mar 26, 14]
Policy and job turmoil. Workers at Bastion Technologies (no SBIR) and elsewhere are caught in a growing conflict between Congress, which has banned NASA from canceling any part of Constellation, and agency leaders who have directed program managers to scale back their work while preserving the parts that would fit into the new space policy proposed by President Obama. [Kenneth Chang, New York Times, Jun 26] The usual Congressional response: cut the deficit somewhere else. NASA SBIR junkies could feel the pinch also. Somewhere, somehow, lots of folks have to lose jobs if the deficit finance is to be fixed without raising revenue (not on our watch, say the Republicans).
Batu Biologics (San Diego, CA; no SBIR) said it has received regulatory permission to begin human testing of its cancer immunotherapy, ValloVax, .. designed to inhibit the growth of new blood vessels that feed tumors. [Bradley Fikes, San Diego Union Tribune, Nov 7, 17]
Batu Biologics (San Diego, CA; no SBIR, founded 2013) raised $1 million to develop its lung cancer immune therapy, the company said ... The therapy, ValloVax, is intended to stimulate an immune response against new blood vessels in the lung that tumors use to grow. In preclinical testing, ValloVax inhibited angiogenesis in melanoma, breast and lung cancer mouse models. [Bradley Fikes, utsandiego.com, Jun 17, 15]
Batu Biologics (San Diego, CA) a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors. ... said that its therapy, ValloVax, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the [FDA] approves [Bradley Fikes, utsandiego.com, Dec 11, 14]
Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt. .... [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." .... a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received: • NanoTailor, $250,000; • Star Vision Technologies, $750,000; • Terrabon, $2.7 million; • Thrombo Vision, $1.5 million; • Nanocoolers, $3 million; • Advanced Receiver Technologies, $250,000; • Bauhaus Software, $500,000; • Net Watch Solutions, $500,000; • Sunrise Ridge Algae, $250,000; • SeprOx, $750,000; • Speer Medical, $2.5 million [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.
Medical device company Baxano (San Jose, CA, no SBIR) said it closed a third round of funding with $30 million.... focuses on products to restore spine function and preserve healthy tissue. It makes a system for decompression during spinal surgery. [Silicon Valley / San Jose Business Journal, Jun 22, 10]
Nearly two months after receiving FDA approval for its surgical screw, Baxano Surgical (Raleigh, NC; no SBIR, founded 2000) reported that its screw has been used for the first time in surgery. .... With medical advances over the years, surgeons are now performing more minimally invasive spine surgeries (MIS surgeries) than ever before, a market Baxano hopes to exploit. [Jason deBruyn, Triangle Business Journal, Jun 30, 14]
Baxano Surgical was put on notice from Nasdaq that its share price had fallen too low for too many consecutive days. [Jason deBruyn, Triangle Business Journal, Jun 6, 14]
Baxano Surgical (Raleigh, NC; no SBIR) reached an agreement to raise $10 million from two institutional investors through a private placement. ... to continue developing its Avance pedicle screw system, “and to execute our commercial growth strategy as we continue to penetrate the minimally invasive spine market,” said Ken Reali, President and CEO .... To date, the company has not turned a profit, accumulating a deficit of $171 million [Jason deBruyn, Triangle Business Journal, Mar 12, 14] Some innovations take a huge investment that is way beyond the scope of a government subsidy program, which is why government should not subsidize where there is no expectation of follow-on capital.
Baxano Surgical agreed to a $6 million settlement, closing a federal inquiry that’s been in play since the company was known as Trans1 Inc. Additionally, the company has created a compliance program that it is now required to maintain as part of the agreement. .... U.S. Attorney for the District of Maryland alleged that Baxano made false claims to the likes of Medicare in order to net larger payments and encourage doctors to bill Medicare for more expensive treatments. [Lauren Ohnesorge, Triangle Business Journal, Jul 3, 13]
Baxano Surgical (formerly Trans1 of Wilmington NC; Raleigh, NC; no SBIR) plans to expand in north Raleigh after acquiring another medical-device company last month, its CEO said .... make medical devices used in spinal surgeries [Chris Bagley, Triangle Business Journal, Jun 10, 13]
BayoTech (Fort Collins, CO; no SBIR, founded 2015), a biotechnology startup announced as the first business to receive money from the $20 million Catalyst Fund. .... licensed its technology from Sandia National Laboratories for $50 million about three years ago, which Eisenach said has made their goal of creating an affordable hydrogen economy a reality. [May Ortega, Albuquerque Business First, May 22, 17] raised a $1.5 million Series A funding round as it works to develop a smaller, more cost-effective system for manufacturing nitrogen fertilizer. [company press release, Sept 2016]
BCD Bioscience (Davis, CA; no SBIR) biotech founded by professors at the [UC]Davis raised $4.8 million in equity investment to research new uses for carbohydrates for nutrition and immunology [to] develop proprietary techniques to transform food-grade substances into products at the cellular level which may have nutritional and immune benefits. [Mark Anderson, Sacramento Business Journal, Dec 3, 2020]
Beacon Biomedical (Scottsdale, AZ; no SBIR) that develops lab and point-of-care blood tests [that fits in the palm of the hand] for colon, breast and lung cancer screenings and their early detection, will open corporate offices and an R&D laboratory at the Center for Entrepreneurial Innovation in Phoenix. [Ilana Lowery, Phoenix Business Journal, Jul 7, 16]
Aerodyne Research (Billerica, MA; 199 SBIR Phase Is and something like $80M total SBIR) will receive five $1-million DOEnergy [SBIR Phase II] grants, and Radiation Monitoring Devices (Watertown, MA; 404 SBIR Phase Is and something like $150M SBIR) will receive three $1 million grants, the department said. ... Other local companies in line to receive Energy Department grants: Conispire (Boston, MA: no SBIR) , Aspen Products Group (Marlborough.MA; $5.6M SBIR), Capesym (Natick, MA; $5.3M SBIR); Nova Scientific (Sturbridge, MA; $9M SBIR); Beacon Power (Tyngsborough, MA; $1M SBIR), the department said. [Chris Reidy, Boston Globe, Jun 29, 12]
Beacon Power that filed for bankruptcy after winning a US loan guarantee, agreed to sell its only plant to Rockland Capital for $30.5 million in cash and a promissary note, plus additional obligations. Rockland will continue operating the 20-megawatt plant in Stephentown, N.Y. Beacon sought protection from creditors Oct. 30 after receiving a $43 million federal loan guarantee to build the world’s first commercial plant using spinning flywheels to retain energy. [Bloomberg, Feb 6, 12]
Beacon Power is going to put its 20-megawatt flywheel plant in Stephentown up for sale after reaching an agreement with the U.S. Department of Energy, which has provided the bankrupt company with $39 million through its loan program. [Larry Rulison, Albany Times Union, Nov 20, 11]
one of the firms Uncle Sam has allowed to lose Beacon Power filed for Chapter 11 bankruptcy, .... makes flywheel-based energy-storage devices designed to help regulate the flow of power into the electric grid from inconsistent alternative energy sources like solar power and wind power. The firm has received at least $67 million in grants and loan guarantees from the federal government [Galen Moore, Boston Business Journal, Nov 1, 11]
Beacon Power which provides "flywheel" technology that helps prevent power surges on the electrical grid, said in June it will need to raise more capital to continue operations into next year.. [Yuliva Chernova, Wall Street Journal, Oct 27]
Beacon Power up 30% [Feb 28, 11]
Beacon Power said it began operation of its flywheel energy storage plant in New York state this week, marking the start of commercial revenue for the company. [Mass High Tech, Jan 25, 11]
Beacon Power (Tyngsboro, MA; $1M SBIR) expects to raise gross proceeds of up to $15 million from a public offering of a newly-designated Series B convertible preferred stock, the company said ... maker of flywheel power storage technology [Mass High Tech, Dec 22, 10]
Beacon Power has been turned down for a loan guarantee to build a second energy storage plant in New York state, the company said. [Mass High Tech, Oct 11, 10]
Beacon Power saw its cash position slip by 53 percent in the second quarter but has closed on a $43 million loan for its energy storage plant in Stephentown, N.Y., the company said in two announcements ... said the plant will begin operating at 20 percent capacity by the end of the year and will be fully operational by the end of the first quarter of 2011. The plant will be the first of its kind in the world and will help stabilize and enhance the performance of the New York power grid, according to Beacon. [Kyle Alspach, Mass High Tech, Aug 9, 10]
New England energy stimulus money for small biz: $2.2 million for an energy storage project at Beacon Power .... $2.1M for Proton Energy (Wallingford, CT; $1.7M SBIR) and Penn State University aim to develop an advanced energy storage device that incorporates a regenerative fuel cell .... General Compression, (Newton , MA; no SBIR) $750K for a novel compressed air energy storage process [Kyle Alspach, Mass High Tech, Jul 13, 10]
Beacon Power said it had reached a deal to sell up to $25 million worth of its shares to a Chicago-based investment fund over the next 26 months. ... Founded in 1997, Beacon Power spun out of SatCon Technology [Mass High Tech, Jul 6, 10]
Beacon Power hopes to raise $20.7 million in a stock offering priced today. .... from a shelf registration [Mass High Tech, Dec 4, 09]
Beacon Power plans to begin construction of its 20-megawatt energy storage plant planned for rural Rensselaer County, N.Y. The $69 million plant would operate with 10 pods of 20 flywheels each and store energy from the electric grid. ... awaiting approval of a $43 million guaranteed loan through the Department of Energy for the project. [The Business Review, (Albany), Nov 10, 09]
Iberdrola SA, the Spanish wind-power giant, was awarded $294 million for five projects. ... as The U.S. government handed out $502 million in grants for a dozen wind- and solar-power projects from Maine to South Texas, the first round in a new subsidy program designed to spur renewable-energy investment. ... The program has no cap and government officials pledged to award grants to all qualified applicants through 2011 [Wall Street Journal, Sep 2] Beacon Power said it has applied to the US Department of Energy for grants totaling $46.7 million to support funding of the its next two flywheel energy storage plants. [Chris Reidy, Boston Globe, Sep 2, 09]
Beacon Power said it has signed a contract with American Electric Power to build a 1-megawatt smart energy matrix regulation facility at an AEP site in Groveport, Ohio [Boston Globe, Feb 23, 09]
Beacon Power received a commitment for the sale of $4.4 million worth of company warrants through a previously filed shelf registration statement. [Mass High Tech, Dec 22, 08] down 19%
Beacon Power received a commitment from an unnamed investor to raise $7.9 million through a private placement of stock and warrants under a previously filed a shelf registration. [Mass High Tech, Oct 10]
Beacon Power has been around for 10 years and has invested $150 million in the [flywheel] concept, with hardly any revenue to show for it so far. Now, the company is building its first large-scale commercial system, capable of storing and releasing 5 million watts of power. [Boston Globe, Sep 15]
Beacon Power wants to build a unique array of 200 flywheel batteries over several acres to store spare power from New York's electrical grid and zap it back as needed. ... to connect the 20-megawatt, short-term energy storage unit to New York's power grid in Stephentown, a rural community near the Massachusetts border. The company claims the matrix of batteries would make the grid more efficient and conserve energy, though they have some final hurdles to clear. [Boston Globe, Jun 14]
...the nation's first flywheel frequency regulation plant, in which an array of massive flywheels spinning at up to 16,000 revolutions per minute will help smooth the electrical grid. .... the $50 million flywheel plant by Beacon Power -- will regulate the grid without burning any fuel. Instead, 200 flywheels -- each a rotating disk standing 7 feet tall and 3 feet wide -- will spin using motors that draw excess energy from the grid when it is not needed. ... A 20-megawatt flywheel plant should prevent the release of up to 12,000 tons of carbon dioxide each year, [says Beacon]. [Brian Nearing, Albany Times-Union, May 13, 08]
Beacon Power (Wilmington MA) got a commitment for $25M in new funding from three of the company's previous investors [Mass High Tech, Oct 26]
Beacon Power up 12% on news of completed tests of a key product.
Beam Therapeutics (Cambridge, MA; no SBIR) seven months after raising $135 million in its series B round, filed to raise up to $100 million in its Nasdaq IPO [Amirah Al Idrus, Fierce Biotech, Sep 28, 19]
Beam Therapeutics (Cambridge, MA; SBIR, founded 2017) developing precision genetic medicines through base editing, today announced the successful completion of a $135 million Series B financing [to] to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific and technical leadership. [company press release, Mar 7, 19] prior funding $87M [crunchbase.com]
Beam Therapeutics (Cambridge, MA; no SBIR) launched with $87 million in new venture cash to pursue medicines based on base editing, a new version of gene modification based on the CRISPR system that Beam founders David Liu, Keith Joung, and Feng Zhang have helped create. [Alex Lash, xconomy.com, May 18, 18]
Beat Biotherapeutics (Seattle, WA; no SBIR) looked like it was in trouble after its co-founder and CEO died suddenly in June 2009. But the University of Washington spinout is definitely back in business, after recruiting a veteran CEO and raising another $2.5 million to advance an experimental treatment for heart failure. ... said today it has raised $2.5 million in seed [debt] funding from CET Capital Partners [Luke Timmerman, xconomy.com, Apr 16, 13]
A spinoff from RTI International that aims to make circuit boards obsolete has raised $5 million.... Beeco's challenge is convincing the market to adopt a game-changing technology. .... A reconfigurable computer, [CEO John ]Goehrke said, is one "that changes its configuration to maximize performance based on the application it is addressing." They're used in applications where "intense computing power is needed," such as gene sequencing. Beeco's computer is expected to cost $70,000 to $75,000 and is planned to hit the market in the third quarter of 2009. ... Goehrke is the former chief operating officer of Luna Innovations, a publicly traded company based in Blacksburg, Va [David Ranii, Raleigh News & Observer, Jun 10, 08]
Beeken Biomedical (Stoughton, MA; no SBIR) a medical device company dedicated to the advancement of bleeding control, raised $1.8M in equity in a $2.5M funding round, per an SEC filing. [Rowan Walrath, BostInno, Aug 18, 20]
Behavioral Recognition Systems (Houston, TX; no SBIR) which provides AI enhanced monitoring software for security cameras, said in an interview with Fox Business Network that an IPO for the company is "around the corner." .... announcement comes off the company's recent deployment at the World Cup, where BRS' technology scanned for potential threats among the crowds. [Josh Cain, Houston Business Journal, Jul 31, 14]
Less than a year after absorbing fellow digital therapeutics maker OxfordVR, BehaVR (Elizabethtown, KY; $1.2M SBIR) is bulking up its business through yet another merger. [Andrea Park, Fierce Biotech, Nov 16, 2023]
Bellerophon Therapeutics down 18% [Nov 23, 20]
Bellerophon Pharma down 20% [May 19, 20] announced the pricing of offerings its common stock at a public offering [company press release, May 19, 20]
Bellerophon Therapeutics up 19% [May 11, 20]
Bellerophon Therapeutics up 17% [Apr 23, 20]
Bellerophon Therapeutics up 20% [Apr 7, 20] reported financial results
Bellerophon Therapeutics up 30% [Mar 25, 20]
Bellerophon Therapeutics down 24% [Mar 24, 20] on plus 11% market day
Bellerophon Therapeutics down 33% [Mar 20, 20]
Bellerophon Therapeutics (Warren, NJ; no SBIR) up 431% [Mar 20, 20] a clinical-stage biotherapeutics company, announced that [FDA] granted emergency expanded access allowing its proprietary inhaled nitric oxide (iNO) delivery system, INOpulse(R), to immediately be used for the treatment of COVID-19. [company press release, Mar 20, 20]
Bellerophon Therapeutics (Warren, NJ; no SBIR), up 168% [Feb 18, 20] a clinical-stage biotherapeutics company, announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study (PHPF-002) of INOpulse(R) for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF). [company press release, Feb 18, 20]
BellerophonTherapeutics up 22% [Feb 18, 20]
Two Texas immuno-oncology companies working on blood cancer treatments received about $32 million in grants from the Cancer Prevention and Research Institute of Texas. Bellicum Pharmaceuticals (Houston, TX; no SBIR) [up 10%, Dec 2, 16] was awarded $16.9 million from the Cancer Prevention and Research Institute of Texas to develop a T-cell therapy for acute myeloid leukemia. [Angela Shah, xconomy.com, Nov 30, 16]
The state of Texas’s canser fund [Cancer Prevention and Research Institute of Texas (“CPRIT”)] granted $32M to two companies: Bellicum Pharmaceuticals ( Houston, TX; no SBIR) a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, announced an award totaling approximately $16.9 million to support clinical studies of its lead product candidate BPX-501 [conpany press releaase, Nov 18, 16]
Molecular Templates, (Georgetown, TX; no SBIR) $15.2 million for its treatment for multiple myeloma [David Holley, xconomy.com, Nov 17, 16]Bellicum Pharmaceuticals (Houston, TX; no SBIR) raised $139.65 million when it priced its upsized [IPO] ... developing cell therapies to treat and prevent cancer ... the first time a Houston biotech company has gone public in 15 years, Xconomy reports. [Olivia Pulsinelli, Houston Business Journal, Dec 18, 14]
Bellicum Pharmaceuticals (Houston, TX; no SBIR, 30 employees) focused on developing cell therapies to treat and prevent cancer, filed for [IPO] [Olivia Pulsinelli, Houston Business Journal, Nov 18, 14] closed a $34.4 million Series B round in Jan 2014
Bellicum Pharmaceuticals (Houston, TX; no SBIR, 21 employees) biotechnology company focused on developing cell therapies to treat and prevent cancer, ... closed a $34.4 million Series B round .... to advance clinical trials for its cellular immunotherapy products [Molly Ryan, Houston Business Journal, Jan 7, 14]
Bellicum Pharmaceuticals (Houston, TX; no SBIR) life sciences startup, announced it started treatment of its first patient in a phase 1 clinical study of its second-generation BPX-201 prostate cancer vaccine, which consists of dendritic cells programmed to fight prostate cancer. [Angela Shah, xconomy.com, Jul 12, 13]
Bellicum Pharmaceuticals (Houston, TX; no SBIR) received a $5.7 million Cancer Prevention and Research Institute of Texas award. ...a biotherapeutics company founded in 2004 to commercialize products aimed at late-stage cancer patients.[Houston Business Journal, Mar 25, 11]
The Belmont Rapid Infuser, manufactured in Billerica, was just used in the first ever liver transplant in Iraq. The trip was sponsored by The Red Crescent and Zheen International Hospital. Two young brothers were involved in the living-donor transplant surgery, which was successful, according to the company. The Rapid Infuser is manufactured by the Belmont Instrument Corporation (Billerica, MA; $400K SBIR in 1990s). [DC Dennison, Boston Globe, Dec 27, 11]
Fast-growing packaging manufacturer Pro Mach (Cincinnati, OH; no SBIR) is continuing its acquisition streak, purchasing two companies ... Benchmark Automation (Athens, GA; no SBIR, 30 employees) and Pace Packaging (Fairfield, NJ; no SBIR, 52 employees) mark Pro Mach’s 12th and 13th acquisitions, respectively, in the last three years. [Andy Brownfield, Cincinnati Business Courier, Sep 12, 14] Pro Mach [in turn] announced that affiliates of AEA Investors LP are acquiring the packaging machinery leader from The Jordan Company. [company press release, Sep 16, 14]
BeneChill, (San Diego, CA; no SBIR) founded in 2004 to develop a portable, battery-powered device for lowering the temperature of heart attack victims, has raised about $600,000 of a planned $1.2 million in debt,... designed for use by emergency medical technicians so hypothermic therapy can begin even before a patient reaches the emergency room. The company raised $13.5 million in a Series C venture round in mid-2009 [Bruce Bigelow, signonsandiego.com, Nov 16, 10]
Construction of the 10 million-gallon-a-year plant, which will cost under $20 million to build, could begin this year or early next, said Rob Tripp, chief executive of Benefuel, (Mt. Prospect, IL) which was formed last year. [Jeff Swiatek, Indianapolis Star, Oct 10] Benefuel's website claims the worlds most advanced, solid catalyst biodiesel refining platform ... and abusiness model of locating multiple, small refineries near the source of inputs and consumption. An economic note: the worldwide demand for fuel and food is driving up the price of both petroleum and crops. Eventually, the feedstock for such bio-source fuel plants will rise to make them unprofitable and a market shake-out will ensue. The tipping point is still unknown as the rush to produce ethanol and bio-diesel is still in full swing.
Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]
Benson Hill Biosystems (St Louis, MO; $700K SBIR, founded 2012), a crop improvement company unlocking the natural diversity of plants, has entered into a partnership with Brownseed Genetics, (Bay City, WI; no SBIR) seed breeder of new corn hybrids that are higher in both oil content and essential amino acids. [Benson press release, Jul 29, 19] Benson total funding $132M including $32M announced Aug 2, 2019 [crunchbase.com]
Benson Hill Biosystems (St Louis, MO; $500K SBIR, founded 2012) a crop improvement company unlocking the natural genetic diversity of plants, announced the first close of its $60 million Series C financing led by Google Ventures [company press release., Sep 10, 18] total funding $95M [crunchbase.com]
St. Louis-based Prolog Ventures participated in a $7.4 million financing deal for New Mexico-based IntelliCyt (Albuquerque, NM; no SBIR), a provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology. ... According to CrunchBase, the IntelliCyt deal was Prolog’s fifth of 2015 — the company also participated in Veran Medical Technologies’ (no SBIR) $41.7 million round in September; Benson Hill Biosystems (no SBIR) $7.3 million deal in August; and EndoStim (no SBIR) $2.5 million funding n May. [Brian Feldt, St. Louis Business Journal, Oct 23, 15]
Benson Hill Biosystems (St Louis, MO; no SBIR, founded 2012, 20 employees) agtech startup raised $7.3 million from a group of investors ... focused on photosynthesis as a pathway to improving crop production. The money will be used to fund field trials and other product development activities. [Brian Feldt,St. Louis Business Journal, Aug 26, 15]
Benvenue Medical (Santa Clara, CA; no SBIR), a spine technology startup, has raised $40 million in [Series E financing] venture capital and $24 million in debt to boost its U.S. commercial presence and scale manufacturing. .... has raised a total of $85.5 million since its [2004] founding [Sarah Drake, Silicon Valley Business Journal, Jun 18, 14]
Johnson & Johnson is paying $140 million upfront to buy oncolytic immunotherapy startup BeneVir Biopharm (Rockville, MD; $400K SBIR, founded 2011). The outlay gives J&J control of preclinical prospects designed to evade the body’s immune system, enabling them to keep killing cancer cells for longer. BeneVir grew out of the research of New York University professor Ian Mohr, Ph.D. [Nick Paul Taylor, Fierce Biotech, May 2, 18] total funding $7M [crunchbase.com]
Montgomery County [MD, a competitor for America's richest county] will dole out $500,000 to investors in 10 life sciences companies through its coveted biotech ax credit, a fifth of which will go to backers of diagnostics company DioGenix (Gaithersburg, MD; no SBIR) ... piggybacks on the $3.5 million in tax credits from the state to those same 46 investors. The incentives are tied to a total $7 million in private biotech investments in the county last year. Also receiving the credits are backers of 20/20 GeneSystems (Rockville, MD; $4.6M SBIR, incl one of $3.3M), Alper Biotech LLC, American Gene Technologies International Inc., BeneVir Biopharm Inc., ConverGene LLC, Creatv MicroTech (Potomac, MD; $11.6M SBIR)., Rafagen Inc., Sequella (Rockville, MD; $10.3M SBIR). and SynAm Vaccine. [Bill Flook,Washington Business Journal, Feb 28, 14]
Berg (Framingham, MA; no SBIR)'s artificial intelligence-developed cancer drug has caught the attention of the federal government, which has plans to conduct preclinical trials to help speed the drug to market. The technology and methodology were developed by Berg using computer algorithms and artificial intelligence, which analyzed large amounts of tumor data and pointed to a drug that could force cancer cells to die. ... entirely backed and co-founded by Silicon Valley real estate billionaire Carl E. Berg. [Jessica Bartlett, Boston Business Journal, Sep 8, 15]
BerrieHill Research (Centerville, OH; no SBIR, founded 2005) landed a $5 million [five year] Air Force deal ... includes developing advanced computational tools that can be used on electromagnetic problems — both now and well into the future — that can’t be solved by current tools, said Jeff Berrie, president and chief technology officer of BerrieHill. ... has about 60 employees [Dayton Business News, May 24, 12]
New York has invested $14 million in 141 clean technology companies in the last few years, including Bess Technologies (Albany, NY; no SBIR, founded 2010) startup aiming to make better batteries [with high-performing electrodes] [Chelsea Diana, Albany Business Review, Feb 23, 16] a spin-off of SUNY Polytechnic Institute - Colleges of Nanoscale Science and Engineering ... has received sizeable technology grants from NSF [and] from the New York State Energy Research and Development Authority (NYSERDA) [company website]
Bess Technologies (Albany, NY; no SBIR) startup focused on building better lithium-ion batteries has secured its first Japanese patent, positioning the company to eventually sell its technology in Japan. ... batteries with more energy storage capacity and faster charging rates for use in consumer electronics, electric vehicles and other applications. ... the first spin off company to come out of SUNY Polytechnic Institute in Albany ... with the intention to manufacture it in New York. [Chelsea Diana, Albany Business Review, Jun 23, 15]
Bess Technologies (Albany, NY; no SBIR) focused on building [lithium-ion batteries with more energy storage capacity and faster charging rates] will receive $250,000 from the Eastern New York Angels (ENYA). [Chelsea Diana,Albany Business Review, Apr 19, 15]
Two Albany area startups in the battery and energy storage industry have been awarded $250,000 in New York state funding for product development. Eonix (Colonie, NY; no SBIR) [startup developing technology to expand the capacity of ultracapacitors] and Combined Energies (Latham, NY; SBIR) [developing distributed generation systems to extend the life of electrochemical batteries] were among the nine companies that received funding from the New York State Energy Research and Development Authority. ... also gave $250,000 to Hollingsworth & Vose (East Walpole, MA; no SBIR) an advanced materials manufacturing company with filtration, battery separator and industrial applications. [Megan Rogers, Albany Business Review, Oct 27, 14] Since 2012, the state agency has funded Paper Battery Co., BESS Technologies (Troy, NY; no SBIR), Rensselaer Polytechnic Institute, and many other state entities.
Start with a little tritium. The University of Rochester (NY) and a startup, BetaBatt have cooked up a betavoltaics-based "nuclear" battery that can run for over a decade on the electrons generated by the natural decay of the radioactive isotope tritium. ... They've actually been tested in labs for 50 years -- but they generate so little power that a larger commercial role for them has yet to be found. So far, tritium-powered betavoltaics, which require minimal shielding and are unable to penetrate human skin, have been used to light exit signs and glow-in-the-dark watches. ... The fabrication techniques may be affordable, but the tritium itself -- a byproduct of nuclear power production [Eric Brown, MIT Tech Review, Jun 16] Sounds straightforward until the question of where to get commercial tritium comes up. The quickest source would the nation's hydrogen bombs being destroyed. The Energy Department studies estimate the cost of a new tritium production for bombs would be several billions. But even if a commercially reasonable cost source could be found, the tritium is environmentally dangerous in groundwater, and the "no-more bomb" critics note that Using commercial reactors to produce tritium is unproven technology and thus poses unknown dangers.
Beta Bionics (Boston,MA; $3M SBIR) announce the successful closure of its Series D funding round securing $100 million in new equity capital. [company oress release, Aug 30, 2023]
Beta Bionics (Boston, MA; $400K SBIR, founded 2015), a startup using machine learning and artificial intelligence to develop the world’s first autonomous bionic pancreas, closed its Series B and B2 rounds of funding, bringing the company’s total capital to $126M. [Sri Kalyanaraman, BostInno, Jul 16, 19]
Beta Bionics (Boston, MA, no SBIR, founded 2105) a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas – announced that the company has now completed its Series B equity financing, which has reached a total of $63 million. [company press release, Jan 8, 19]
Beta Bionics (Boston, MA; no SBIR, founded 2015) leveraging lifelong machine learning and artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas, announced up to $2 million [NIH SBIR]... the developer of the iLetTM Bionic Pancreas System, which is currently undergoing home-use clinical trials in adults and children with type 1 diabetes (T1D). [company press release, Oct 2, 18] Earlier, announced raising $50m of a Series B equity financing. [company press release, Sep 27, 18]. prior funding $11M [crunchbase.com]
Researchers in Wisconsin over the next two years will strive to bring down the cost to produce energy-saving LED lights, under a pair of federal projects awarded funding Tuesday.Eaton has been awarded $2.4 million to develop a new manufacturing process to streamline the design of LED light fixtures. The Department of Energy awarded the funds, which will be matched dollar-for-dollar by Eaton and the other four recipients of $10.1 million in funding. The two-year research projects aim to bring down the cost of manufacturing light-emitting diodes, or LEDs. Cree, that bought Ruud Lighting and BetaLED of Sturtevant in 2011, was awarded $2.3 million. [Thomas Content, Milwaukee Journal Sentinel, Jun 4, 13]
New York State Energy Research and Development Authority awarded $250K to Bettergy (Peekskill, NY; $300K SBIR) to scale-up and develop a prototype for its low-cost rechargeable zinc-based battery. ... expected to sell at a significantly lower cost than similar batteries, has a long cycle life and can last up to 20 years. It would be attractive to electric grid and transportation storage applications, and would also be more environmentally safe than other batteries of this type. [Oct 27, 14]
Bexion Pharmaceuticals (Covington, KY; $2M SBIR) is to receive $2.9 million [three-year NIH SBIR] to conduct a clinical trial of an agent to combat brain tumors. The trial, which would involve people, could lead to a less invasive treatment for an aggressive brain cancer known as glioblastoma multiforme, the company said. ... to help Bexion further development of BXQ-350 nanovesicles, an agent that contains a human protein that sticks to a cancer cell’s membrane. Treatment of cancer with BXQ-350 nanovesicles has already been tested in animals. [Barrett J. Brunsman, Cincinnati Business Courier, Oct 14, 13]
On the cusp of going public, BG Medicine has pulled its IPO (for the second time) ... still in the development phase with its BGM Galectin-3 test, which measures levels of galectin-3, a protein related to heart failure, in the blood. BG projects continued losses into the coming years, [Mass High Tech, Dec 17, 10]
BG Medicine (Waltham, MA; no SBIR) is expected to announce an initial public offering of up to $71.2 million next week, according to IPO tracker Renaissance Capital. .... developer of biomarker-based diagnostic tools ... expects to use up to $25 million of the net proceeds from the offering to fund the commercial launch of its lead product, BGM Galectin-3 ... founded in 2000, first filed for an $80 million IPO on Euronext in August 2007, before abandoning it just a few months later [Mass High Tech, Dec 10, 10]
BG Medicine (Waltham, MA; no SBIR) garnered $40 million in fourth-round funding for use in commercialization of its first two biomarker-based diagnostic tools. [Mass High Tech, Jul 17, 08]
BG Medicine (Waltham, MA; no SBIR) raised $40 million in its latest round of venture capital, in addition to $52 million it had previously raised. The company had originally tried to raise money through an initial public offering, but yanked the IPO filing in January citing market turmoil. No venture-backed companies have been able to go public so far this year in Massachusetts. BG, which has 39 employees, is trying to develop novel medical tests for congestive heart failure and other maladies based on proteins and other molecules found in the body. [Boston Globe, Jul 18]
Bicycle Therapeutics (Cambridge, UK and Cambridge, MA) is developing a new class of drugs that it says can offer a more targeted approach, and it has raised $52 million [Series B]to support plans to bring its lead drug into clinical trials. ... claiming that its drugs combine the advantages of other types of drugs. Large molecule drugs, made from proteins, offer the ability to bind to specific sites on a cell’s surface. But their large size keeps them from penetrating the cell itself. Meanwhile, the size of small molecule drugs allows them to reach almost anywhere in the body, and including the inside of cells [Frank Vinluan, xconomy.com, Jun 1, 17]
biotech Bien-Etre Labs (High Point, NC; no SBIR, founded 2018) raised $700,000 in a private equity offering, according to [SEC] filing ... focuses on novel platform technology for the production and manufacturing of bioactive agents in order to support healthy aging and longevity. [Lily Skopp, North Carolina Business News Wire, December 4, 18]
BigHat (San Carlos, CA; one SBIR) has capped off a $75 million series B, with Big Pharmas Amgen and Bristol Myer Squibb joining the round as new investors. [Gabrielle Masson, Fierce Biotech, Jul 20, 2022
Bina Technologies (Redwood City, CA; no SBIR, founded 2011), a gene data analysis technology company, has raised $6.25 million from investors ... also said it had entered a partnership with the Medical College of Wisconsin focusing on speeding up newborn whole genome sequencing and screening in the neonatal intensive care unit. [Patrick Hoge, San Francisco Business Times, Mar 26, 13]
Moderna Therapeutics of Cambridge, has now entered an agreement to collaborate on a cancer nanomedicine with another Cambridge company --- Bind Therapeutics. “Bind could receive upfront and pre-approval milestone payments totaling $69 million, and more than $130 million in regulatory and sales milestones and other payments as well as tiered single to double-digit royalties on future sales,” the two companies said in a press release. For Bind, this is its third global partnership with a big pharma in four months. [Chris Reidy, Boston Globe, Apr 22, 13]
According to a pair of releases, the [Russian] firm RUSNANO participated in separate but identical $47.25 million investments to both Selecta [Biosciences] (no SBIR) and Bind [Biosciences] (one SBIR). Since both companies are involved in nanotechnology for drug delivery – Selecta makes nanoparticle immunomodulatory drugs to treat human disease, and Bind makes nanoparticle technology that concentrates a drug at the intended site of action while minimizing exposure to the rest of the system – it makes sense that they are getting the funds from a firm that describes itself as an open joint-stock company created “through reorganization of state corporation Russian Corporation of Nanotechnologies.” [Rodney Brown, Mass High Tech, Oct 27, 11
Bind Biosciences (Cambridge, MA; one SBIR) a nanoparticle-based drug developer, has raised $4.75 million in a new financing round, federal documents show. ... develops nanoparticle technology that concentrates a drug at the intended site of action while minimizing exposure to the rest of the system, improving efficacy and reducing side effects. The company was co-founded in 2006 by Langer and Farokhzad [Rodney Brown, [Mass High Tech, Oct 13, 11]
Thirty Massachusetts life sciences companies have been awarded a total of $23.9 million in tax incentives by the state in an effort to spur job creation. The awards range from as much as $5.85 million to as little as $55,000. The companies receiving the awards have committed to creating nearly 1,000 new jobs in the Commonwealth over the coming year. ... Last year, the program's first, the state awarded $24.5 million to 26 companies that pledged to create 800 jobs in the state. As of June 30th, those companies had created around 400 jobs, according to the state's Life Sciences Center. [DC Dennison, Boston Globe, Dec 22] That's $24000 per job created IFF the recipients create the 1000 jobs. Last year's cost per actual job was about $70000. What do you think should be the state's limit on amount spent per job created? Or is it all sound-bite politics anyway and that real economics don't matter? And if so, how many federal programs do the same thing, only bigger? SBIR firms taking the money are: BIND Biosciences, Cytonome, Merrimack Pharmaceuticals, Organogenesis, Vertex Pharmaceuticals.
BIND Biosciences (Cambridge, MA; one SBIR) biopharmaceutical company that looks to use a proprietary medicinal nanoengineering platform to develop new drugs, said it has secured a $12.4 million Series C-1 financing. [Boston Globe, Jun 29, 10]
Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon. Among the fifty most innovative: A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences. [MIT Tech Review, M/A10]
Bind Biosciences, (Cambridge, MA; one SBIR) nanoparticle-based drug developer co-founded by MITs Robert Langer and Harvard Medical School’s Omid Farokhzad, has raised $11 million in a third round of financing [Julie Donnelly, Mass High Tech, Jan 12, 10]
Bind Bioscience (Cambridge MA; no prior SBIR) got a $150K NIH Phase 1 SBIR to advance a treatment for hormone refractory prostate cancer. ... was co-founded by MIT professor Robert Langer, has raised more than $2.5 million in VC seed capital [Mass High Tech, Oct 8, 07]
Bind Therapeutics (Cambridge, MA; no SBIR) said that Pfizer has won a bankruptcy auction for all of its assets with a $40 million bid. ... Bind was valued at over $200 million when it went public three years ago [Ben Fidler, xconomy.com, Jul 27, 16]
Bind Therapeutics filed for bankruptcy, pushed into court protection when a lender demanded payment for a roughly $15 million loan. [Ben Fidler, xconomy.com, May 5, 16]
BIND Thera up 18% [Dec 16, 15]
BIND Thera down 33% [Dec 14, 15]
BIND Thera up 12% [Apr 13,15]
BIND Thera up 11% [Apr 7,15]
BIND Thera up 11% [Mar 17, 15]
BIND Thera down 10% [Jan 13, 15]
BIND Thera up 37% [Jan 8, 15]
BIND Thera down 20% [Nov 19, 14]
Bind Therapeutics is adding Merck & Co. to its list of big pharma partners for its method of making cancer drugs more potent without the risk of side effects through nanoparticle technology. ... Bind's specialty since it was founded in 2007 has been its so-called "Accurin" nanoparticles which encapsulate cancer-killing drugs in a biodegradable polymer shell which can bring it specifically to cancer cells, avoiding healthy ones ... already has existing partnerships with Pfizer and AstraZeneca, and previously had one with Amgen which ended in July without either company opting to continue developing any drugs. [Don Seiffert, Boston Business Journal, Nov 6, 14]
BIND Thera down 10% [Oct 31, 14]
BIND Thera up 14% [Oct 30, 14]
BIND Therapeutics down 12% [Jul 17,14]
BIND Thera down 10% [Jul 3,14]
BIND Thera up 15% [Apr 8, 14]
Bind Thera down 10% [Apr 7, 14]
BIND Thera up 15% [Jan 16, 14]
BIND Thera up 12% [Dec 26, 13]
BIND Thera up 10% [Dec 13, 13]
Bind Thera up 15% [Dec 4,13]
BIND Therapeutics said that Pfizer has agreed to pay it $160 million per drug as part of a collaboration to develop targeted medicines using nanotechnology which use particles measured in billionths of a meter. BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease, and inflammatory disorders. [AP, Apr 3, 13]
M/A-COM Technology Solutions Holdings, said it would acquire BinOptics (Ithaca, NY; no SBIR, founded 2000) for $230 million [cash]. ... BinOptics manufactures optoelectronic components based on indium phosphide and other semiconductor materials. [Sara Castellanos, Boston Business Journal, Nov 18, 14]
Following the successful completion of The Angel® Catheter Clinical Trial, BiO2 Medical (San Antonio, TX; no SBIR, founded 2006) reports that it has raised approximately $9 million from the Company's Series D Preferred round ... the Angel® Catheter, which will be the first mechanical pulmonary embolism protection device with a prophylactic indication [company press release, Jan 6, 16]
BiO2 Medical (San Antonio, TX; no SBIR, founded 2010) will use biosciences firm DSM’s (Exton, PA; no SBIR) lubricous coating on the Angel Catheter, its flagship product. Placed at a patient’s bedside, the Angel is designed to protect intensive care patients from pulmonary embolism, or the blockage of an artery by a blood clot. [Sanford Nowlin, San Antonio Business Journal, Nov 12, 13]
BiO2 Medical (San Antonio, TX; no SBIR) has received $500,000 in venture capital funding that the company will use to further commercialize a technology that will help prevent blood clods from reaching the lung. ... received its initial $1 million in funding from angel investors in 2007. The company was awarded an additional $1 million from the Texas Emerging Technology Fund late last year. [San Antonio Business Journal, Oct 7, 09]
Bio2 Technologies (Woburn, MA; no SBIR) raised about $4.3M as it continues with a clinical trial of its Vitrium resorbable orthopedic biomaterial for musculoskeletal surgery. It seeks to raised about $2.2M more, according to an SEC filing. [Srividya Kalyanaraman, BostonInno, Sep, 9. 19]
Bio2 Technologies (Woburn, MA; no SBIR) has taken in $1.1 million in equity financing, according to [SEC] filing. ..... makes tissue engineering scaffolds, intended for orthopedic use, based on its cross-linked microstructure (CLM) that Bio2 licenses from Geo2 Technologies (no SBIR). [Mass High Tech, Jul 7, 10]
BioAdvanTek (Angola, IN; founded in 2006) has developed an antimicrobial technology that can be incorporated into almost anything -- from grocery-cart handles to hospital supplies to children's toys. ... while not the first to tackle antimicrobial issues -- is the first that doesn't leach out of products and into the environment. ... not yet recorded any sales, but is working with a large manufacturer of an industrial-strength shrink- wrap-type product, as well as a "significant" orthopedic specialist. [Chuck Bowen, Indianapolis Star, Nov 20]
BioAffinity (San Antonio, TX; no SBIR), the maker of a cancer diagnostic test, is in the process of raising a $5 million Series B round, according to CEO Maria Zannes. .... to commercialize its diagnostic, CyPath, for lung cancer in the U.S. and the European Union. CyPath is a noninvasive test that analyzes sputum—mucus from deep in the lung—for cancer cells. ... had previously raised $9 million [David Holley, xconomy.com, May 15, 18]
iRobot announced that it has signed a definitive agreement to acquire privately-held Robopolis SAS based in Lyon, France. .... for $141 million [company press release, Jul 25, 17]
bioAffinity Technologies (San Antonio, TX;no SBIR) announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030. [company press release, May 3, 17]
bioAffinity Technologies (San Antonio, TX; no SBIR) was awarded a U.S. patent that protects a proprietary kit used for the early detection of cancer and the prognosis of how patients will respond to cancer therapy, the company announced. That kit contains the CyPath assay, the company said. And the new patent relates to the use of the porphyrin-based CyPath assay for detecting dysplastic, precancerous and cancerous cells from tissue samples both in vitro and in situ. Specifically, CyPath is said to preferentially bind to cancer cells, resulting in a fluorescence when viewed by an imaging system. [company press release, Aug 25, 16]
bioAffinity Technologies (San Antonio, TX; no SBIR) is still in its developmental stage, but the biotech company is wasting no time pursuing a larger presence in the war on cancer. It’s launching a new company, OncoSelect Therapeutics, to help fight the deadly disease. ... seeking to make its mark with a proprietary CyPath test, which labels cancer cells, making them easier to detect. [W. Scott Bailey, San Antonio Business Journal, Jun 23, 16]
bioAffinity Technologies (San Antonio, TX; no SBIR) is moving closer to commercializing its initial cancer diagnostics technology via a combination of new funding and strategic hires, according to President and CEO Maria Zannes. .... The privately-held, development-state biotech company has launched a Series A funding round and is seeking to raise $12M [W. Scott Bailey, San Antonio Business Journal, Apr 4, 16] advancing proprietary screening and early‐stage diagnostic technology applicable to a broad range of cancers [company website]
China awarded a Certificate of Invention Patent to bioAffinity Technologies (San Antonio, TX; no SBIR) for its proprietary CyPath assay, which could have a profound impact on cancer detection globally. ... latest accomplishment could especially affect China, which has more lung cancer diagnoses and deaths annually from the disease than any other country in the world, according to bioAffinity President and CEO Maria Zannes. ...has secured 41 patents in 21 countries and has an additional half-dozen patents pending. [W. Scott Bailey, San Antonio Business Journal, Dec 14, 15]
San Antonio’s bioscience industry has gained more critical exposure courtesy of BioAffinity Technologies (San Antonio, TX; no SBIR). ... was invited to present its novel technology for the detection and diagnosis of early-stage lung cancer at a Pharmaceutical/Medtech Dealmaking Symposium ... seeking to raise $15 million Series A [W. Scott Bailey, San Antonio Business Journal, Oct 20, 15]
BioAffinity Technologies (San Antonio, TX; SBIR, founded March 2014) a development-stage biotech company .. focused on non-invasive, early-stage cancer screening and diagnosis. ... now seeking to raise as much as $15 million in a Series A funding round and has already locked in a collaborative research agreement with the University of Texas Health Science Center at San Antonio. ... “Our investors are largely from New York. They are big investors and large investment firms,” Zannes told me. A number of those investors became involved in Zannes efforts when she acquired technology from a New Mexico company [W. Scott Bailey, San Antonio Business Journal, Oct 12, 15]
Biotech firm BioAmber (Plymouth, MN; no SBIR), which makes chemicals from renewable materials, has raised $80 million via an [IPO] [Katharine Grayson, Minneapolis / St Paul Business Journal, May 10, 13]
BioAmber (Plymouth,MN; no SBIR) that uses renewable bio-materials to create chemicals, has set terms for its IPO to raise $129M on the NYSE.[Katherine Grayson, Minneapolis / St Paul Business Journal, Apr 15, 13]
BioAmber (Plymouth, MN; no SBIR) (also Montreal, France, and Shanghai) founded 2008 as DNP Green Technology last winter BioAmber, another bio-based chemical company, raised $30 million and announced collaborations with other producers to make catalysts for fuels. [Neal St Anthony, Minneapolis Star Tribune, Sep 2, 12] BioAmber (Plymouth, MN; no SBIR), a next-generation agricultural chemical start-up, said it plans to raise $150 million in an initial public offering, which would be one the biggest IPOs in Minnesota since 2009. T... has already attracted a $45 million venture capital investment this year. BioAmber is drawing a lot of investor interest because it specializes in the renewable chemistry sector. ... manufacturers bio-succinic acid by fermenting sugar from agricultural crops. [Wendy Lee and Patrick Kennedy, Minneapolis Star Tribune, Nov 14, 11]
BioAmber, (Plymouth, MN; no SBIR) renewable chemistry business, said it will partner with Japanese trading firm Mitsui & Co. to build a manufacturing facility in Canada. ... BioAmber broke a national record for the most venture capital raised for a U.S.-based biotech chemical products business earlier this year. The company raised $45 million in venture capital in the second quarter, according to the MoneyTree Report, [Wendy Lee, Minneapolis Star Tribune, Nov 8, 11]
BioAmber (Plymouth, MN; no SBIR, formerly known as DNP Green Technology) renewable chemistry company said it secured $45 million in venture capital financing. The company said part of the money will go toward building a large-scale plant in North America and speeding the commercialization of some of its products. It will also help fund research and development in other areas, BioAmber said. ... core business is the production of renewable succinic acid using agricultural feedstocks [Wendy Lee, Minneapolis Star Tribune, May 5, 11] [In 2010] acquired a controlling stake in Sinoven Biopolymers [which] is backed by a ten-year development collaboration with the Chinese Academy of Sciences and Beijing Industry & Commerce University [BioAmber website] Investors are mostly international, France and Japan.
Bioanalytical Systems up 33% [Dec 20, 10]
Bioanalytical doubled [Nov 25, 08]
Bioanalytical Systems down 11% [Sep 26, 08]
Bioanalytical Systems up 11% [Sep 23, 08]
Bioanalytical Systems down 11% [Sep 9, 08]
Bioanalytical Systems down 10% [Jun 30, 08]
Bioanalytical Systems up 13% [Jun 27, 08]
Bioanalytical Systems up 27% [Jun 10, 08]
Bioanalytical Systems down 10% [Jan 14, 08]
BioAtla (San Diego, CA; $600K SBIR) down 46% [Jan 10, 2023] announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. [company press release, Jan 10, 2023]
BioAtla (San Diego CA; $600K SBIR) up 48% [Aug 16, 2022]
BioAtla (San Diego CA; $600K SBIR) up 83% [Aug 10, 2022] announced its financial results for the second quarter, and provided an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in NSCLC as well as an operational update on its ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071) addressing multiple tumor types. [company press release, Aug 9, 22]
BioBehavioral Diagnostics (Westport, MA; no SBIR) a medical device maker for attention deficit hyperactivity disorder (ADHD), has taken in almost $3.1 million of a planned $5.5 million debt funding round ... markets the Quotient ADHD System, a tool that aids in the assessment of attention deficit hyperactivity disorder symptoms. The test, which takes 15 minutes, measures hyperactivity, impulsivity and inattentiveness. The measurements are compared to an age and gender database. [Mass High Tech, Sep 23, 11]
Tax Before Profit. BioBehavioral Diagnostics (no SBIR) raised millions of dollars in venture capital and invested heavily in its technology to get its medical device to market. Now, with revenues just beginning to roll in, the six-year-old start-up faces another hurdle as it reaches for success: a new federal tax that will take a cut of every sale it makes. ... developed a system that tests for attention deficit and hyperactivity disorder, is an example of why Massachusetts business and political leaders worry about the medical device tax, recently enacted as part of federal health care reform. The 2.3 percent excise tax, which takes effect in 2013 to help finance the expansion of coverage, will be levied on sales, not profits, [Boston Globe, Apr 14, 10]
BioBehavioral Diagnostics (Westford, MA; no SBIR) developer of a diagnostic tool for attention-deficit hyperactivity disorder, has closed a $10 million Series B funding round.... Founded in 2006, first landed a $8.5 million Series A round in 2007 [Mass High Tech, Feb 1, 10]
A four-organization biotech group led by nonprofit BioBridge Global (San Antonio, TX) has been awarded a $7.8 million contract from the (Army's) Medical Technology Enterprise Consortium (MTEC). The funds will enable the development of large-scale manufacturing capabilities for clinical-grade stem cells for research and therapeutic use. BBG led a group including the U.S. Army Institute of Surgical Research (USAISR) Coagulation and Blood Research, StemBioSys (San Antonio, TX; no SBIR), and RoosterBio (Frederick, MD; no SBIR) in submitting the proposal for funding. [BBG press release, Oct 3, 16]
Biocardia (San Carlos, CA; $200K SBIR) dive into its paused phase 3 heart failure trial has failed to identify reasons to be optimistic about the primary endpoint. Weeks after the monitoring board recommended pumping the brakes, the biotech has revealed the study is unlikely to meet its main objective [Nick Paul Taylor, Fierce Biotech, Sep 5, 2023[
BioCardia (San Carlos, CA; two SBIRs a decade ago) received the go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed for heart failure. [Conor Hale, Fierce Biotech, Dec 6, 2022]
BioCardia down 26% [Dec 17, 20] announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP(TM) Heart Failure Trial. The DSMB based its review on all available data for the 86 patients enrolled in the trial, including 60 randomized patients who have reached their one-year follow-up. The DSMB performed a risk-benefit assessment, indicated no safety concerns, and recommended that the study continue as designed. [company press relese, Dec 17, 20]
BioCardia (San Carlos, CA; $200K SBIR) up 50% [Dec 15, 20] announced it has entered into definitive agreements with investors for the purchase and sale of [$8.5M in common stock] [compsny press release, Dec 15, 20]
Biocardia up 53% [Apr 28, 20] announced the issuance of United States Patent entitled "Drug Delivery Catheters that Attach to Tissue and Methods for Their Use." This new patent provides additional, broad protection for the Helix(TM) Biotherapeutic Delivery System and covers the use of the helical needle delivery system with a deflectable guide catheter. [company press release, Apr 28, 20]
BioCardia (San Carlos, CA; no SBIR) up 46% [Jan 13,20] announced the issuance of three new patents for the company's technology.
BioCardia (San Carlos, CA; $240K SBIR) up 25% [Sep 17, 19] announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety follow-up results on 35 patients and all additional data available on the 50 patients randomized in the trial as of August 31, 2019. The DSMB indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. [company press release, Sep 16, 19]
BioCardia down 64% [Aug 2,19] Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq [company press release, Aug 2, 19]
Regenerative medicine startup BioCardia (no SBIR) formally withdrew plans for an IPO that it filed for last year. [Cromwell Schubarth, Silicon Valley Business Journal, Apr 18, 16]
Gene therapy startup BioCardia (San Carlos, CA; no SBIR, founded 2002) plans to raise up to $61.9 million in its IPO, according to a new filing ... plans to begin enrolling patients this year in a pivotal trial of what it says could be the first cell-based therapy to treat heart failure to reach the market. However, the company doesn't expect to receive key data on the trial until the second half of 2017. [Gina Hall, Silicon Valley Business Journal, Jul 6, 15]
BioCardia (San Carlos, CA; no SBIR) biotech working on therapies for heart diseases, disclosed plans to raise up to $58 million in an IPO. ... plans to begin enrolling patients this year in a pivotal trial of what it says could be the first cell-based therapy to treat heart failure to reach the market [Cromwell Schubarth, Silicon Valley Business Journal, Jun 17, 15]
BioCentra Molecular Innovations LLC (Georgetown, TX; no SBIR, parent BioCentra founded 2008) raised $16,510 from three investors. [Christopher Calnan, Austin Business Journal, Aug 14, 15] ... developing low-cost, simpler and rapid molecular diagnostic tools that are becoming increasingly essential in delivering personalized care therapies to the patients with diseases ranging from viral and bacterial infections to cancer and metabolic diseases worldwide. [company website]
Biocept up 13% [Aug 30, 18]
Biocept down 10% [Aug 24, 18]
Biocept up 18% [Aug 23, 18]
Biocept up 12% [May 4,15]
Biocept up 43% [Apr 20,15]
Biocept up 10% [Mar 30,15]
Biocept up 12% [Mar 19, 15]
Biocept up 15% [Mar 2, 15]
Biocept down 10% [Feb 27, 15]
Biocept down 26% [Feb 26, 15]
Biocept up 40% [Feb 25, 15]
Biocept (San Diego, CA; one SBIR)up 54% [Feb 24, 15] announced that its blood-based diagnostic, OncoCEE-BR(TM), was used to determine hormonal status of metastatic breast cancer patients in a prospective study performed at the Columbia University College of Physicians and Surgeons in New York City. Findings from the Columbia study were recently published in the peer-reviewed journal Clinical and Translational Oncology. [company press release]
Biocept up 11% [Nov 26, 14]
Biocept down 10% [Nov 13, 14]
Biocept up 40% [Nov 12, 14] announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. [company press release]
Biocept Thera (Carlsbad, CA; one SBIR) down 17% [Oct 8, 14]
Biocept Thera (Carlsbad, CA; one SBIR) up 24% [Oct 6, 14]
Shares of newly public Biocept (Carlsbad, CA; one SBIR) fell after they began trading on Nasdaq. [down] 8% .... makes a test that assists in cancer diagnostics by detecting circulating tumor cells and their DNA in a blood sample. .... raised $19 million .... has one test on the market, called OncoCEE-BR [Bradley Fikes, utsandiego.com, Feb 6, 14]
Biocept (San Diego, CA; one SBIR, founded 1997) developer of cancer diagnostics, has raised $2.3 million of a planned $7.1 million round of equity financing [Ryan McBride, signonsandiego, Aug 16, 10]
Biocept (San Diego, CA; one 1998 SBIR) working on cell separation technology, has raised $3.6 million of a planned $4.05 million equity offering, according to an SEC filing. ... developing diagnostic assays for detecting and monitoring cancer. [Erin Kutz, signonsandiego.com, Apr 15, 10]
Federal securities regulators filed civil fraud charges against BioChemics (Danvers, MA) no SBIR) and its chief executive, alleging that they lied to investors in a scheme to raise $9 million.[SEC] said BioChemics and its chief, John Masiz of Topsfield, and two others ran a fraudulent scheme that raised at least $9 million from 70 investors in 19 states, according to a complaint filed in federal court in Boston. [Beth Healy, Boston Globe, Dec 15, 12]
BioCircuit Technologies® (Atlanta, GA; one $1M SBIR), a medical device company focused on peripheral nerve repair and neuromodulation, announces the close of a $9 million round of financing. [company press release, Sep 27, 2022]
BioClin Therapeutics (San Ramon, CA; no SBIR) raised $30 million to move forward with more tests of its experimental treatment for bladder cancer. ... says it has now raised a total of $59 million from investors. ... lead drug candidate, B-701, is a monoclonal antibody developed to target fibroblast growth factor receptor 3 (FGFR3), a protein that is often mutated in patients with bladder cancer. So far, BioClin has tested its treatment in two Phase 1 clinical trials [Frank Vinluan, xconomy.com, Mar 22, 17]
BioCold Genesys (Santa Ana, CA; no SBIR) developing novel immunotherapies used to treat cancer, has closed on $22 million in financing. [I-Chun Chen, LA Biz News, Mar 18, 19]
Bioconnect Systems (Ambler, PA; no SBIR) is planning to conduct a clinical study its OptiFlow device before the end of the year. ... designed to create precisely controlled surgical connections that join a patient’s vein and an artery for dialysis treatments. ... raised $9 million in a private [Series B] stock sale during the third quarter [John George, Philadelphia Business Journal, Nov 21, 13] raised $8 million in Series A financing in 2007 [Company website]
Bioconnect Systems (Ambler, PA; no SBIR) raised $9.1 million in a private stock sale ... specializes in developing surgical implants and techniques that form precisely controlled vascular connections. [John George, Philadephia Business Journal, Sep 27, 13]
BioConsortia (Davis, CA; no SBIR, founded 2014), innovator of microbial solutions for natural plant trait enhancement and yield improvement, has closed a [$10M] round of equity financing for the commercial development of a number of novel microbial consortia products — focused toward corn, wheat, soy, tomatoes, and leafy veg. [company press release, Mar 29, 19] prior funding $27M [crunchbase.com]
BioConsortia (Davis, CA; no SBIR), innovator of microbial solutions for natural plant trait enhancement and crop yield improvement, announced that it has raised this year a total of $12 million for future growth. Last week, BioConsortia closed an $8 million equity round of investment financed by existing investors ... has developed a revolutionary Advanced Microbial Selection (AMS) process for crop trait enhancement that uses iterative rounds of plant phenotyping and selection to co-select for beneficial changes in the microbiome. [company press release, Nov 7, 16]
biotech BioConsortia (Davis, CA; no SBIR) has been granted a patent for a process that underlies its technology to improve the performance of crops. ... has been using the technology to quickly discover groupings of microbes that increase crop yields or that protect crops from harm. ... In April 2014, BioConsortia raised $15 million [Mark Anderson, Sacramento Business Journal, Oct 13, 15]
BioConsortia (Davis, CA; no SBIR), the agricultural biotechnology company that raised $15 million in venture capital earlier this year, has opened its headquarters office and laboratory space in Davis. .... CEO Marcus Meadows-Smith is a former CEO of AgraQuest (Davis, CA; $1M SBIR) that was sold to Bayer CropScience for $425 million in 2012. [Mark Anderson, Sacramento Business Journal, Aug 28, 14]
A $50 million venture capital fund is being organized in Davis (CA) to invest in early-stage agriculture and life science technology companies. The AgTech Innovation Fund, structured as a limited partnership, likely would invest $250,000 to $500,000 in initial seed rounds of funding into promising companies ..... AgraQuest (Davis, CA; $1M SBIR) was a biotechnology company founded by Pam Marrone. It was bought by Bayer CropScience for $425 million in 2012. Marrone’s next company, Marrone Bio, last August closed the Sacramento region’s first successful initial public offering in nearly a decade, when it netted $56.4 million for expansion. In April, Davis-based agricultural biotechnology company BioConsortia raised a $15 million round of funding from Khosla Ventures and Otter Capital LLC. [Mark Anderson, Sacramento Business Journal, May 5, 14]
Ag biotech BioConsortia (Davis, CA; no SBIR) raised a $15 million round of funding .... uses accelerated microbial selection and genomic techniques to create crops with improved traits. [Mark Anderson, Sacramento Business Journal, Apr 7, 14]
BioCritica (Indianapolis, IN; no SBIR) small biotech company springing up has already signed a licensing agreement with Eli Lilly for the rights to sell the pharmaceutical giant's medicine for severe sepsis, Xigris. The new company will create up to 70 jobs by 2015, according to an announcement Monday from the Indiana Economic Development Corp. ... up to $2.9 million in performance-based tax credits and up to $175,000 in training grants. [Indianapolis Star, May 24, 11]
Just a few months after discontinuing its most advanced pipeline asset, BioCryst Pharmaceuticals is now delaying testing of its only remaining clinical candidate. The oral factor D inhibitor, dubbed BCX10013, is designed to treat complement-mediated diseases. [Gabrielle Masson, Fierce Biotech, Feb 23, 2023]
BioCryst trimmed its pipeline to two drugs last month. Fast forward 45 days, and BCX9930 is headed to the garbage can too. [Annalee Armstrong, Fierce Biotech, Dec 15, 2022]
BioCryst trimmed its pipeline to two drugs last month. Fast forward 45 days, and BCX9930 is headed to the garbage can too. [Annalee Armstrong, Fierce Biotech, Dec 15, 2022]
BioCryst Pharmaceuticals up 23% [Aug 4, 2022]
BioCryst Pharmaceuticals up 15% [Apr 13, 22]
BioCryst Pharmaceuticals (Durham NC; ) down 38% [Apr 8, 22] announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients. [company press release, Apr 8, 22]
BioCryst Pharmaceuticals up 28% [Jan 10, 22] announced financial results and forecast
BioCryst was ready for the public markets, but after shares sank 14% in the wake of the announcement, ... has withdrawn a proposed $200 million public offering after deciding “current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders.” [Fierce Biotech, Nick Paul Taylor, Aug 11, 2021]
BioCryst Pharma up 21% [May 6, 21] reported quarterly earnings
BioCryst Pharmaceuticals up 39% [Feb 1, 21]
BioCryst Pharma up 19% [Dec 4, 20] announced that [FDA] has approved oral, once-daily ORLADEYO(TM) (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. [company press release, Dec 3, 20]
BioCryst Pharmaceuticals up 18% [May 11, 20]
BioCryst Pharma up 20% [May 8, 20] announced financial results
BioCryst Pharma up 30% [Apr 17, 20]
BioCryst Pharmaceuticals has begun enrolling COVID-19 patients in a clinical trial of its antiviral drug galidesivir. The trial builds on in vitro evidence that the adenosine nucleoside analog is effective against pathogens including the MERS and SARS coronaviruses. [Fierce Biotech, Apr 10, 20]
BioCryst Pharma up 15% [May 30, 19]
BioCryst Pharma down 53% [May 21, 19] announced that the randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of hereditary angioedema (HAE) attacks achieved its primary endpoint [company press release, May 21, 19]
BioCryst Pharma announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period. [company press release, Sep 4, 18]
BioCryst Pharmaceuticals up 13% [Aug 9, 18]
BioCryst Pharmaceuticals announced the completion of a public offering with gross proceeds of $57M .... [also] announced that the Company has been granted [FDA] Fast Track Designation for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE). [company press releases, Aug 6, 18]
BioCryst Pharmaceuticals (Durham, NC) is ending a plan to merge with Idera Pharmaceuticals and form a single company focused on rare diseases. ... following a meeting that saw shareholders vote overwhelmingly against the proposal. [Frank Vinluan, xconomy.com, Jun 10, 18]
BioCryst Pharmaceuticals announced that the European Medicines Agency (EMA) has approved peramivir with the brand name of ALPIVAB, a single intravenous (I.V.) infusion for the treatment of uncomplicated influenza in adults and children from the age of 2 years. [company press release, May 1, 18]
BioCryst Pharmaceuticals (Research Triangle Park, NC; $1.4M SBIR) and Idera Pharmaceuticals (Exton, PA; no SBIR) announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. The combined company will be renamed upon closing [joint companies press release, Jan 22, 18]
BioCryst Pharma up 14% [Dec 8, 17]
On the heels of an $80 million public offering, BioCryst Pharmaceuticals landed [FDA] approval for its injectable flu treatment in pediatric patients. [Jennifer Henderson, Triangle Business Journal, Sep 21, 17]
BioCryst Pharma up 20% [Sep 7, 17] announced final results from its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 was a 3-part dose ranging trial designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of orally administered once-daily (QD) BCX7353 for 28 days, as a preventative treatment to reduce the frequency of attacks in HAE patients. This final analysis evaluated data from all patients in Parts 1, 2 and 3 of the trial. [company press release, Sep 5, 17]
BioCryst Pharma down 13% [Aug 7, 17]
BioCryst Pharma down 14% [May 26,17]
BioCryst Pharma up 31% [May 25,17] Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial. 125 mg dose of BCX7353 showed a reduction of 73% in overall attack rate (p=0.002) [company press release, May 25, 17]
BioCryst Pharma down 11% [May 4, 17]
BioCryst Pharma, focused on the development and commercialization of treatments for rare diseases, announced plans to explore a new oral liquid formulation of BCX7353 for the treatment of acute attacks in patients with hereditary angioedema (HAE). The Company has received initial regulatory approvals in Europe to initiate the ZENITH-1 exploratory clinical trial this summer. [company press release, Apr 12, 17]
BioCryst Pharmaceuticals announced that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment of relapsed/refractory PTCL (Peripheral T-Cell Lymphoma) by the Ministry of Health, Labor and Welfare in Japan. ... makes Japan the first country in the world to make Mundesine available for treatment of PTCL. [company press release, Apr 3, 17]
BioCryst Pharma down 10% [Mar 20, 17]
BioCryst Pharmaceuticals announced the pricing of an underwritten public offering [with] gross proceeds expected to be $45.0 million [company press release, Mar 9, 17]
BioCryst Pharma up 10% [Mar 1,17]
BioCryst Pharma up 13% [Feb 28,17]
BioCryst down 11% [Jan 9,17]
BioCryst Pharma up 11% [Dec 19, 16]
BioCryst Pharma up 10% [Dec 16,16]
BioCryst Pharma up 15% [Nov 7, 16] reported lower revenue and a smaller net loss in the third quarter [Raleigh News & Oberver]
BioCryst Pharmaceuticals announced positive results from a proof-of-concept study of its broad spectrum antiviral, BCX4430, for the delayed treatment of Ebola virus infection in rhesus macaques. [company press release, Sep 7, 16]
BioCryst Pharma up 12% [Sep 7,16]
BioCryst Pharmaceuticals is abandoning an experimental drug, avoralstat, which earlier this year failed to meet expectations in a clinical trial. BioCryst is continuing with the development of another drug, BCX4430, for the same condition: hereditary angioedema. [John Murawski, Raleigh News & Observer, Aug 4, 16]
BioCryst Pharma up 14% [Jul 27, 16]
BioCryst Pharmaceuticals
announced that [NIH]
provided
additional funding for efficacy studies
of BCX4430 in
non-human primates to further assess effective dose regimens.
The funding represents an additional
BioCryst Pharma down 10% [Jun 10, 16]
BioCryst Pharma down 13% [Jun 9, 16]
BioCryst Pharma down 10% [Feb 29,16]
BioCryst Pharma down 71% [Feb 8, 16] reported disappointing mid-stage study results for its drug to treat a rare genetic condition characterized by swelling of the face and airways. [Dow Jones News Wire, Feb 8, 16]
BioCryst Pharma up 11% [Nov 9, 15]
Biocryst Pharma down 10% [Oct 9,15]
Biocryst Pharma down 18% [Oct 8,15] after the company said it could stop developing one experimental drug and also reported frequent side effects in patients taking another drug it has under development. [John Murawski, Raleigh News & Observer, Oct 8, 15]
BioCryst Pharmaceuticals drew down $5.4 million from a federal contract to continue developing [experimental drug BCX4430] that could one day fight viruses like Ebola and Marburg. [Jason deBruyn, Triangle Business Journal, Sep 1, 15]
BioCryst Pharma up 12% [Aug 10, 15]
BioCryst Pharma down 24% [Aug 7, 15] announced it will delay a Phase I clinical trial of BCX7353, a medication being developed for a potentially fatal genetic condition, hereditary angioedema. [Raleigh News& Observer, Aug 7]
BioCryst Pharmaceuticals announced that it has licensed the worldwide rights to its flu treatment Rapivab to CSL Limited, an Australia-based drug company. Under the terms of the deal, BioCryst will receive an upfront payment of $33.7 million from bioCSL, a subsidiary of CSL, and could receive up to $12 million in regulatory milestone payments. The company also will receive royalty payments based on sales. [David Bracken, Raleigh News & Observer, Jun 17, 15]
BioCryst Pharmaceuticals will test an experimental treatment for hereditary angioedema (HAE) in humans for the first time. ... trial will involve about 60 healthy volunteers to assess basic safety aspects of the drug and to see how humans respond to its chemical makeup. In subsequent trials, BioCryst would test the drug in humans with HAE to test how effectively the drug attacks the disease. ... HAE is a rare, severely debilitating and potentially fatal genetic condition that occurs in approximately 1 in 50,000 people. [Jason de Bruyn, Triangle Business Journal, May 13, 15]
BioCryst Pharmaceuticals said it began testing an experimental treatment on human volunteers for a rare and potentially fatal genetic disorder called hereditary angioedema ... the first human test of BCX7353, BioCryst’s second-generation treatment for hereditary angioedema that is based on taking one pill a day. [John Murawski, Raleigh News & Observer, May 13, 15]
BioCryst Pharma up 10% [Apr 1,15]
BioCryst Pharmaceuticals announced that the [US] Biomedical Advanced Research and Development Authority(BARDA) within [HHS] has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This ASPR/BARDA contract includes a base contract of $12.1 million to support BCX4430 drug manufacturing, as well as $22.9 million in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0 million. Filoviruses represent serious threats to national security and the [USG] has made this a top priority for medical countermeasure development. [company press release, Mar 31, 15]
BioCryst Pharmaceuticals said it has been granted Fast Track designation for its experimental drug to fight a rare and potentially fatal genetic disorder called hereditary angioedema. ... The BioCryst drug, called BCX4161, will next be tested on nearly 100 people in the United States and Europe in a clinical trial with placebos. [John Murawski, Raleigh News & Observer, Jan 26, 15]
BioCryst Pharmaceuticals received an orphan drug designation for its angioedema treatment under development, an important measure because it allows BioCryst to accelerate its development time line. ... The drug under development, called BCX4161, was discovered by BioCryst scientists and is intended for the prevention of acute attacks of angioedema in patients with hereditary angioedema (HAE). [Jason deBruyn, Triangle Business Journal Dec 24, 14]
BioCryst Pharmaceuticals has dosed its first patient in an Ebola treatment trial. The in-development drug at the heart of the project, dubbed BCX4430, will treat hemorrhagic fever viruses, including Ebola and Marburg, if it passes FDA muster. [Lauren K. Ohnesorge, Triangle Business Journal, Dec 15, 14]
BioCryst Pharmaceuticals [a 24-year-old company with no drug products on the market] reported an increase in federal funding in the third quarter as the company shifts its focus from developing an intravenous influenza treatment to developing an anti-viral for Ebola and other deadly viruses. ... The company’s stock is up 45 percent this year. [John Murawski, Raleigh News & Observer, Nov 6, 14]
BioCryst Pharma up 15% [Oct 15, 14]
BioCryst Pharma up 12% [Oct 3, 14]
BioCryst Pharma up 12% [Oct 2, 14]
BioCryst Pharma up 10% [Sep 24, 14]
BioCryst Pharmaceuticals defaulted on a loan ... the royalties [in Japan] were not enough to cover the payments due on the PhaRMA Notes, and BioCryst defaulted. Consequently, BioCryst forfeits the right to future royalty payments from Shionogi. [Jason deBruyn, Triangle Business Journal, Sep 3, 14]
BioCryst Pharmaceuticals announced this week that it is eligible to receive $4 million in addition federal research funds to accelerate the development of a potential treatment for the deadly virus Ebola. [NIH] exercised two additional options under its contract with BioCryst to test its experimental antiviral drug, which is known by the code BCX4430. .... The amendments made to BioCryst’s agreement with NIAID bring the value of the contract up to $26.3 million, if all options are exercised. [David Bracken, Raleigh News & Observer, Sep 19, 14]
BioCryst Pharmaceuticals reported in a regulatory filing that it has defaulted on some debt after the royalty payments from its Japanese partner didn't cover the accrued interest on the debt. [Raleigh News & Observer, Sep 2, 14]
BioCryst Pharmaceuticals received another $2.4 million to continue work on an experimental Ebola treatment. .... has a contract with [NIH] to develop and test a drug called BCX4430 for now, which BioCryst executives think could show promise in treating Ebola and similar diseases like, for example, the Marburg virus. ... means BioCryst has received nearly $16 million of the award that could be worth up to $24 million. BioCryst will use the money to test its drug in non-human primates. [Jason deBruyn, Triangle Business Journal, Aug 29, 14]
In an attempt to bring out a treatment for Ebola, BioCryst Pharmaceuticals plans to test a new drug in humans early next year. ... has a contract with [NIH] that could be worth up to $22 million to develop the treatment. [Jason deBruyn, Triangle Business Journal, Aug 7, 14]
BioCryst’s antiviral candidate got a federal boost .... [NIH] released an additional $1.89 million for [antiviral dubbed BCX4430] development. .... If all contract options are exercised, BioCryst stands to snag $22 million from the agency over five years. [Lauren K. Ohnesorge, Triangle Business Journal, Jun 23, 14]
BioCryst Pharmaceuticals announced that it sold $115 million worth of shares common stock ... to fund the accelerated development BCX4161, a drug that yielded positive results last week. [Meredith Hamrick, Triangle Business Journal, Jun 3, 14]
BioCryst Pharmaceuticals announced that it is planning to sell $100 million in stock in a public offering. The proceeds are to be used for general corporate purposes and to fund the development of BCX4161, the Durham drug developer’s oral treatment for angioedema, a rare disease that results in swelling and painful welts. .... a so-called “shelf” registration process that allows the company to sell any combination of securities for a total sum of $100 million. [David Bracken, Raleigh News& Observer, May 28, 14]
BioCryst Pharmaceuticals up 17% [May 27, 14] said its experimental drug to treat a rare immune disorder was found effective in reducing attacks related to the condition, in a mid-stage trial. [Reuters, May 27, 14]
BioCryst Pharma (38-employees) down 14% [May 8, 14] after the company reported another potential setback for its intravenous flu treatment peramivir. .... peramivir is approved [only] in Japan and Korea [John Murawski, Raleigh News & Observer, May 8, 14]
Biocryst Pharma down 10% [Apr 4, 14]
BioCryst Pharma up 11% [Feb 25, 14] said that federal regulators have accepted the company’s Peramivir flu treatment for safety review, keeping the medication on track for introduction in the United States for the 2014-15 flu season [Raleigh News & Observer, Feb 25]
BioCryst Pharma up 11% [Feb 18, 14]
Biocryst Pharma down 15% [Jan 27, 14]
BioCryst Pharmaceuticals received an additional $2.5 million in federal funding to further develop a treatment for Marburg virus disease. [Raleigh News & Observer, Dec 30, 13]
BioCryst Pharmaceuticals announced that it has submitted a new drug application for its flu treatment Peramivir.The move marks a remarkable turn in the drug’s fortunes in the U.S., where BioCryst has no drugs on the market. [David Bracken, Raleigh News & Observer, Dec 20, 13]
Biocryst Pharma up 10% [Nov 29, 13]
BioCryst Pharmaceuticals announced that it has contracted with the National Institute of Allergy and Infectious Diseases to develop one of its drugs for the treatment of Marburg Virus Disease. The contract includes an initial award of $5 million, and could total $22 million for the Durham drug developer over five years. The goal of the contract is to file new drug applications for the drug, BCX4430 [to treat viruses that pose a threat to health and national security] and begin phase 1 clinical trials. [D Bracken, Raleigh News & Observer, Sep 17, 13]
Biocryst Pharma up 14% [Aug 26, 13]
Biocryst Pharma up 10% [Aug 2, 13]
Biocryst up 21% [Aug 1, 13]
BioCryst up 11% [Jul 31, 13] plans to issue stock to raise up to $20 million to fund operations through December 2014. [Raleigh News & Observer]
BioCryst Pharmaup 22% [Jun 23, 13]
BioCryst Pharma up 51% [Jul 22, 13] announced that the Phase 1 clinical trial for its drug to treat hereditary angioedema met all of its objectives. [Raleigh News & Observer]
BioCryst Pharmaceuticals in 2012. This time last year, the company was immersed in developing peramivir, a flu treatment whose development was backed by as much as $235 million in federal government money. ... Unhappliy in November Trials of peramivir were suspended. [Lauren Ohnesorge, Triangle Business Journal, Dec 28, 12] Which raises the question of when should government "market-failure" programs declare graduation. Probably never if the politicians and small biz pleaders have any say in suppoort for local interests.
BioCryst Pharmaceuticals said it is cutting half its staff in the wake of a failed merger attempt and two suspensions of experimental drugs. BioCryst, with employees in Alabama and Durham, plans to operate with 37 employees, a move designed to save $15 million to $18 million next year and intended to stretch BioCryst’s finances through 2014. [John Murawski, Raleigh News & Observer, Dec 7, 12]
BioCryst Pharmaceuticals and Presidio Pharmaceuticals said that they have mutually agreed to end their agreement for Presidio to be purchased by BioCryst. [AP, Nov 30, 12]
BioCryst Pharmaceuticals stock plummeted 40 percent after the company said late Wednesday it is suspending development of an influenza treatment that had been supported with $235 million in federal research funding. [John Murawski, Raleigh News & Observer, Nov 8, 12]
BioCryst down 29% [Oct 31, 12]
BioCryst Pharmaceuticals is buying Presidio Pharmaceuticals (San Francisco, CA; no SBIR) for $101 million in stock.... in a bid to achieve together what neither company has been able to do alone: produce new treatments for the debilitating hepatitis C infection that afflicts 170 million people worldwide..... despite more than $200 million spent on research and development. [John Murawski, Raleigh News & Observer, Oct 19, 12]
BioCryst Pharma down 10% [Aug 14, 12]
Biocryst Pharma down 11% [Aug 1, 12]
BioCryst Pharma down 12% [Jun 6, 12]
BioCryst Pharma up 18% [Mar 5, 12]
Biocryst Pharma up 12% [Feb 15, 12]
BioCryst Pharma up 15% [Jan 27, 12]
BioCryst Pharmaceuticals (Durham, NC; $1.3m SBIR in Alabama) announced positive results from a recent study involving its experimental gout treatment. CEO Jon Stonehouse said on a conference call with analysts that the company will meet with federal regulators in the coming months to extend the current studies involving the treatment. "These results give us momentum as we enter 2012 and make it a very exciting year for BioCryst," he said. BioCryst has yet to have any of its drugs approved for the U.S. market. Its flu treatment peramivir was approved in Japan and Korea in 2010. [David Bracken, Raleigh News & Observer, Jan 10,12]
BioCryst Pharma up 13% [Jun 13, 11]
BioCryst Pharmaceuticals closed on a $30 million financing transaction that monetizes future royalty and milestone payments made by its Japanese partner Shionogi & Co., Ltd on BioCryst’s influenza drug peramivir. [Triangle Business Journal, Mar 10, 11]
BioCryst Pharma up 14% [Apr 28, 10]
BioCryst Pharma up 18% [Feb 10, 10]
BioCryst Pharma up 10% [Dec 24, 09]
BioCryst Pharma up 13% [Oct 26, 09] after the FDA issued a so-called emergency-use authorization late Friday that allows doctors to use the Birmingham, Ala., biopharmaceutical firm's peramivir drug in certain hospitalized adult and pediatric patients with confirmed or suspected H1N1 influenza. [Wall Street Journal, Oct 27]
[In a tale of biotech snapback, Forbes [Matthew Herper, Oct 16, 09] notes that BioCryst Pharma is up 1014% from its 52-week low. Antigenics (Woburn, MA; $700K SBIR) is up 1032%.
Biocryst Pharma up 15% [Jul 27,09]
Biocryst Pharma up 11% [Jul 24,09]
Biocryst Pharma up 22% [Jul 21,09] after the company announced positive results from its Phase III flu vaccine study. [tickerspy.com, Jul 21]
Biocryst Pharma up 41% [Jul 17,09] announced positive results on two late-stage studies for influenza treatment peramivir [Wall Street Journal, Jul 18]
BioCryst Pharma up 10% [Jun 26, 09]
BioCryst Pharma up 11% [Jun 11,09]
BioCryst Pharma up 19% [May 18, 09]
BioCryst Pharma up 32%[May 15, 09]
BioCryst down 18%[May 4, 09]
BioCryst Pharma down 10% [Apr 29, 09]
BioCryst Pharma up 76% [Apr 27, 09]
BioCryst Pharmaceuticals up 12% [Jul 28, 08] after the company said an injectible version of its experimental seasonal flu drug met a midstage study goal of alleviating symptoms. [AP]
BioCryst Pharmaceuticals up 14% [Mar 31, 08]
BioCryst Pharmaceuticals up 11% [Mar 26, 08]
BioCryst Pharma down 12% [Mar 10, 08]
BioCryst Pharmaceuticals up 11% [Feb 4, 08]
BioCryst Pharmaceuticals (Birmingham AL; $1M SBIR) down 32%, after an injectable formulation of a flu treatment failed to exhibit statistically significant improvement on placebo in a midstage clinical trial for the biopharmaceutical concern., Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases and viral infections. [Wall Street Journal, Sep 21]
BioDelivery Sciences International up 53% [Feb 14, 22] on buyout report
BioDelivery Sciences (Newark, NJ; $1.9M SBIR) announced that it has entered into a definitive merger agreement for Collegium Pharmaceutical, to purchase all outstanding shares of BDSI [for] approximately $604 million [company press release, Feb 14, 22]
BioDelivery Sciences tripled its third-quarter revenue and said it expects its 2-year-old opioid addiction patch to become profitable by the end of next year. [Raleigh News & Observer, Nov 9, 16]
BioDelivery Sciences International announced the addition of BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) as a preferred drug to the Texas Medicaid formulary from its previous non-formulary status. [company press release, Oct 24, 16]
BioDelivery Sciences up 10% [Sep 23, 16]
BioDelivery Sciences International licensed U.S. rights to Onsolis, the company’s treatment for breakthrough cancer pain, to Collegium Pharmaceutical (Canton, MA; no SBIR). The deal includes $2.5 million up front to BDSI, $4 million upon first commercial sale in the United States, and up to $17 million in potential milestones tied to sales, plus royalties. Collegium adds Onsolis to a drug portfolio of pain treatments. [Frank Vinluan, xconomy.com, May 16, 16]
BioDelivery Sciences down 15% [May 6, 16]
Biodelivery Science up 10% [Mar 29,16]
BioDelivery Sciences down 12% [Mar 11,16] reported fourth-quarter earnings that badly missed Wall Street estimates. [Raleigh News & Observer, Mar 11, 16]
Actavis (US name for Allergan (Ireland). formerly known as Watson Pharmaceuticals) files patent claims against Raleigh's BioDelivery Sciences [Jason deBruyn, Triangle Business Journal, Feb 16, 16]
BioDelivery Sciences up 17% [Jan 21, 16]
BioDelivery Sciences International announced that it will receive a $50 million milestone payment after its application for a new drug to treat chronic pain was approved by [FDA]. ... will receive the payment from Endo Pharmaceuticals, the company it had partnered with to develop the treatment. The treatment, BEMA Buprenorphine, is being marketed under the name Belbuca. [David Bracken, Raleigh News & Observer, Oct 26, 15]
BioDelivery Sciences down 10% [Oct 21,15]
BioDelivery Sciences International disclosed that it has secured a two-year contract with Tennessee Medicaid, giving its opiod-dependence drug Bunavail “preferred coverage status” on its preferred drug list. [Lauren K. Ohnesorge,Triangle Business Journal, Sep 8, 15] How much that means is probably caught up in the state legislature's following Republican politics in refusing Medicaid expansion under Obamacare.
BioDelivery Sciences International shelved $150 million in shares, a practice by some publicly traded companies as a precursor toward raising more money from public markets. [Jason deBruyn, Triangle Business Journal, Jul 6, 15]
BioDelivery Sciences International filed plans last week to raise as much as $150 million through a public stock sale. [Raleigh News & Observer, Jul 6, 15]
BioDelivery Sciences up 10% [Jun 30, 15]
BioDelivery Sciences International borrowed an additional $21 million to help the pharmaceutical company launch a newly approved drug. ... BioDelivery received approval to sell Bunavail, a treatment for opioid dependence, last year, but sales have started slow, largely because BioDelivery did not immediately reach managed care deals. [Jason deBruyn, Triangle Business Journal, Jun 5, 15]
BioDelivery Sciences down 24% [Mar 30,15] announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance [company press release, Mar 30]
BioDelivery Sciences International announced that it will receive a $10 million milestone payment after its new drug application for its treatment of chronic pain was accepted by the Food and Drug Administration. ... will receive the payment from Endo Pharmaceuticals, the company it has partnered with to development the treatment. [Raleigh News & Observer, Feb 23, 15]
BioDelivery Sciences International announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico, back to BDSI. BDSI originally licensed such rights to Meda in 2007, and ONSOLIS was approved by the FDA)and originally commercially launched in the United States in 2009. [company press release, Jan 27, 15]
BioDelivery Sciences up 10% [Dec 17, 14]
BioDelivery Sciences down 10% [Oct 10, 14]
BioDelivery Sciences International announced positive Phase 3 clinical trial results for its experimental treatment for chronic pain .... The positive test results triggered a $10 million milestone payment from Endo [David Bracken, Raleigh News & Observer, Jul 7, 14]
BioDelivery Sciences International took a step forward today in making its diabetic complication treatment available to patients. .... confirms it has completed enrollment in its Phase 3 study ... The treatment, Clonidine Topical Gel, aims to treat painful diabetic neuropathy [Lauren K. Ohnesorge, Triangle Business Journal, Jun 27, 14]
BioDelivery Sciences received some of the best news in company history Friday when the FDA approved its new drug application for Bunavail, a treatment for opioid dependence ... plans to launch Bunavail in late third quarter 2014 and anticipates peak sales potential of up to $250 million in the United States [Jason deBruyn, Triangle Business Journal, Jun 6, 14]
BioDelivery Sciences International has enrolled its first patient in a Phase 3 trial to test a topical gel for the treatment of painful diabetic neuropathy. The gel is called Clonidine Topical Gel, which BioDelivery licensed from Arcion Therapeutics (Baltimore, MD; no SBIR) in March 2013. [Jason deBruyn, Triangle Business Journal, Apr 3, 14]
BioDelivery Sciences International parlayed its recent good news about the company's phase 3 trials hitting the clinical endpoints. Essentially, the company's pain management therapy met all the clinical endpoints required to move the process forward. The positive results triggered a $10 million milestone payment from Endo just weeks ago. Now comes word that a group of institutional investors have agreed to pump an additional $60 million [Sougata Mukherjee,Triangle Business Journal, Feb 10, 14]
BioDelivery Sciences International announced that is raising $60 million by selling a block of shares to a group of institutional investors. [David Bracken, Raleigh News & Observer, Feb 10, 14]
Biodelivery Sciences down 14% [Jan 27, 14]
BioDelivery Sciences International stock jumped 51 percent after company reported positive clinical trial results for its experimental treatment for chronic pain. BioDelivery Sciences and Malvern, Penn.-bsed Endo Pharmaceuticals announced late Thursday that results from the first phase of a Phase 3 clinical trial of BEMA Buprenorphine improved chronic pain relief when compared to a placebo. The results triggered a $10 million milestone payment from Endo to BioDelivery Sciences. [David Bracken, Raleigh News & Observer, Jan 24, 14]
BioDelivery Sciences International announced that it engaged in a positive meeting with the [FDA] regarding the clinical development program for Clonidine Topical Gel that will allow the program to proceed to Phase 3 clinical studies in the first quarter of 2014. [company press release, Dec 2, 13]
BioDelivery Sciences submitted an application for a new drug to treat opioid dependence, something CEO Mark Sirgo called “another major milestone” for the company. .... BDSI financed development on its own. BDSI carries all the risk, but could also reap all the reward if the drug is successful. [Jason deBruyn, Triangle Business Journal, Aug 1, 13]
BioDelivery Sciences International borrowed $20 million to help it push through the final development stages before filing an application for a drug that could bring peak annual sales of $250 million. Called Bunavail, the drug under development would treat opioid dependence. [Lauren Ohnesorge, Triangle Business Journal, Jul 12, 13]
Drug developer BioDelivery Sciences (Raleigh, NC; $1.7M SBIR in NJ) said it is on track to file a New Drug Application (NDA) on a drug that it expects to have peak sales of $250 million. [Jason deBruyne, Triangle Business Journal, Jun 10, 13]
BioDelivery Sciences up 12% [Sep 6, 12]
BioDelivery Sciences (Raleigh, NC; $1.7M SBIR in New Jersey a decade ago) stock rose 12 percent after the company announced it had extended [for seven years] the patent protection for its experimental treatment for chronic pain and received a $15 million milestone payment from partner Endo Pharmaceuticals. [David Bracken, Raleigh News & Observer, Apr 18, 12]
BioDelivery Sciences International submitted a new drug application for Bunavail, a treatment for opioid dependence. The review by the U.S. Food and Drug Administration is expected to take 10 months. [D Bracken, Raleigh News & Obsever, Aug 1, 13]
BioDelivery Sciences down 59% [Sep 29, 11]by announcing its improvement over an existing drug doesn’t actually work. ... The company also says it’s not giving up on the drug. In fact, it plans to conduct another study in the near future [Brett Chase, minyanville.com, Sep 29]
Biodelivery Sciences up 15% [Dec 30, 10]
Biodelivery Sciences down 12% [Nov 10, 10]
BioDelivery Sciences down 14% [Apr 20, 10] after the company announced plans to raise $10 million through the sale of additional shares. [Triangle Business Journal, Apr 20]
BioDelivery Sciences up 13% [Sep 28, 09]
BioDelivery Sciences International (Newark, NJ; $1.7M SBIR) is shutting down its New Jersey laboratory and consolidating its operations in Raleigh, a move that will save nearly $1 million a year. ... [said] it no longer needs its Newark research facility now that the experimental drug Bioral Amphotericin B, an anti-fungal treatment, is in clinical trials. [David Ranii, Raleigh News & Observer, Sep 2, 09]
BioDelivery Sciences International (Raleigh, NC; $1.7M SBIR) finally won regulatory approval for their first product, an oral pain patch for cancer patients. ... will get millions in milestone payments from a Swedish partner, money it will use to develop other products. [Raleigh News & Observer, Jul 17, 09]
BioDelivery Sciences International(Raleigh, NC; $1.7M SBIR) is apparently on the verge of winning approval for its first drug, the culmination of a regulatory process that began more than 18 months ago. .... founded in 1997 in New Jersey. In 2004, it moved its headquarters to the Triangle shortly after it acquired Arius Pharmaceuticals, a Research Triangle Park startup. ... Shares have more than tripled since August. [Raleigh News & Observer, Jun 25, 09]
BioDelivery Sciences up 21% [Apr 21, 09]
BioDelivery Sciences down 12%% [Apr 3, 09]
BioDelivery Sciences up 10% [Mar 17, 09]
Biodelivery Sciences down 12% [Mar 2, 09]
Biodelivery Sciences up 13% [Dec 31, 08]
Biodelivery Sciences up 21% [Sep 19, 08]
BioDelivery Sciences International up 33% [Aug 29, 08]
Up 26%as U.S. regulators have laid the groundwork for approval of BioDelivery Sciences International’s first drug, the company said Thursday, though approval will take longer than the company would have liked. [Triangle Business Journal, Aug 28]
BioDelivery Sciences International up 17% [Jul 31, 08]
BioDelivery Science (Raleigh, NC; $1.5M SBIR) announced that its marketing partner has taken the first official step toward obtaining European Union approval of Bema Fentanyl, BioDelivery's experimental cancer pain drug. [Raleigh News&Observer, Apr, 3, 08]
BioDelivery Sciences up 24% [Dec 7, 07]
BioDelivery Sciences International lost 12% [Apr 18,07]
BioDelivery Sciences International up 21% [Feb 22, 07] despite no news.
BioDelivery Sciences Internationalrose 27% on report that the FDA approved human clinical testing of its Bioral drug delivery system.
Biodesix (Boulder, CO; no SBIR), a molecular diagnostics company, announced that [it] acquired Integrated Diagnostics (Seattle, WA; $1M SBIR) The agreement includes the XL2 test, Indi’s lead oncology product, which offers a noninvasive means of ruling out cancer for patients with suspicious lung nodules. Financial terms not disclosed. [Biodesix press release, Jul 9, 18]
Biodesix (Boulder, CO; no SBIR, founded 2005) said it's raised an additional $11 million ... developing cancer drugs, said that from 2013 through 2015, it's raised a total of $35 million. ... for "ongoing new product development and expansion of commercial efforts to support Biodesix’ commercialized products ... as well as new product launches in 2015–2016." [Ben Miller, Denver Business Journal, Jun 23, 15]
BioDirection (Boston, MA; no SBIR) raised $4 million to help commercialize a product called Tbit, a blood test meant to diagnose concussions and other brain injuries in less than 90 seconds. [Ben Fidler, xconomy.com, Feb 5, 16]
CytoBioscience (San Antonio, TX; $200K SBIR) acquired BioDtech (Birmingham, AL; $600K SBIR, founded 2003) [W. Scott Bailey, San Antonio Business Journal, Nov 28, 18] BioDtech develops technologically advanced products geared toward the endotoxin market [company web site]
BioE (Vadnais Heights, MN; no SBIR) is being sued on behalf of More than 470 angel investors, the majority of them from Minnesota, invested more than $30 million in the company. ... The suit alleges that a "fraudulent" financing maneuver left the investors empty-handed and seeks class action status on behalf of "hundreds" of investors. [Janet Moore, Minneapolis Star Tribune, Feb 7, 11]
Moving for Subsidy. Lured by the state's tax credits for investments in high-growth companies, a biotech start-up said it was moving to Wisconsin. VitalMedix (Minneapolis, MN; no SBIR) is developing a drug that first responders, trauma center surgeons and military medics could use. The drug, Tamiasyn, has the potential to allow humans to endure severe blood loss and inhibit organ damage during resuscitation. .... Minnesota legislators tried to create a similar program but failed. .... The credits had lured another biotech company. Rapid Diagnostek (no SBIR) moved to Hudson last year from St. Paul to take advantage of the credits. The top executive at BioE (no apparent SBIR) a Twin Cities tech company, praised Wisconsin's embrace of tech companies and didn't rule out a move. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 10, 09]
BioE (Vadnais Heights, MN; no SBIR) said it has won clearance from federal regulators to sell its signature product, a system that processes umbilical cord blood for use in treating a variety of diseases. ... the privately held company, which has been working with the [FDA] for more than seven years so it could sell the system in the USA. [Minneapolis Star Tribune, Jan 14, 09]
The Department of Energy has awarded $53 million [of SBIR] to multiple small businesses to develop clean energy materials and systems in support of the Biden administration’s net-zero emission goals. Proposals include a lithium-ion electric vehicle battery from Bioenno Tech (Santa Ana, CA; $4M prior SBIR), a bio-based composite material from Z&STech (no apparent SBIR) and a direct air capture system from Advanced Cooling Technologies (Lancaster, PA; $80M prior SBIR; competitor in same city,Thermacore; $32M prior SBIR). ... Charles River Analytics (Cambridge, MA; $270M SBIR) proposed a method to detect an attack on critical infrastructure assets such as power grid, while Cornerstone Research Group (Miamisburg, OH; $127M prior SBIR) offered a predictive health monitoring tool to maintain electric grid systems. [Mary-Louise Hoffman, govconwire.com, May 19, 2022] prior SBIR data from SBA
BioExcel Therapeutics (Branford, CT; no SBIR) up 18% [Nov 15, 19]
BioFactura (Frederick, MD; $3M SBIR, founded 2001) announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox. [company press release, Sep 26, 19] prior funding $8M [crunchbase.com]
BioFactura (Frederick, MD; $3.2M SBIR, founded 2001) develops and manufactures high-value biosimilars, raised $6 million Series B round [crunchbase.com, Apr 29, 19]
A race to detect Ebola:
BioFluidica (Chapel Hill, NC; $200K SBIR in Louisana) , a specialty health care company with roots in UNC-Chapel Hill, raised $2 million, closing the company’s first round of private funding. [Jason deBruyn, Triangle Business Journal, Jun 8, 16] BioFluidica's platform to analyze Circulating Tumor Cells, CTC's, consists of simple instrumentation that works in conjunction with a disposable, test-specific cartridge, approximately the size of a standard credit card. [company website]
Biogenic Reagents (Minneapolis, MN; no SBIR) closed on $9.5 million in financing that it will put toward expanding a carbon-products plant in Marquette, Mich. ... uses biomass to make activated carbon products .... opened a $30 million plant in Michigan ... to make carbon products for controlling mercury emissions at power plants [Katherine Grayson, Minneapolis / St Paul Business Journal, Aug 1, 13]
Biogenic Reagents (Marquette, MI; no SBIR), a clean-tech startup that uses biomass to make carbon products, has opened a $30 million production plant in Marquette ... has raised about $9.47 million in capital over the past two years, [Katharine Grayson, Minneapolis / St Paul Business Journal, Nov 12, 12]
BioGreenChoice (Centerville, OH, no SBIR) an environmentally-friendly food packaging products company plans to grow its Dayton-area operations through a $2.5 million private offering. [Joe Cogliano, Dayton Business Journal, Apr 12, 13]
Bioheart (Sunrise, FL; no SBIR) that has tried to sell shares for more than four months made a surprise debut on the Nasdaq .. raised $5.8M by selling 1.1 million shares for $5.25 a share -- far below the $57M it had hoped to raise by selling 3.6 million shares [Wall Street Journal, Feb 20, 08]
Biohaven Pharmaceutial (New Haven, CT; no SBIR) reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo for the treatment of patients with Generalized Anxiety Disorder (GAD). ... Biohaven has a deep and broad portfolio of assets in development with five ongoing Phase 3 trials across it its calcitonin gene-related peptide (CGRP) antagonists, glutamate modulators and myeloperoxidase inhibitor platforms. [company press release, Feb 10, 20]
Ovid Therapeutics (New York, NY; no SBIR) raised $75 million in an IPO, continuing a recent flurry of biotech offerings—among them BioHaven Pharmaceuticals (New Haven, CT; no SBIR) and UroGene Pharma (New York, NY; no SBIR) —that have all met or exceeded their share price projections. [Ben Fidler, xconomy.com, May 5, 17]
Bioheart and Elixir Biopharm going public this week. Neither used SBIR. [Jan 08]
Bioheart(Sunrise FL: no SBIR) an“adult” stem-cell company has slashed its IPO price range — essentially halving the company’s expected market value. David Hamilton, over at VentureBeat Life Sciences, says: "I told you so: Eat your Bioheart out." The company's treatment is supposed to reverse damage caused by heart attacks. However, none of Bioheart’s data so far seems to suggest the treat does what it is supposed to do, and the company can’t even offer a plausible theory as to why it should work. [Matt Marshall, Venture Beat, Oct 12] The company's website says Our lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from the patient’s body, for the purpose of improving cardiac function in chronic heart failure patients. The core technology used in MyoCell has been the subject of human clinical trials conducted over the last six years involving 84 enrollees and 70 treated patients In 2007 it reported Although not statistically significant due, in part, to the limited number of patients treated, the lead investigator indicated in his presentation that the safety of MyoCell is strongly suggested and the preliminary efficacy data demonstrates a trend towards an improvement in scores for six-minute walk distance, or Six-Minute Walk Distance, and an improvement in quality of life, or Quality of Life. If Hamilton's criticism is true, or even just credible, both the FDA and all but the most dreamy-eyed IPO investors should be able to see the problem. It does have a large and varied Scientific Advisory Board and several VCs on its board of directors.
A spinoff of New England BioLabs (Beverly, MA; $5M SBIR) Biohelix (Beverly, MA; also $5M SBIR) is leaving the nest and establishing its own headquarters after five years under its parent’s wing. ... developing diagnostics for infectious and sexually transmitted diseases. [Mass High Tech, Aug 28, 09]
Bio-Imaging Technologies said it is selling its CapMed Division to Metavante Technologies (no SBIR) for $500,000 plus future payments over a two-year period. [Philadelphia Business Journal, Jan 7, 09]
Bioincept (Cherry Hill,NJ; no SBIR) raised $1.34 million in a private stock sale this week, according to [SEC] documents ....which develops technologies related to animal and human diagnostic and therapeutic products, raised $1.8 million toward that goal in a stock sale completed in August. [John George, Philadelphia Business Journal, Apr 29, 14]
Bioincept (Cherry Hill, NJ; no SBIR) biotechnology company, raised $1.8 million in a private stock sale...... develops technologies related to animal and human diagnostic and therapeutic products, is seeking to raise a total of $6.5 million [John George, Philadephia Business Journal, Aug 27, 13]
Biointervene (San Diego, CA; no SBIR) announded Series A $30M financing [to] guide its lead compound, BIO-205, into human testing for neuropathic pain. [Sarah de Crescenzo, xconomy.com, Jan 7, 19]
BioIQ (Atlanta, GA; no SBIR) a healthcare engagement and clinical adherence technology platform company, announced today availability of the first home test for COVID-19 that combines COVID-19, Flu A / Flu B, and a 21 Test Respiratory Panel from a single saliva sample. Partnering with P23 Labs, one of the first laboratories to receive Emergency Use Authorization (EUA) from the [FDA] for home saliva collection for COVID-19, the availability of this home test signifies a major step forward in the next phase to combat COVID-19. [company press release, Jun 15, 20]
Five-year-old BioKier (Chapel Hill, NC; no SBIR) has three employees and is five years away from commercial viability, Nolan said. The company has raised more than $3 million and is conducting small clinical trials in Greenville and at the Mayo Clinic in Minnesota. .... developing a pill to trick the body into thinking it has undergone bariatric surgery, commonly known as stomach stapling. [John Murawski, Raleigh News & Observer, Feb 26, 14]
Biolex Therapeutics (Pittsboro, NC; no SBIR) has withdrawn its IPO plans. [Raleigh News&Observer, Feb 4, 08]
Biolex Therapeutics (Pittsboro, NC; no SBIR) with plans for a Wall Street debut could soon face financial straits that would force it to slash spending or look for other sources of cash. Biolex and its Dutch partner, OctoPlus, planned to raise money from public and private investors to pay for operations and to continue testing of Locteron, the Hepatitis C treatment the two companies are working on. [Sabine Vollmer, Raleigh News& Observer, Dec 13, 07]
The hosiery mill is gone now, along with much of the Carolina textile industry ... But the old brick building ... is occupied by a biotechnology company, Biolex Therapeutics (no SBIR) ... the retooling of this old brick building on Credle Street underscores how, despite its oft-pronounced demise, American manufacturing is in many regards stronger than ever. ... The United States makes more manufactured goods today than at any time in history, as measured by the dollar value of production adjusted for inflation -- three times as much as in the mid-1950s, the supposed heyday of American industry.. [Peter Goodman, Washington Post, Sep 3]
Biotech 3D printing startup BioLife4D (Buffalo Grove, IL; no SBIR) announced it has successfully demonstrated its ability to 3D bioprint human cardiac tissue – specifically, a human cardiac patch. ... has raised more than $1 million selling public securities [company press release, Jun 25, 18] currently looking to raise $50 million. [3dprinting.com, Feb 2, 18]
BioLife Solutions (Owego, NY; $1.3M SBIR) up 43% [Nov 10, 2022] reported Record revenue of $40.7 million increased 21% over Q3 2021 [company press release, Nov 10, 2022]
BioLife Solutions (Bothell, WA; $1M SBIR) down 23% [Mar 20, 20]
BioLife Solutions down 17% [Nov 12, 18]
BioLife Solutions down 16% [Oct 3, 18]
Biolife Solutions up 14% [Sep 7, 18]
BioLife Solutions up 16% [Aug 21, 18]
Biolife Solutions up 10% [Jul 13, 18]
Biolife Solutions up 10% [Jul 12, 18]
Biolife Solutions up 11% [Jul 3, 18]
BioLife Solutions (Bothell, WA; $1.3M SBIR) up 31% [Jul 2, 18] the leading developer, manufacturer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, 103% increase from the second quarter of 2017 [company press release, Jul 2, 18]
BioLife Solutions (Bothell,WA; $1M SBIR) up 15% [Nov 10, 17] announced quarterly earnings
BioLife Solutions (Bothell, WA; $1.1M SBIR in New York state, 36 employees) down 13% [Oct 25, 17]
Pharmaceutical developer BioLink Life Sciences (Cary, NC; $200K SBIR) was awarded three patents for four novel drugs for the treatment of epilepsy, bipolar disorder and migraine headaches. [Raleigh News & Observer, Sep 24, 08]
Biolinq (San Diego, CA; $2.2M SBIR) announced securing a hefty $100 million in investor support to kick-start the development of its wearable, noninvasive glucose sensor patch. [Conor Hale, Fierce Biotech, Nov 2, 2021]
Biolinq (San Diego, CA; no SBIR) tacked on an extra $4.75 million to the total of its series A round to help fund additional clinical trials and development of its coin-sized sensor patch for monitoring blood glucose levels and other biomarkers. [Conor Hale, Fierce Biotech, Apr 1, 19]
Biolinq (formerly Electrozyme, San Diego, CA (formerly Electrozyme, San Diego, CA; no SBIR, founded 2012, seven employees), a start-up that’s developing pain-free blood glucose sensors, said it has raised $10 million in venture capital led by M Ventures and Hikma Ventures.The money will help launch clinical studies required to get Biolinq’s sensor technology approved by the U.S. Food and Drug Administration, said Chief Executive Jared Tangney. .... “Our first product is not just another continuous glucose monitoring technology, but a platform we built from the ground up with a focus on the end user,” said Tangney [Bradley Fikes, San Diego Union Tribune, Nov 20, 17]
Biologics (Cary, NC; no SBIR) announced that the company has entered into a definitive agreement to be acquired by McKesson Specialty Health, a business unit of the McKesson Corporation. Biologics, an oncology pharmacy services, offers specialty pharmacy and patient support services specifically in the areas of oncology and other complex therapeutic categories. [company press release, Feb 25, 16] Biologics has grown substantially in the past half decade, from 68 employees in 2010 to 362 now [Triangle Business Journal, Feb 26]
Private investment continues to boost young Triangle companies. Biologics (Raleigh NC; no SBIR) oncology pharmacy, $20M; . Aldagen (Durham NC; no SBIR) biotech company, $9 M; HyperBranch Medical Technologies (Durham NC; one SBIR) medical device startup, $1.5M. [Sabine Vollmer, Raleigh News & Observer, Sep 15] Those who can, do; those who can't or won't depend on government handouts.
BioMagnetic Solutions, (State College PA; no SBIR, founded 2011) entered the circulating tumor cells (CTC) world with a system that will be able to detect and capture circulating tumor cells (CTC) and cancer stem cells significantly earlier than current technology. “This novel system offers the potential to isolate cancer stem cells and T-cells that can be engineered to use the body’s own immune system to attack cancers at an earlier stage and eliminate them” – Ted Liberti, COO & VP Business Development BioMagnetic Solutions plans to develop a CTC prototype system and have sufficient data to show potential partners within the next six months. Minimal initial investment will be required as the company plans to adopt a corporate partnering strategy to finance growth. Ben Franklin Technology Partners of Central & Northern Pennsylvania, www.cnp.benfranklin.org was an initial seed investor and funded the company’s startup activities in the amount of $275,000 in 2013/2014. [http://cnp.benfranklin.org]
BioMarck Pharmaceuticals (Durham, NC; $3M SBIR), which is working on new medicines for pulmonary diseases, has received $6.3 million from investors to complete a clinical trial of an experimental treatment for chronic obstructive pulmonary disease. Portions of a $3 million [NIH SBIR] grant is also helping to finance the trial. ... a spinoff of N.C. State University, is developing an experimental treatment that promises to control the mucus buildup and inflammation that accompany respiratory diseases such as COPD, asthma, chronic bronchitis and cystic fibrosis. If the drug receives regulatory approval, BioMarck plans to market it with the help of a large pharmaceutical partner. [Sabine Vollmer, Raleigh News & Observer, Apr 20, 09]
The FDA approved BioMarin Pharmaceutical (San Rafael, CA: $300K SBIR)’s triangle gene therapy Roctavian for hemophilia A, marking an impressive streak for an industry that is still in its infancy and has faced numerous struggles, from safety concerns to manufacturing hurdles. It would also be a relief for BioMarin and its investors, who have waited nearly three years since the FDA rejected the drug in August 2020, citing the need for longer-term data. [David Wainer, Wall Street Journal, Jun 29, 2023]
Biomarin Pharma (San Rafael, CA; $300K SBIR) down 41% [Aug 19, 20] after U.S. regulators rejected the company’s potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime treatment. The [FDA] rejection means the company will have to complete an ongoing late-stage patient study, likely delaying possible approval till late in 2022. [LINDA A. JOHNSON, AP, Aug 19, 20]
Four years after BioMarin’s vosoritide posted proof-of-concept data, the drug hit the mark in phase 3, helping children with achondroplasia, the most common form of dwarfism, grow more quickly than those on placebo. [Amirah Al Idrus, Fierce Biotech, Dec 16, 19]
BioMarin Pharmaceutical will file for US and Europe approvals of its hemophilia A gene therapy, known in shorthand as valrox, by the end of the year. [Alex Lash, xconomy.com, Jul 12, 19]
BioMarin Pharmaceutical (San Rafael, CA; $300K SBIR) included in FDA naming and shaming list of makers of brand-name drugs that have been the target of complaints [of] fight for patent extensions, seek new uses for old products and, sometimes, prevent generic drug companies from obtaining samples. [Sheila Kaplan, New York Times, May 17, 18] Apparently completely legal under US patent laws.
Spark Thera down 35% [Dec 11, 17] after the company reported data from trials of a hemophilia treatment that analysts said look less competitive than a rival product from BioMarin Pharmaceutical [MarketWatch, Dec 11, 17]
BioMarin Pharmaceutical notched FDA approval for cerliponase alfa (Brineura), the first drug ever to treat the rare genetic Batten disease. BioMarin announced an annual list price of $702,000. [Alex Lash, xconomy.com, Apr 28, 17]
Rare-disease drug developer BioMarin Pharmaceutical (San Rafael, CA; $300K SBIR) sues to stop generic version of its $90K-a-year drug ... sued an Indian drug maker that plans to make and sell a version of one of BioMarin's top-selling drugs. [Ron Leuty, San Francisco Business Times, Feb 6, 17]
BioMarin Pharmaceutical killed development of an experimental treatment for a rare muscle-weakening disease and a trio of potential follow-on drugs, the company said, dealing a blow to patients and advocates pressing for FDA approval of a therapy. .... faced regulatory roadblocks in its attempts to win approval for its drug, called drisapersen or Kyndrisa, in the United States and Europe as a treatment for some patients with Duchenne muscular dystrophy. .... landed drisapersen in its $680 million acquisition of Prosensa Holding NV. Unlike previous BioMarin deals, it didn't hedge its bet, though, paying the money upfront and promising $80 million if the drug was approved in the United States and another $80 million if it won approval in Europe. [Ron Leuty, San Francisco Business Times, May 31, 16]
Wall Street cheered promising data released Wednesday by BioMarin (Novato, CA; $300K SBIR) for a small and early stage clinical trial that tested the hemophilia therapy BMN 270. [Johanna Bennett, Barron's, Apr 20, 16]
BioMarin Pharmaceutical said the FDA had rejected its new drug application for a treatment of a fatal form of muscular dystrophy because of questions about the drug’s effectiveness. [Wall Street Journal, Jan 15, 16]
[FDA] pushed back its deadline to decide on drug developer BioMarin Pharmaceutical ($300K SBIR) lead drug, not rejecting it outright, making shareholders optimistic. [Vidya L Nathan, Reuters, Dec 18, 21]
[FDA] staff reviewers said clinical data to date did not merit approving BioMarin Pharmaceutical muscle-wasting disorder drug.
A cancer-fighting drug that BioMarin Pharmaceutical (Novato, CA; $300K SBIR) picked up in a $97 million acquisition five years ago is at the center of a potential $570 million deal with fellow Bay Area drug developer Medivation (San Francisco CA; no SBIR). The late-stage drug — dubbed talazoparib, or BMN-673 — is a so-called PARP inhibitor, a class of drugs that block enzymes, which cancer cells use to repair themselves after chemotherapy or other stresses. ... BioMarin landed talazoparib with its 2010 acquisition of LEAD Therapeutics (San Bruno, CA; no SBIR). The San Rafael company has since taken the drug into a Phase III trial against advanced breast cancer, but it also has investigated the drug across multiple tumor types, including ovarian cancer. [Ron Leuty,San Francisco Business Times, Aug 25, 15]
BioMarin Pharma (Novato, CA; $300K SBIR) up 12% [Jun 18, 15]
BioMarin Pharma up 11% [Mar 27,15]
BioMarin Pharmaceutical (San Rafael CA; $300K SBIR 1998-2001) said it agreed to pay up to $840 million to buy Dutch company Prosensa Holding NV, a biopharmaceutical company that currently has no market products. The deal represents a bet that Prosensa will get regulatory approval for a muscular dystrophy drug. .... The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to it. [Wall Street Journal, Nov 24, 14]
BioMarin Pharmaceutical (San Rafael, CA; $300K SBIR) is facing a [unidentified] generic challenger [to FDA] to its rare disease drug Kuvan, which since its approval seven years ago has rung up sales of more than $700 million. ... is developing a next-generation PKU treatment, called BMN-165, that targets those patients who don't respond to Kuvan. The drug is in the final stage of the human clinical trial process, with data expected to read out in fourth-quarter 2015. [Ron Leuty, San Francisco Business Times, Sep 25, 14]
Competing for growers. Already home to a trio of orphan drug developers — including BioMarin Pharmaceutical, the Buck Institute for Aging Research and a Genentech Inc. biologic drug-making facility — the North Bay is hoping to nab early-stage and growing life sciences companies looking for room to grow. Led by Novato city government’s economic development but gathering a handful of players across Marin, Sonoma, Napa and Solano counties, the North Bay Life Science Alliance was formally unveiled [Ron Leuty, San Francisco Business Times, Jun 25]
European regulators approved a BioMarin Pharmaceutical (Novato, CA; $300K SBIR) treatment for Mucopolysaccharidosis type IVA, or Morquio A syndrome [a disorder caused by a defective enzyme] .... BioMarin's CEO said 85 percent of Morquio A patients live outside the United States, so this approval is "a key milestone" for the company. [Steven E.F. Brown, San Francisco Business Times, Apr 28, 14]
Inside its
latest rare-drug
approval, BioMarin
Pharmaceutical (San Rafael, CA; $300K SBIR) unwrapped a valuable thank you
note: a
voucher it can use to accelerate the Food and Drug Administration's
review process on any future drug. [Ron Leuty, San
Francisco
Business Times, Feb 21, 14]
BioMarin Pharmaceutical (San Rafael, CA; $300K SBIR) orphan drug specialist will spend $2 million upfront — with the potential to pay $160 million in milestones — to Repligen ($1.7M SBIR) for a portfolio of experimental neurological drugs. [Ron Leuty, San Francisco Business Times, Jan 21, 14]
BioMarin Pharmaceutical (San Rafael, CA: $300K SBIR) and Myriad Genetics will work together to identify tumor types that could respond to BioMarin's experimental cancer drug. .... BioMarin whose rare disease drug Vimizim won a positive recommendation Tuesday from a Food and Drug Administration advisory panel, will use Myriad's homologous recombination deficiency test with the BioMarin drug BMN-673. [Ron Leuty, San Francisco Business Times, Nov 20, 13]
BioMarin (Novato, CA: $300K SBIR) bought Zacharon Pharmaceuticals (San Diego, CA; $2.7M SBIR) for $10 million. [Stephen EF Brown, San Francisco Business Times, Jan 7, 13]
BioMarin Pharma said it has purchased San Diego-based Zacharon Pharmaceuticals (San Diego, CA; $2.4M SBIR), which is developing drugs for Tay-Sachs and other diseases. ... paid $10 million up-front for Zacharon, and may make additional payments if the biotech company's drugs make clinical, regulatory and commercial milestones. BioMarin ranks as one of the country's most highly valued biotech companies, with a market value of more than $6.5 billion. [Bradley Fikes, utsandiego.com, Jan 7,13]
BioMarin Pharmaceutical started a late-stage trial of an experimental drug to treat a rare autoimmune disease called Lambert-Eaton Myasthenic Syndrome, or LEMS. [Ron Leuty, San Francisco Business Times, Jun 7, 11]
BioMarin (Novato, CA; $300K SBIR) will buy ZyStor Therapeutics (Milwaukee, WI; no SBIR) and a possible treatment for a rare degenerative muscle disease in a deal that could be worth up to $115 million. It is the fourth major deal in less than a year for Novato [Ron Leuty, San Francisco Business Times, Aug 20, 10]
Zystor Therapeutics (Wauwatosa. WI; no SBIR) has been acquired by BioMarin Pharmaceutical (Novato, CA; $300K SBIR), a deal that could attract investors for other Midwestern companies and venture funds. ... agreed to pay $22 million initially for privately held Zystor, based in Wauwatosa. BioMarin will pay as much as $93 million more if certain development, regulatory and commercial milestones are achieved, the company said. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 17, 10]
BioMarin Pharmaceutical (Novato, CA; $200K SBIR) agreed to buy Lead Therapeutics (San Bruno, CA; no SBIR) which has a cancer drug in early development, for $18 million. [SEF Brown, San Francisco Business Times, Feb 4, 10]
Biomarin Pharma up 11% [Jul 31,09]
BioMarin Pharma up 12% [Feb 24, 09]
BioMarin Pharma down 32% [Feb 19, 09]
BioMarin Pharma down 10% [Jan 20, 09]
BioMarin Pharma down 14% [Dec 1, 08] On a stock bloodbath day
Biomarin Pharma down 13% [Oct 27, 08]
BioMarin Pharma down 12% [Oct 23, 08]
BioMarin Pharma up 14% [Oct 13, 08]
Biomarin Pharma down 12% [Oct 10, 08]
Biomarin Pharma down 12% [Jun 23, 08]
BioMarin Pharmaceutical up 22% [Dec 14, 07] on news that the government approved its Kuvan treatment for use in slowing progression of an inherited disease called phenylketonuria. ... expects $35 -$70 M in revenue in 2008 from Kuvan
bioMASON (Raleigh, NC; no SBIR, founded 2012) backers are betting $1.5 million in new equity capital that it will prove profitable. She’s developed what she calls a natural chemical process to create cement-based building materials using bacteria. ... has partnerships in place with multiple brick manufacturers for the technology, but can’t be specific due to non-disclosure agreements [Lauren K. Ohnesorge, Triangle Business Journal, Dec 23, 15]
Biomerica up 18% [Sep 4, 20]
Exact Sciences (Madison, WI; no SBIR) announced the acquisition of Biomatrica (San Diego, CA; $1.4M SBIR) , a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. ... Exact Sciences intends to use Biomatrica's proprietary technology to support ongoing and future development of its own blood-based cancer detection tests. [Exact press release,, Oct 18, 18]
Biomatrica (San Diego, CA; one SBIR), a 22-person biotech that has begun to revolutionize a $63 billion industry: the storage and transportation of the world’s biological specimens, from DNA to blood. ... By mimicking nature with synthetic chemistry, Biomatrica can now store plastic file cases of DNA at room temperature like DVDs in an entertainment cabinet. And reactivate the samples with water, at will. [Steve Chapple, signonsandiego, Dec 4, 11]
BiomeSense (Chicago, IL; $500K SBIR) biotech company, closed a $3M funding round with participation from both existing and new investors. The oversubscribed funding round will help with the company's commercial launch, which is expected to happen within the year, according to CEO Kevin Honaker. [Chicago Inno, May 12, 2023]BioMedical Enterprises (San Antonio, TX; $400K SBIR) maker of nickel-titanium [shape-memory alloy Nitinol] implants used to help small bones heal, has been acquired by a DePuy Synthes, a group of medical device companies owned by Johnson & Johnson. Terms were not disclosed. [David Holley, xconomy.com, May 11, 16]
BioMedical
Enterprises
(San Antonio, TX; $500K SBIR)
unveiled a new product that should help more orthopedic surgeons fix
patients’ bones via implants. ... called the Speed Titan
Nitinol
Bone Fixation Implant and it is the latest device within BioMedical
Enterprises’ Speed Fixation System. had been in use by
orthopedic
surgeon on foot procedures for the past several months. However, the
product is now available for commercial use in the US.
[James Aldridge, San Antonio Business Journal, Apr 2, 15]
BioMedical Enterprises (San Antonio, TX; $1.9M SBIR), a pioneer in shape memory technology for small-bone fixation, is now rolling out its Speed Shift Continuous Active Compression System technology nationally. ... a unique, super-elastic nitinol bone fixation device with an offset bridge to accommodate uneven bone surfaces. The device provides foot and ankle surgeons with intraoperative options for reconstruction of flatfoot and high arch conditions. [W. Scott Bailey, San Antonio Business Journal, Apr 28, 14]
Biomedical Enterprises (San Antonio, TX; $500K SBIR) manufactures and markets metal implants used in orthopaedic reconstructive surgery and fracture management .... CEO, Keith Peeples, says BME has grown its revenues by more than $15 million over the last four years and is on pace to see a 20 percent gain in 2014. ... Last month, BME filed a lawsuit in the United States District Court for the Western District of Texas against Memphis-based Solana Surgical LLC. BME alleges that Solana has infringed on one of its patents [W. Scott Bailey, San Antonio Business Journal , Feb 10, 14]
BioMedical Enterprises (San Antonio, TX; $600K SBIR) leader in orthopedic shape memory implants, announced that it filed a patent infringement lawsuit on January 30, 2014 in the United States District Court against Solana Surgical (Memphis, TN; no SBIR) BME’s orthopedic shape memory implants are fabricated from Nitinol, a nickel-titanium alloy, and change shape when exposed to predetermined temperatures to provide fixation of bone or soft tissue to bone. [company press release, Jan 30, 14]
BioMedical Enterprises (San Antonio, TX; $500K SBIR in the 1990s) received FDA clearance for an upgrade to its patent-pending HammerLock Nitinol Intramedullary Fixation System [W. Scott Bailey, San Antonio Business Journal, Nov 27, 13] ..... leader in orthopedic shape memory implant technology, [ the only Nitinol small bone fixation manufacturer in the U.S] announces the nationwide launch of the HammerLock™ Intramedullary Nitinol Fixation System for use in the correction of hammertoes. [company press release, Oct 18, 13]
Medical device company BioMedical Enterprises(San Antonio, TX, $0.5M SBIR). said that the company has launched a new implant on the market that is designed to approximate soft tissue that is anchored to bone. [San Antonio Business Journal, Jun 2]
Med-tech firm BioMedix (St Paul, MN; no SBIR, founded 1997) has cut its staff by 90 percent over the past year and sold off a software division in an effort to stay afloat. [Mark Reilly, Minneapolis / St Paul Business Journal, Apr 22, 13] a leader in Health Information Technology designed to optimize practice and disease management while growing and supporting collaborative care networks ... Named One of the 100 Best Companies to Work For in 2012 [company website]
Biomedical Structures (Warwick, RI; no SBIR) said it has received an equity financing ... founded in 2003, supplies custom-designed biomaterials and textiles to medical device manufacturers for applications such as orthopedics, reconstructive surgery and tissue engineering. [Mass High Tech, May 24, 10]
Biomeme (Philadelphia, PA; no SBIR) announced it's working on a multimillion dollar contract with the U.S. government. ... co-founder van Westrienen declined to elaborate further citing the deal's negotiations ... has developed technology that turns a smartphone into a low-cost lab [Dan Norton, Philadelphia Business Journal, May 11, 16]
Biomeme (Philadelphia, PA; no SBIR) that has developed technology to turn smartphones into low-cost diagnostic labs, raised almost $1 million in a debt financing. ..... among the 10 companies that last year participated in the DreamIt Health accelerator program in Philadelphia. [John George, Philadelphia Business Journal, Jan 30, 14]
Biomerica up 38% [Oct 1, 21] announced that it has entered into a General Merchandise Supplier Agreement with Walmart for the sale of the Company's EZ Detect(TM) colorectal disease screening test within the Walmart retail system. [company press release, Oct 1, 21]
Biomerica (Irvine, CA; no SBIR) up 27% [Jan 12, 21] announced it has received CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 infection. The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. [company press release, Jan 12, 21]
Biomerica down 20% [Oct 16, 20]
Biomerica down 24% [Jul 21, 20]
BioMerica up 18% [Jul 16, 20]
Biomerica up 21% [Jun 22, 20]
Biomerica up 19% [Jun 9, 20]
Biomerica up 22% [Apr 13, 20]
BioAmerica down 17% [Mar 24, 20] on plus 11% market day
Biomerica up 23% [Mar 23, 20]
Biomerica down 55% [Mar 20, 20]
Biomerica up 55% [Mar 19, 20]
Biomerica (Irvine, CA; no SBIR) up 335% [Mar 18, 20] announced it has commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere, e.g. airports, schools, work [company press release, Mar 18, 20]
BiomeSense (Chicago, IL; $500K SBIR) biotech company, closed a $3M funding round with participation from both existing and new investors. The oversubscribed funding round will help with the company's commercial launch, which is expected to happen within the year, according to CEO Kevin Honaker. [Chicago Inno, May 12, 2023]
Biometric Signature ID (Dallas, TX; no SBIR) won $550,000 from the Texas Emerging Technology Fund [Austin American Statesman, Feb 10, 11]
BioMimetic Thera up 74% [Nov 19, 12] Local medical device manufacturer Wright Medical Group will purchase Nashville-based BioMimetic Therapeutics in a deal worth up to $380 million, the companies announced. [Cole Epley, Memphis Business Journal, Nov 19]
BioMimetic Thera up 11% [Oct 27, 11]
BioMimetic Thera up 121% [Jul 12, 11]
BioMimetic Thera down 12% [May 13, 11]
BioMimetic Therapeutics up 21% after company announced positive results from a late-stage trial comparing its synthetic bone growth product to a procedure typically used in foot and ankle fusion surgery [Wall Street Journal, Oct 15, 09]
Biomimetic Thera up 12% [Oct 6, 09]
BioMimetic Thera down 10% [Jun 29, 09]
Confidence. A director ofBioMimetic Thera bought $8M worth of shares. [Wall Street Journal, Apr 11, 09]
BioMimetic up 10% [Apr 8, 09]
BioMimetic Thera up 11% [Mar 3, 09]
BioMimetic up 11% [Feb 26, 09]
BioMimetic Thera up 10% [Jan 15, 09]
Biomimetic Thera down 10% [Jan 9, 09]
BioMimetic Tech up 25% [Nov 24,08]
Biomimetic Thera up 13% [Nov 13, 08]
Biomimetic Thera up 10% [Nov 4,08]
Biomimetic Thera up 12% [Oct 31, 08] and up 50% for the week.
Biomimetic Thera up 15% [Oct 30, 08]
Biomimetic Thera down 18% [Oct 15, 08]
BioMimetic Therapeutics down 10% [Oct 6, 08]
Biomimetic Thera down 14% [Oct 9, 08]
BioMimetic Therapeutics up 12% [Apr 3, 08]
BioMimetic Therapeutics up 30% [Mar 28, 08] as Wall Street brushed off anxiety over Food and Drug Administration concerns linking a competitor's diabetic foot ulcer treatment to higher cancer risk. [AP]
BioMimetic Therapeutics down 56% [Mar 27, 08]
BioMimetic Therapeutics up 11 % after announcing a 30% earnings increase in the fourth quarter >
BioMimetic Therapeutics announced a 30% earnings increase in the fourth quarter over a year ago ... "This past year has been an extraordinary one for BioMimetic; we advanced our lead orthopedic product candidate into pivotal clinical trials in the U.S., EU and Canada while efficiently raising capital, giving us nearly $100 million in cash," says Dr. Samuel Lynch, president and CEO [Nashville Business Journal, Mar 20, 08] but still fell 11%.
BioMimetic
Therapeutics
up
10%
after the company said its
system for fusing damaged bones had a 90% success rate
Japan’s biggest pharmaceutical company plans to invest $25 million in BioMotiv, a Shaker Heights company that aims to commercialize all sorts of new drugs. The five-year investment gives Takeda Pharmaceutical Co. the right to make the first offer on any therapies BioMotiv (Shaker Heights, OH; no SBIR) develops related to heart disease, diabetes and other so-called cardiometabolic conditions, as well as any disease involving inflammation and the immune system. ... BioMotiv is the for-profit arm of the Harrington Project for Discovery and Development. Launched by University Hospitals in 2012, the project includes a nonprofit branch that gives grants to scientists in the early stages of developing new drugs. [CHUCK SODER, Crain’s Cleveland Business, Sep 24, 14]
Bionano Genomics (San Diego, CA; $4M SBIR) up 19% [Mar 5, 19], a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announced the publication of the largest study of human genomes on its platform to date. [company press release, Mar 5, 19]
Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive. .... Genome sequencers from Illumina took second and third place [Bradley Fikes, utsandiego.com, Dec 1, 14] Other winners: BioNano Genomics, RainDance Technologies (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape. [The Scientist, Dec 1, 14]
Four months after relocating to San Diego from Philadelphia, BioNanomatrix ($3M SBIR) changed its name to BBioNano Genomics. ... as it prepares to begin selling its first commercial product, the nanoAnalyzer System. ... technology revolves around a silicon chip that contains enough microscopic channels to hold an entire, stretched-out length of a human DNA strand. [Keith Darce, signonsandiego.com, Oct 12, 11]
BioNano Genomics (San Diego, CA; no SBIR, founded 2003) maker of a genome mapping instrument, has raised $53 million. ... The company’s Irys System goes beyond the genomic DNA sequence to describe the location and order of functional components and other structural variations. Differences in the arrangement of these components have been linked to cancer and other diseases. ... founded by Han Cao, chief scientific officer, as a spinoff from Princeton University. [Bradley Fikes, utsandiego, Nov 19, 14]
Four months after relocating to San Diego from Philadelphia, BioNanomatrix ($3M SBIR) changed its name to BBioNano Genomics. ... as it prepares to begin selling its first commercial product, the nanoAnalyzer System. ... technology revolves around a silicon chip that contains enough microscopic channels to hold an entire, stretched-out length of a human DNA strand. [Keith Darce, signonsandiego.com, Oct 12, 11]
Four months after relocating to San Diego from Philadelphia, BioNanomatrix ($3M SBIR) changed its name to BioNano Genomics. ... as it prepares to begin selling its first commercial product, the nanoAnalyzer System. ... technology revolves around a silicon chip that contains enough microscopic channels to hold an entire, stretched-out length of a human DNA strand. [Keith Darce, signonsandiego.com, Oct 12, 11]
In the corner of the small lab is a locked door with a colorful sign taped to the front: "$100 Genome Room--Authorized Persons Only." BioNanomatrix (Philadelphia, PA $800K SBIR), the startup that runs the lab, is pursuing what many believe to be the key to personalized medicine: sequencing technology so fast and cheap that an entire human genome can be read in eight hours for $100 or less. [Lauren Gravitz, MIT Tech Review, M/A09] One of MIT's nominees for hot technologies of 2009.
Techne will pay $104 million to buy Bionostics Holdings (Devens, MA; no SBIR), a company that develops quality-control services and technologies that ensure diagnostic systems work properly.[Katherine Grayson, Minneapolis / St Paul Business Journal, Jun 18, 13]
Bio-Path Holdings down 22% [Nov 21, 19]
BioPath Holdings up 33% [Jul 16, 19]
Bio-Path Holdings up 33% [Apr 12, 19]
Bio-Path Holdings up 19% [Mar 22, 19]
Bio-Path Holdings down 15% [Mar 20, 19]
Bio-Path Holdings up 54% [Mar 11, 19]
Bio-Path Holdings down 46% [Mar 8, 19]
Bio-Path Holdings up 223% [Mar 7, 19]
Bio-Path Holdings up 160% [Mar 6, 19] announces a clinical update to the previously reported interim analysis from the Phase 2 trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML) and provides its plans for the compound's clinical development moving forward toward registration. [company press release, Mar 6, 19]
Bio-Path Holdings (Bellaire, TX; no SBIR) up 197% [Mar 1, 19] a biotechnology company leveraging its proprietary DNAbilize(R) antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting [company press release, Mar 1, 19] total fundng $2.3M [crunchbase.com]
Bio-Path Holdings
(Houston, TX, no SBIR) , leveraging
its proprietary DNAbilize™ liposomal delivery
and antisense
technology to
develop a portfolio of targeted nucleic acid drugs, announced it has
agreed to the sale and issuance of common stock and warrants
with
gross proceeds of approximately $10.0 million.
[company
press release, Jun 29, 16] is collaborating with Thomas
Jefferson
University in Philadelphia to evaluate an experimental immunotherapy
treatment targeting brain cancer. [John George,
Philadelphia Business Journal, Jul 5, 16]
Biophan Technologies (West Henrietta, NY; one SBIR) said a prepayment agreement would eliminate $2.3 million in senior debt, leaving the company with cash available for a year. .... calls itself a technology development and holding company focused on the creation and sale of novel patent-protected technologies and medical devices. [Rochester Business Journal, Sep 24, 08]
Biophan
Technologies
(West
Henrietta, NY; one SBIR) said it
has acquired the patent portfolio (more than 15 issued patents) of
Nanoset
LLC (no SBIR), a private company. ... Biophan’s stock was trading
slightly above 3 cents a share, up nearly 3 percent. [Rochester
Business Journal, May 13,08]
BioPhysical (Austin, TX; $1.1M SBIR, founded 1982, 53 employees) raised $4.1 million of a $5 million round of funding that it will use to pay for an office expansion in Houston and Austin in 2015. ... has yet to turn a profit [Chad Swiatecki, Austin Business Journal, Nov 14, 14] manages and markets biomarker-based health assessments direct to consumers and corporations ... provides the most comprehensive blood-based assessments of an individual's health. ... history: 1982 Inland Labs (no SBIR) is founded; 1995 Luminex ($1.1M SBIR) is formed from Inland Labs; 2002 Rules Based Medicine (no SBIR) is formed from Inland Labs; 2005 Biophysical forms from Rules Based Medicine. [company website]
Biophysical (Austin, TX; no SBIR) received $4.2 million of a planned $5 million financing. ... announced that it was was teaming with California-based SignatureMD Inc. to market a pre-diabetes biomarker test to SignatureMD’s affiliated medical practices. [Christopher Calnan, Austin Business Journal, Jun 23, 12]
Seahorse Bioscience’s (no SBIR) local expansion has been so successful, the company made a second in-state acquisition, of BioProcessors (Woburn, MA; $500K SBIR) in March 2009. The Woburn company creates an instrument that helps biologic makers decide how to design their manufacturing process to maximize cell yield.... Founded in 2001, [Seahorse] has grown from around 60 employees two years ago to about 100 now, through hiring and acquisitions.... acquisition of Innovative Microplate (Chicopee, MA; no SBIR). five years ago has led to continued hiring through the recession and an expansion of the manufacturing facility there, to 25,000 square feet from 14,000 square feet. Seahorse’s lead product is a bench-top scientific instrument that measures the energy production activity of cells. [Julie Donnelly, Mass High Tech, Jun 23, 10]
Biotech materials company Seahorse Bioscience (no SBIR). has taken in $6 million in a Series D round of funding, to help it purchase BioProcessors .(Woburn, MA; $600K SBIR) maker of systems for improving biologic drug manufacturing. [Mass High Tech, Mar 10, 09]
Real seed investment. On average, every dollar N.C. Biotech loans to young life science companies is met with $118 in additional funding to those firms from disease philanthropy and government grants, angel and venture investment and other financial support, according to the center. Every grant dollar is met with an average $28 in additional funding. ... loans and grant made by the Biotech Center in the second fiscal quarter: $50,000 in a Company Inception Loan to Spyrix (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, developing a treatment for cystic fibrosis. The loan is intended to help position the company for outside investor and foundation funding and to help with preclinical development of its product. $75,000 to Eppin Pharma (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, to help in its development of a reversible, oral, non-hormonal male contraceptive pill. This money will help support toxicology and other testing of the company's lead drug candidate and help position Eppin to seek additional funding from investors, federal grants and foundations. $250,000 to Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees), developing a novel drug to help people with spinal injuries clear their bladders and bowels when they choose to do so. The loan will support studies of the drug's safety and help Dignify develop a final formulation of the remedy, for use in clinical trials. $458,000 to Bioptigen (Morrisville, NC; $2.9M SBIR), to support late-stage development and clinical testing needed for FDA approval of its intrasurgical optical coherence tomography device for real-time guidance of ophthalmic surgery. $500,000 to Baebies (Durham, NC; no SBIR), to help it develop its products to diagnose health risks in infants from a single dried blood spot, using a technology called digital microfluidics. This loan supports the company's newborn screening tests for three devastating disorders (Pompe, biotinidase deficiency and galactosemia). [Jason deBruyn,Triangle Business Journal, Feb 4, 15] SBIR has no chance of such rewarding results because about three-fourths of the money is spent by agencies that just want what they can use for their own purposes with no regard for whether there is any widespread economic payoff, nor any payoff to society. SBIR can hide these facts behind privacy of private business whihc is OK with Congress as long as the small biz get the prescribed handouts.
Bioptigen (Durham, NC; $2.8M SBIR) said that two of its ophthalmic devices have received marketing clearance from the FDA. The hand-held devices allow physicians to image the eyes of children, anesthetized patients and others where it’s difficult for them to stand still. Bioptigen employs about 20 people locally. [Lauren Ohnesorge, Triangle Business Journal, May 18, 12]
Venaxis (Castle Rock, CO; no SBIR) medical device company, said it has acquired BiOptix Diagnostics (Boulder, CO; $250K SBIR) for $2M worth of Venaxis stock. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance (“E SPR”) technology platform for the detection of molecular interactions. ... Venaxis, Inc. is an in vitro diagnostic company which had been focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company’s rapid blood based test for appendicitis. [Venaxis press release, Sep 13, 16]
Bioptix up 18% [Oct 9, 17]
Bioptix (Castle Rock, CO; $250K SBIR) is changing its name to Riot Blockchain Inc. as it shifts its focus [from biotech] to buying up cryptocurrency and blockchain companies. ... Formerly known as Venaxis Inc., and before that, AspenBio Pharma, the company had developed a blood test to detect a protein associated with inflammation of the appendix, but received a negative response from the FDA in 2014, the company said. It also owns intellectual property rights related to veterinary products. [Bloomberg, Oct 5, 17]
Bioptix up 15% [Jan 4, 17]
Bioptix up 10% [Dec 14, 16]
Bioptix (Boulder, CO; $250K SBIR) down 16% [Dec 13, 16]
BioPulping International, (Madison,WI; $900K SBIR) developing a commercial application for pretreating wood chips and other biomass material for pulping, has received a $400,000 federal grant [from USDA] ... co-founded by CEO Masood Akhtar in 1996 to commercialize biopulping. Akhtar was biopulping project leader at the U of Wisconsin Biotechnology Center/USDA Forest Products Laboratory from 1989 to 1996. [Milwaukee Journal Sentinel, Jun 11, 10]
At least five Massachusetts biotechs — Dynogen Pharmaceuticals, Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure and Altus — have more or less ceased operations since the stock market meltdown in September 2008. [Julie Donnelly, Mass High Tech, Mar 5, 10]
Biopure, that was working on developing a human blood substitute, has run out of time and money. The company said it filed for Chapter 11 bankruptcy protection [Boston Globe, Jul 18, 09]
Biopure a developer of blood-replacement technologies, has received — and will not challenge — a delisting notice from NASDAQ for falling below the exchange’s minimum equity-value requirement. [Craig Douglas, Boston Business Journal, Jun 30, 09]
Biopure reports that it has signed an agreement for a private placement of a package of common stock and warrants for up to $2.3 M, which the Cambridge-based maker of oxygen therapeutic blood replacement products says it will use for working capital and general corporate purposes. [Mass High Tech, Jul 3, 08]
Biopure lays off 50, needs cash to stay open past fall [Boston Globe, Jun 21]
Biopure, a developer of blood-replacement therapies, reports it has succeeded in defending its European patent for a purification process [Mass High Tech, May 19, 08]
Biopure reports the Naval Medical Research Center (NMRC) has landed $3.4 million from the DOD to develop its Hemopure product. [Mass High Tech, May 8] Even though it is all government money for government purposes, it still qualifies for commercialization because it is creating economic activity downstream of the SBIR.
Biopure regained its nominal stock price range by a 1:5 reverse split. [Oct 2, 07]
Biopure says that an FDA committee has recommended denial of the Navy's proposal to conduct a Phase 2b/3 clinical trial of the company's blood replacement product, Hemopure. The committee did recommend continuation of small scale experiments on the project to extract the goodies from cows' blood. [Mass High Tech, Dec 15] The stock took another 24% dive but is already below the buck and a far, far reach from its 2000 bubble high near 300 (adjusted for the 1:6 reverse split in 2005).
Biopure will raise $14M in stock and warrants. [Dec 06]
An independent safety board has cleared Biopure to continue a Phase 2 trial of its Hemopure blood-oxygen treatment after reviewing preliminary results from the study, according to company officials. [Mass High Tech, Nov 7, 06] The stock traders were not impressed.
Biopure says that NASDAQ is on the verge of delisting the stock for failng to maintain a buck price for 30 days. Days ago, the company said it was selling another $55M of securities. Biopure had a trickle of SBIR in the 1990s.
medical device startup Biorasis (Stoors, CT; $900K SBIR) recently was awarded the MassChallenge’s top prize at its annual awards ceremony. ... cash prize of $100,000. also receive the Sidecar Award, providing an additional $200,000 in non-dilutive funding. The technology developed by Biorasis, the GlucowizzardTM, is an ultra-small implantable biosensor for continuous, reliable glucose monitoring. This needle-implantable device wirelessly transmits glucose levels to a watch-like unit for real-time display, which in turn communicates with personal digital accessories like a smartphone. [Jessica McBride, http://updates.uchc.edu/, Nov 6, 15]
Connecticut Innovations has invested $269,160 antibiotics developer BioRelix (New Haven, CT; no SBIR), its second investment in the firm after a $500,000 infusion in December. ... developing antibiotics using "riboswitches," which are "short stretches of messenger ribonucleic acid (mRNA) that bind small molecules and control genes that are essential for the survival of many human pathogens," first identified in the laboratory of Yale professor Ron Breaker. The firm is developing a treatment for a hospital-acquired infection. [Hartford Courant, Apr 3, 12]
BioRelix (New Haven, CT; no SBIR) has taken in $3.6 million of a planned $5.3 million equity offering. ... makes treatments for infectious diseases, using RNA targets called RiboSwitches found in bacteria and fungi. The developments are based on scientific research by Ronald Breaker, who discovered RiboSwitches in his lab at Yale University. [Mass High Tech, Sep 6, 11]
BioRelix (New Haven, CT; no SBIR) has taken in $2.4 million of a planned $4.8 million debt and warrants financing, ... develops infectious disease treatments using RNA targets called RiboSwitches, which are found in bacteria and fungi, the BioRelix website explains. It was founded upon scientific research by Ronald Breaker, who discovered RiboSwitches in his lab at Yale University. ... made news in October, announcing a research collaboration with a Merck & subsidiary to discover new antibacterial drug targets [Michelle Lang, Mass High Tech, Dec 23, 10]
BioResource International, (Morrisville, NC; $360K SBIR) that makes additives for animal feed, is building a second manufacturing facility in China to capitalize on the growing demand for its products in emerging markets. The company said last week that it has partnered with two Taiwanese companies, Yung Zip Chemical Industrial Co. and Yung Shin Pharmaceutical Co., on the plant. It is expected to cost less than $10 million and be completed by the end of 2012. ... 15 employees, will own 40 percent of the venture. ... One product, Valkerase, breaks down the tightly woven protein that makes up chicken feathers and allows those feathers to be used as feed. The other, Versazyme (now sold in more than 80 countries) [$300K USDA SBIR in 2003 for commercialization], is a supplement to animal feed that helps chickens, hogs and turkeys absorb more of the protein in soybeans. [David Bracken, Raleigh News & Observer, Apr 18, 11] A small SBIR for late-stage commercialization followed by international sales
BioRestorative Therapies (Melville, NY; $500K SBIR) down 24% [Jun 28, 2023] announced that the independent Data Safety Monitoring Board (“DSMB”), which is overseeing the Company’s ongoing Phase 2 clinical trial to treat chronic lumbar disc disease (“cLDD”), unanimously recommended the continuation of BioRestorative’s study in accordance with the current version of the protocol with no changes. [company press release, Jun 27, 2023]
BioRestorative Therapies (Melville NY; no SBIR) down 48% [Nov 5, 21] announced the pricing of the underwritten public offering [company press release, Nov 5, 21]
BioRestorative Therapies (formerly Stem Cell Assurance, Jupiter, FL, 3 employees, founded 1997) will move its headquarters to Melville, NY after the state offered a half-million dollars in tax incentives. [Celia Ampel,South Florida Business Journal, Sep 11, 14] develops medical procedures using cell and tissue protocols, primarily involving adult stem cells that are designed for patients to undergo minimally invasive cellular-based treatments. [Bloomberg Business Week]
BioSante Pharma down 13% [Jul 17, 12]
BioSante Pharma (one SBIR) Shares are now down 76.1%in afterhours trading, following the company's disclosure of negative trial results for its LibiGel drug. [seeking alpha.com, Dec 14]
Biosante Pharma up 13% [Jul 8, 11]
BioSante Pharmaceuticals (Lincolnshire, IL; $200K SBIR) fell 2% despite receiving an "orphan drug" designation for its vaccine for the treatment of chronic myeloid leukemia, giving the Lincolnshire, Ill., company another set of tax breaks and seven years of exclusivity. [Wall Street Journal, Jun 8,10]
BioSante Pharmaceuticals (Lincolnshire, IL; $200K SBIR) will buy troubled South San Francisco business Cell Genesys for $38 million in stock. ... already cut about 95 percent of its staff, from 290 persons to 16, by eliminating all research and development, manufacturing, clinical and regulatory activities. [Silicon Valley/San Jose Business Journal, Jun 30, 09]
BioScale (Cambridge,MA; $4.5M SBIR) biological analytics firm brought in $15.7 million in an equity and warrants offering that is expected to net $25 million total, according to [SEC] filing ... makes life science tools including its BioMEMS-based Acoustic Membrane and Microparticle (AMMP) technology, which enables biomolecular detection at a picogram level. [Michelle Lang, Mass High Tech, Jun 11, 10]
BioSense Technologies, (Woburn, MA; $2.2M SBIR) five-person biotech company to get just under $2 million in [stimulus] funding from the NIH ... developing a technology that will help detect bacteria in blood platelets, reducing the incidence of bacterial infections and sepsis in patients who have blood transfusions. [Julie Donnelly, Mass High Tech, Jun 21, 10] too late for any political gain since the stimulus opponents long ago claimed it a failure when unemployment didn't immediately drop dramatically.
BioSensics (Watertown, MA; $200K SBIR plus about six Phase Is and six Phase IIs not yet in SBA database) received [NIH] grant [Commercialization Readiness Pilot Program] funding to develop HDWear, a novel telecare solution for Huntington’s disease. HDWear, powered by BioSensics’ PAMSys sensor technology, will enable continuous remote monitoring of Huntington’s disease motor symptoms. [company press release, Sep 20, 17] [in Sep 2017] was awarded an additional $1.2M to develop a fracture risk test for patients with bone cancer based on skeletal CT scans. [company website] Note: SBA SBIR data base runs 2-3 years behind actual awards. The awarding agencies have no great interest in SBA nor in success of SBIR.
BioSentinel Pharmaceuticals (Madison, WI; no SBIR) said Tuesday it has released a new test to detect the most deadly strains of botulinum toxin. The BoTest offers a nearly 300-fold increase in sensitivity compared to other tests on the market for detecting botulinum neurotoxin, one of the most deadly toxins in the world, the Madison company said. BoTest is the start-up company's first commercial product. "BioSentinel's groundbreaking assay will help protect our citizens at home and our troops in the field, and the expanded research opportunities hold much promise for future health care benefits," U.S. Rep. Tammy Baldwin (D-Wis.) said in a statement. Baldwin helped secure federal funds for BioSentinel's research. [Kathleen Gallagher, Milwaukee Journal Sentinel, Apr 29, 09]
Mayo Clinic secured a big potential stock ownership position in Twin Cities-based medical device startup BioSig Technologies (Minneapolis, MN; no SBIR) in connection with a long-term research collaboration with the Rochester institution and its licensing arm, Mayo Clinic Ventures ... in the development of its PURE electrophysiology (EP) platform, which uses proprietary technology to filter out electromagnetic interference from equipment in a typical EP lab. [Don Jacobson, Twin Cities Business, May 31, 17]
BioSig Technologies (Minneapolis, MN; no SBIR), a medical device company developing the PURE EP System, a proprietary platform designed to improve the clinical outcomes of electrophysiology procedures, today announced the Company closed a private placement with net proceeds of $4.5M. [company press release, May 2, 16]
med-tech company BioSig Technologies (Golden Valley, MN; no SBIR) that moved its headquarters from Los Angeles earlier this year has closed on $1.02 million in financing. ... makes an electrophysiology recording system .. it is seeking $7M. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Nov 23, 15]
Seeking the action place. Medical-device company BioSig Technologies (Golden Valley, MN; no SBIR) is moving its headquarters from Los Angeles to Golden Valley, where it plans to hire about a dozen workers. BioSig picked the Minneapolis/St. Paul area largely because of its strong med-tech workforce, CEO Greg Cash said. Cash lives in the Twin Cities and worked at Medtronic for about 15 years. ... makes an electrophysiology recording system physicians use to diagnose abnormal heart rhythms. The technology aims to shorten procedure times by allowing doctors to more quickly identify which areas of the heart are causing problems, Cash said. ... has raised about $12 million in funding since its founding in 2009, including $4 million earlier this year. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Apr 14, 15]
A startup Biosortia Pharmaceuticals (Dublin, OH; no SBIR) seeking potential new drugs within blooms of algae has raised $500,000 and is moving its headquarters to San Diego to take part in a business accelerator run by pharmaceutical giant Johnson & Johnson. [Carrie Ghose, Columbus Business First, Dec 31, 15]
research partnership Dublin-based Biosortia Pharmaceuticals (Dublin, OH; no SBIR) formed this month with British pharmaceutical giant AstraZeneca Plc – but the potential for new drug discoveries in the deal widens to a river from a trickle. .... a subsidiary of Marysville-based Algaeventure Systems (Marysville, OH; no SBIR), has technology to harvest and remove water from huge mats of algae living in inland lakes and other bodies of water, preserving complex communities of warring microorganisms and the compounds they secrete. The resulting concentrated samples are sent to several university and hospital partners to isolate the compounds of interest. [Carrie Ghose, Columbus Business First, Jul 19, 13]
BioSphere Medical (Rockland, MA; no SBIR) has agreed to be acquired by Merit Medical Systems Inc. of Utah, for $96 million in cash. ... has developed bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations. [Mass High Tech, May 14, 10]
Biostage (Holliston, MA;$200K SBIR) developing bioengineered organ implants to treat cancer and other life-threatening conditions of the esophagus, bronchus and trachea, raised $1.3M in equity, according to an SEC filing. [Rowan Walrath, BosontInno, Sep 21, 19] prior funding $16M [crunchbase.com]
Biostage (formerly Harvard Apparatus Regenerative Technology, Holliston, MA; no SBIR) developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea today announced significant, pre-clinical data, including the complete regeneration of a segment of the esophagus, from its collaborative large-animal study of its Cellspan™ organ implants with Mayo Clinic. [company press release, May 12, 16]
Bioventus (Durham, NC; no SBIR,spun out of Smith & Nephew and has been a stand alone entity since May 2012) acquired BioStructures (Newport Beach, CA; no SBIR), a maker of bioresorbable bone graft products. ... In 2014, Bioventus acquired the OsteoAMP product line, intellectual property and commercial business from Advanced Biologics (no SBIR). [Jason deBruyn, Triangle Business Journal, Nov 30, 15]
NuVascular that specializes in medical devices that use a fibrous material that can be infused with stem cells has spun out a separate firm called NuVascular Technologies (Ashland, MA; no SBIR) to commercialize its first two products.... has the same four core employees as Biosurfaces, ($2.7M SBIR) hold the exclusive license to develop and sell a minimally-invasive treatment for heart disease developed by Biosurfaces and Worcester Polytechnic Institute. ... Another device currently in development is a biological pacemaker. Instead of using a battery-powered mechanical device to control electrical impulses in the heart to beat the correct way, the device would use modified stem cells, overcoming some of the limitations of mechanical devices, including the need to change batteries and infection. [Don Seiffert, Boston Business Journal, Jan 23, 15]
life science software maker Accelrys (formerly Biosym Technologies; San Diego, CA; founded in 1984, $1.6M SBIR 1985-1991, employs about 750 people) has been sold for about $750 million to 3D software vendor Dassault Systèmes (France), the companies said [Bradley Fikes, utsandiego.com, Jan 31, 14] Sounds like a good case for SBIR that funds early technology development that the firm then takes to the capital markets for its future. This firm expanded, weaned itself from government support, grew handsomely, and expanded its reach by joining a global firm with more market power. Government's role, SBIR or other, should belimited to reducing the technical risk of the new technology to the level of a mere business risk, and then leave the company to the markets. It should not keep handing out SBIR contracts to the company for just ordinary government R&D, like it does for so many companies. It should not be SBIR's objective to provide employment for families nor save the company from bankruptcy nor keep a firm in its political locality. All those home-cooking objectives are mere political niceties.
BioSystem Development (Madison, WI; no SBIR, founded 2002) that raised nearly $1 million from angel investors a year ago will be acquired by Agilent Technologies .... creates and manufactures products to improve protein analysis methods for drug development. Agilent said it hopes to complete the acquisition by the end of the year. [Kathleen Gallagher, Milwaukee Journal Sentinel, Dec 1,11]
BioSystem Development (Madison WI, no SBIR) pulled in $600,000 in a second financing round ... George Mosher, a Silicon Pastures member and BioSystem investor. Mosher says he has put money into over 40 young companies since he sold Milwaukee-based National Business Furniture in 2006 to K+K America for $82 million. [Kathleen Gallagher, Milwaukee Journal-Sentinel, Nov 2, 07]
BioSystem has a very committed founder who is committed to making the company a success, has an incredible Rolodex and knows how to get his foot in the door at pharmaceutical companies. And he has a lot of credibility because he's worked in start-ups previously," said Teresa Esser, managing director of Silicon Pastures. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 9] BioSystem got a $700K angel investment after a top prize in the Governor's Business Plan Contest in 2004
Biota Pharmaceuticals (Rockville, MD; no SBIR) is moving to Alpharetta, GA. ... focuses on the development of anti-infective products to prevent and treat potentially life-threatening viral and bacterial infectious diseases, ... also has an advanced program for the treatment of human rhinovirus infection. ...will initially employ up to 20 .... has an R&D operation in Melbourne, Australia and an office in Oxford, England. Biota is led by two former executives at Inhibitex (Alpharetta, GA; one SBIR in 1999) clinical-stage drug development company acquired by Bristol-Myers Squibb Co. [Urvaksh Karkaria, Atlanta Business Journal, Apr 15, 13]
Bio-Techne (Minneapolis, MN; no SBIR) maker of biotech research supplies is acquiring Advanced Cell Diagnostics (Newark, CA; $4.2M SBIR, 100 employees) biotech firm for $250 million, marking a step into new territory, the company announced this week. [Covey Son, Minneapolis Star Tribune, Jul 8, 16]
Five bioscience
companies
winners of [Wisconsin] BIOforward’s 2014 Emerging Company Showcase. ...
chosen because they have transitioned successfully out of research and
development, with good proof of concept for their products.
BioTechnique
(Madison,
WI; no SBIR) will make
cancer-fighting drugs and other types of drugs for other companies;
Cellara
(Madison, WI; no
SBIR) working on a
small-platform
modular
robotic system for use in stem cell production;
Gel Combs
(Madison, WI; no
SBIR) designs and makes
improved
combs for gel electrophoresis applications as well as custom plastic
parts for the microscopy and microbiology industries; Kosmetikos (Marshfield,
WI; no
SBIR) a skin care
company start-up;
and Organic Research
(Milwaukee, WI; no SBIR) develops
digital pathology software tools to provide critical decision support
to pathologists by automatically identifying disease
markers. The winning companies receive
high-visibility
exhibit space at the Oct. 8 Bioscience Vision Summit, recognition at
one of the summit’s large plenary sessions, a free year of membership
in BIOforward, and specialized one-on-one technical assistance ranging
from business planning and investor introductions to collaborative
partnerships. ... BioForward was founded
in 1987, as
the Wisconsin Biotechnology Association, a partnership among leaders in
Wisconsin’s emerging biotechnology industry.
[Bob
Van Enkenvoort, Wisconsin State Journal, Sep 26, 14]
KAER Biotherapeutics (no SBIR), a company spawned from Larta Alumni company BioTechPlex (San Diego, CA; $6.2M SBIR), develops a variety of services and devices for the treatment of lung diseases including new methods of delivering biologic pharmaceuticals in aerosol form. When considering other aerosol drug delivery systems available in the market today, KAER’s patented SUPRAER technology has been deemed superior due to its ability to provide deeper lung treatment. [Gaby Huizar, May 13 ]
Biotectix (Ann Arbor, MI; no SBIR) is putting some of its new financial firepower to work. ... a spinoff from the University of Michigan, said that it acquired the intellectual property portfolio of Chameleon BioSurfaces in Cambridge, England ... developing polymer materials designed to improve how implantable medical devices interact with the body and tissues, over time, such as by enhancing stability and preventing foreign body reactions to the devices. [Thomas Lee, xconomy.com, Mar 28, 11]
Med-tech firm Biotel’s (Eagen, MN; no SBIR, 45 employees) deal to be sold to a Pennsylvania company is on again, more than a year after a previous acquisition agreement between the businesses fell apart. This time, the purchase price is set at $11 million, about $3 million less than the buyer CardioNet (Conshohocken, PA; no SBIR) had agreed to pay for Biotel in 2009. [Sam Black, Minneapolis St Paul Business Journal, Nov 8, 10]
BioTelemetry (formerly formerly CardioNet, Malvern, PA; no SBIR) has entered into a definitive agreement to buy VirtualScopics (Rochester, NY; one SBIR) for $15.5 million. [John George, Philadelphia Business Journal, Mar 28, 16]
Following a three-year legal battle, BioTelemetry (formerly known as CardioNet, Malvern, PA; no SBIR) won a key verdict in a patent infringement lawsuit it filed against a competing medical-device company MedTel (Boca Raton, FL; no SBIR). ... BioTelemetry said it has invested more than $100 million in developing and commercializing its patented technology. ... has also filed patent infringement against several other medical-device makers in recent years. [John George, Philadelphia Business Journal, Oct 12, 15]
Medtronic (now Irish by US tax dodge) said it will spend up to $105 million to buy Visualase (Houston, TX; no SBIR, founded 2005 as a spin-off from BioTex (Houston, TX; $10M SBIR)) that has developed a system using an MRI-guided laser for minimally invasive surgeries. [Evan Ramstad, Minneapolis Star Tribune, Jul 28, 14]
Biothera (Eagan, MN; one SBIR) developing immune-system treatments, has raised $3.5 million in financing, according to [SEC] ... has two divisions: One is focused on pharmaceuticals for treating diseases, the other markets ingredients used in food products and nutritional supplements. ... goal is to raise $25 million [Kathryn Grayson, Minneapolis St Paul Business Journal, Apr 15, 10]
BioTheranostics (San Diego, CA; no SBIR) a leader in molecular diagnostics for cancer, announced that it has closed a $32 million financing ... will be spun out from bioMérieux, which will remain a minority shareholder, and operate as an independent company. [company press release, Jan 20, 16] has operated since 2008 as a division of the French diagnostics conglomerate bioMérieux [Bruce Bigelow, xconomy.com, Jan 22, 16]
drug developer [Incyte] has paid out $7 million upfront to BioTheryx (Chappaqua, NY; $300K SBIR), with potentially $6 million to follow in R&D funding and up to $347 million in milestone payments. In return, Incyte gets to use BioTheryx’s PRODEGY platform to identify and initially develop molecular glue degraders for “multiple historically undruggable oncology targets,” according to this morning’s release. [James Waldron, Fierce Biotech, Apr 5, 2023]
AgeX Therapeutics up 99% [Nov 30, 18], a subsidiary of BioTime (Alameda, CA; $2.3M SBIR) focused on the development and commercialization of therapeutics targeting human aging, announced that its common stock is now trading on the NYSE American exchange [company press release, Nov 29, 18]
BioTime (Alameda, CA; $300K SBIR) picked up 400 patents and applications plus other intellectual property dealing with human embryonic stem cells from Geron [Stephen EF Brown, San Francisco Business Times, Jan 7, 13]
BioTime (Alameda, CA; $300K SBIR) raised $9.2 million as investors exercised warrants [Ron Leuty, San Francisco Business Times, Aug 20, 10]
BioTime (Alameda, CA; $300K SBIR) up 28%... a biotechnology company focused on regenerative medicine, published a scientific paper with collaborators that appears to strengthen the case for an emerging field in that area. [Wall Street Journal, Mar 17]
The California Institute for Regenerative Medicine, the state stem cell agency, has awarded $1B so far in research money. SBIR companies got $10M of it.Bio Time (Berkeley, CA; $300K SBIR) $4.7M; Vistagen Therapeutics (Burlingame, CA; $600K SBIR) $970K; Gamma Medica Ideas (Northridge, CA; $2.8M SBIR) $950K; Vala Sciences (San Diego, CA; $3M SBIR) $900K; Invitrogen (Carlsbad, CA; $4M SBIR) $870K SBIR; Fluidigm (South San Francisco, CA: $1.2M SBIR) [CIRM press release, Oct 28]
Biotix (San Diego, CA; no SBIR) that supplies pipette tips, reagent reservoirs, and other laboratory consumables, has raised $2 million of a planned $4 million Series B equity round, ... plans to use the proceeds “to help with the growth" ... founded in 2005 to develop high-end and heavily engineered pipette tips solely for robotic equipment used in life sciences and research laboratories [Bruce Bigelow, xconomy.com, Apr 5, 11]
NuVasive (San Diego, CA; no SBIR), a leading medical device company focused on transforming spine surgery, and Biotronic NeuroNetwork (Ann Arbor, MI; no SBIR, founded 1982), a provider of intraoperative neurophysiological monitoring services, announced that they have entered into a definitive agreement under which NuVasive will acquire Biotronic for $98 million in cash. [NuVasive press release, Jun 6, 16] On Jun 1: Biotronic NeuroNetwork announces the acquisition of NuWave Monitoring, LLC (Homewood, IL; no SBIR), an intraoperative neuromonitoring company servicing patients, surgeons, and health care facilities in Illinois and Indiana. [Biotronic press release, Jun 1, 16]
The first patients have been implanted with a new cardiovascular device made by Biotronik (Lake Oswego, OR; no SBIR). ... called an Itrevia HF-T QP cardiac resynchronization defibrillator. What makes it unique is that it includes a special algorithm called CLS that’s capable of adapting heart rate in response to physiological demands, independent of body movements or respiratory rate. [Elizabeth Hayes, Portland Business Journal, Jul 21, 15]
BioTrove (Waltham, MA; noSBIR) elected to withdraw its registration for a $75 million IPO. [Mass High Tech, Dec 18, 08]
BioTrove (Woburn, MA; no SBIR) which makes systems used to analyze genetic information and chemical compounds, plans an initial public offering of common stock, [Boston Globe, Apr 1, 08]
Thomas Jefferson University (Philadelphia, PA) with a national reputation for transdisciplinary learning and innovation, and BioVaxys LLC (NYC, NY; no SBIR), clinical stage biotechnology company, announced they have entered into an exclusive worldwide license agreement for a technology comprising highly-targeted, patient-specific, immunotherapeutic vaccines to treat ovarian cancer, melanoma, and other solid tumor types. [Thomas Jefferson pressrelease, Jul 9, 18]
Bioventus (Durham, NC; no SBIR), a global leader in orthobiologic solutions, announced it has received US FDA approval for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA). .... in 2015 acquired BioStructures LLC, a proprietary developer and marketer of bioresorbable bone graft products for a broad range of spinal and orthopaedic surgical applications. ... Acquired DUROLANE Assets from Galderma (Durham, NC; no SBIR) in 2014 [company press release, Sep 5, 17]
medtech startup Bioventus (Durham, NC; no SBIR, founded 2012) registered to raise up to $150 million in an [IPO]. [John Murawski, Raleigh News & Observer, Jun 30, 16]
Bioventus (Durham, NC; no SBIR,spun out of Smith & Nephew and has been a stand alone entity since May 2012) acquired BioStructures (Newport Beach, CA; no SBIR), a maker of bioresorbable bone graft products. ... In 2014, Bioventus acquired the OsteoAMP product line, intellectual property and commercial business from Advanced Biologics (no SBIR). [Jason deBruyn, Triangle Business Journal, Nov 30, 15]
Biovest International, a biotech company that received $350,000 in loans from Minnesota government agencies to expand in Coon Rapids, has filed for Chapter 11 ... planned to produce a personalized cancer vaccine that treats non-Hodgkin's lymphoma. .... The company's plan to emerge from bankruptcy calls for eliminating $44 million in senior secured debt by converting it into common stock. The plan also would allow it to raise $5.6 million in new funding. [Katherine Grayson, Minneapolis / St Paul Business Journal, Mar 11, 13]
BioVex (Woburn, MA; no SBIR) biotechnology company that raised $40 million in venture capital in March to develop a novel cancer-fighting treatment, today will disclose it has raised another $30 million. ... to complete an ongoing late-stage clinical study of its drug, OncoVex, to treat recurrent and metastatic melanoma, [Boston Globe, Nov 10, 09]
“NASA iTech is an innovation incubator that brings together the right people to the right place and time, giving entrepreneurs an opportunity to present their technologies as a future commercial market product solution for both Earth and NASA,” said Kira Blackwell, program executive for the Space Technology Mission Directorate at NASA Headquarters. Blackwell, also said the top 18 companies that have previously participated in NASA iTech have reported raising more than $50 million in private investments over the last 12 months. The top ten competitors for the grand prize: BioVirtua (San Francisco, CA; no SBIR) Humanizing Telehealth in Four Dimensions; FGC Plasma Solutions (Argonne, IL; no SBIR) Novel Fuel Injectors to Enable Clean, Compact Propulsion ; Germfalcon (Los Angeles, CA; no SBIR) Germicidal UVC Emitting Robot for Commercial Aircraft; H2 Energy Now (Boalsburg,PA; no SBIR) New Technology for H2 Generation from Water in Space by Use of Electromagnetic Waves; Hyperloop Tansportation Technologies (Los Angeles, CA; no SBIR, 500-1000 employees) Augmented Voyage; iFirst Medical Technologies (Honolulu, HI; no SBIR, founded 2016) The iFirst Analyzer: Handheld Laboratory-grade Diagnostics Platform for Extreme Environments; Million Concepts (Lemont, PA; no SBIR) The Arisian Lens: A Novel Solution for Low-cost, Lightweight Microscopy; New Frontier Aerospace (Livermore, CA; no SBIR, founded 2015) Affordable, Powered Recovery for Small Launch Vehicles; Rice Technology (Milwaukee, WI; no SBIR) Smart Real-Time Multipurpose Sensor - Dissolved and Suspended Solids, Bacteria, Phosphorus and Viruses; Somatic Labs (Phoenix, AZ; no SBIR, founded 2015) Tactile Interfaces for Augmented Reality to Enhance Communication.
BioXcel Therapeutics up 17% [Dec 23, 19]
BioXcel Therapeutics (Branford, CT; no SBIR) filed to raise $69 million through a Nasdaq IPO. BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia. onnecticut-based BTI is a near-wholly-owned subsidiary of BioXcel, a data analytics company that made its name through deals with Alexion, Alnylam, Sanofi, Takeda, Teva and Vertex. [Nick Paul Taylor, Fierce Biotech, Feb 13, 18] pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. [company website]
Alexion Hires BioXcel (Banford, CT; no SBIR) for data analysis consulting, ... BioXcel has a database of more than 9,000 rare diseases, associated genes, and suggestions for antibody, protein, RNA, small molecule and gene therapy approaches that could work for these diseases. It has added about 2,000 diseases in just the past six months. ... much of the work is done in Gurgaon in the New Delhi area of India, where more than 50 scientists, software experts, business development professionals and others work. [Mara Lee, Hartford Courant, Jan 28, 15]
Bird Rock Bio (La Jolla, CA; no SBIR), a clinical stage biopharmaceutical company, announced that today it has requested approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1). The trial is anticipated to provide important safety, tolerability and biomarker efficacy data for namacizumab to support differentiated clinical potential in fibrotic and metabolic disease. [company press release, Oct 27, 2016 ]
Bird Rock Bio (formerly RuiYi, La Jolla, CA; no SBIR) said two recent studies show that its lead drug candidate, an antibody for rheumatoid arthritis and other inflammatory diseases, is both safe and effective at very low doses. CEO Paul Grayson said that the dosage required—less than 50 milligrams a year—could allow Bird Rock to set the price of its drug, gerilimzumab, at $2,000 per patient, a fraction of the price for currently approved biologics like adalimumab (Humira) or tocilizumab (Actemra). [Alex Lash, xconomy.com, Mar 18, 16]
Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market. .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies: A&G Pharmaceutical (Columbia, MD; no SBIR), Rehabtics LLC (Baltimore, MD; no SBIR) High Impact Environmental (Church Hill, MD; no SBIR), Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR), Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no SBIR), vCalc (Hagerstown, MD; SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094) [Sarah Gantz, Baltimore Business Journal, Feb 26, 14]
Supernus Pharmaceuticals (Rockville, MD; no SBIR) focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that it entered into a merger agreement to acquire Biscayne Neurotherapeutics (Miami, FL; no SBIR, founded 2017), developing a novel treatment for epilepsy. ... for an upfront $15M [and] $73 million contingent on achieving certain development milestones and up to $95 million contingent upon achieving certain sales milestones [Supernus press release, Sep 13, 18]
Supernus Pharmaceuticals (Rockville, MD; no SBIR) reached a deal to acquire Biscayne Neurotherapeutics (Miami, FL; no SBIR) in a deal worth up to $185 million. Supernus, which specializes in creating therapies for central nervous system diseases, will pay $15 million upfront, followed by an additional $73 million based on development milestones and up to $95 million for sales milestones, according to an announcement. The deal is expected to close in the next few weeks. (Washington Business Journal, Sep 17, 18])
Bitstream (no SBIR) fell 31% after reporting lower profits. It makes Internet browsers and special fonts for wireless devices
Bivacor (Houston, TX; $3M SBIR) raised $22 million through a Series B capital raise and a grant award .. to support the first human studies using its artificial heart device. [Chris Mathews, Houston Inno, May 19, 21]
Grove Biopharma (Chicago, IL; no SBIR), a startup that's creating a novel class of “protein-like polymers” to make drugs that could treat Parkinson's, Alzheimer's, Multiple Sclerosis and other difficult to treat conditions, raised $4 million [Chicago Inno, May 10, 21]
Bivacor (Houston, TX; $2M SBIR) recently closed a series B funding round for a total of $19 million, ... also received another $3 million from the National Institutes of Health, in the form of a small business grant from the National Heart, Lung and Blood Institute. [Andrea Park, Fierce Biotech, May 20, 21]
Black Diamond Therapeutics [Cambridge, MA; no SBIR) up 107% [Jan 30, 20] priced its IPO to raise $200M; pioneering the discovery and development of small molecule, tumor-agnostic therapies [company press release, Jan 29, 20]
Black Diamond Therapeutics (Cambridge, MA; no SBIR, founded 2016) filed for an IPO [with] a $100 million goal. ... is developing drugs to treat cancers with defined genetic mutations. The company has developed proprietary technology, dubbed Mutation Allostery Pharmacology (MAP), to analyze population-level genetic sequencing data in order to find mutations that drive cancer growth, according to the filing. [Frank Vinluan, xconomy.com, Jan 7, 19] total funding $197M [crunchbase.com]
Black Diamond Therapeutics (Cambridge, MA; no SBIR, founded 2016 in New York) biotech startup developing precision medicines for cancers, raised $44.2M in an $87.2M funding round, according to an SEC filing. [Rowan Walrath, BostInno, Jul 17, 19] prior funding $112M [crunchbase.com]
Black Diamond Therapeutics (Cambridge, MA and Switzerland) developing next-generation precision medicines for cancer, announced the completion of an oversubscribed Series B financing of $85 million [to] accelerate the development of Black Diamond’s pipeline and to expand its mutation, allostery and pharmacology (MAP) computational and discovery platform for identifying and targeting allosteric oncogenic mutations [company press release, Jan 10, 19]
a robotic vehicle designed to disarm car and truck bombs ... be used by the State Police Logan bomb squad to fight domestic terrorism ... LandShark Series D robot, manufactured by Black-I Robotics (Tyngsborough, MA; no SBIR) was funded by a congressional earmark sponsored by US Representative Niki Tsongas [Boston Globe, Jan 12, 10] founded in 2005
Two chip-design startups from Austin will be sending marketing teams to Barcelona, Spain, next week to talk to the titans of the cell phone business ... [Black Sand Technologies and Javelin Semiconductor, neither had SBIR] are developing innovative chips that serve as signal amplifiers for advanced 3G cell phones. [Austin American Statesman, Feb 11, 10]
Austin Ventures figures that Black Sand (Austin TX; no SBIR) will be one of those rare chip companies that doesn't need a huge infusion of money or people to achieve its first product design. Typically, it takes $20 M or more to develop a chip prototype. Black Sand just completed raising $8.2 M in its first investment round ... That's expected to be long enough for designs to be completed for chips that will change the way cell phones and other wireless devices amplify the signals for voice and data transmissions. Experts in the field call it one of the toughest design challenges in the wireless business. [Kirk Ladendorf, Austin American-Statesman, Oct 1]
Black Sand has its own tight team of brilliant engineers, most of whom formerly worked for Silicon Labs (no SBIR) ... another genius bet by Austin Ventures in 1996 when three brilliant chip engineers bolted from Cirrus Logic to start their own company. That startup turned out to be Silicon Laboratories ... the most successful home-grown chip company in Austin and one of the biggest investment payoffs for Austin Ventures. [Kirk Ladendorf, Austin American-Statesman, Oct 1]
BlackThorn (South San Francisco, CA; no SBIR) is making its first formal announcement. It’s closed a $40 million Series A round, with participation from the venture arm of Johnson & Johnson .... disclosed plans to develop drugs for neurobehavioral diseases—such as obsessive compulsive disorder, depression, and schizophrenia—and test them in a way that its executives believe can help overcome some of the field’s notorious roadblocks. .... This year alone, antipsychotic drugs developed by Alkermes, Intra-Cellular Therapies , and the now-defunct Forum Pharmaceuticals have failed Phase 3 trials, and all three cited a high level of placebo effect in the control group as a significant problem. [Ben Fidler, xconomy.com, Oct 19, 16]
Automation-software firm BladeLogic Inc. outshined three other new stocks yesterday [Jul 25, 07] continuing the strong showing of IPOs from the technology sector. BladeLogic soared 47% on its first day of trading. [Wall Street Journal, Jul 26]
Battery Ventures, Waltham MA VC firm, has two IPOs in the next two weeks: Netezza (Framingham, MA) and BladeLogic (Waltham, MA). [Boston Globe, Jul 13] Neither did SBIR.
Blasch Precision Ceramics (Albany, NY; $2.3M, 100 employees) making ceramics parts designed to last longer and withstand hotter temperatures than the competition. .... signed on earlier this year: Saudi Aramco, the government-owned oil and natural gas company of Saudi Arabia [Adam Sichko, Albany Business Review, Dec 17, 13]
Blaze Bioscience (Seattle, WA; no SBIR, founded 2010) Raises $5M to Help Surgeons See Tumors From Healthy Tissue developing “tumor paint” that could help surgeons tell the difference between normal and cancerous tissue [Jeff Buchanan, xconomy.com ,Feb 20, 19] total funding $35M [crunchbase.com]
Blaze Bioscience (Seattle, WA; no SBIR, founded 2010) a spinout from the Fred Hutchinson Cancer Research Center that’s developing “tumor paint” to help surgeons differentiate healthy tissue from tumors that should be removed, has raised a $16.1 million Series B-1 round of funding from existing investors ... to complete work on the company’s early-stage clinical trials and to prepare for a late-stage study in pediatric brain cancer, says president and CEO Heather Franklin [David Holleyxconomy.com, Oct 11, 17]
life sciences company Morphotek (Exton, PA; one SBIR plus multiple other USG funding, founded 2000) trimmed its workforce by 27 positions. [John George, Philadelphia Business Journal, Mar 18, 16] has several monoclonal antibodies in clinical development for cancer and inflammatory disease. ... In 2007, was acquired by Eisai, a global health care pharmaceutical company [having already raised abiout $80M] .... In 2015 Announces a License Agreement With Blaze Bioscience (Seattle WA; $1.7M SBIR) For The Development of Novel Oncology Imaging Technology [company website]
Blaze Bioscience (Seattle, WA; no SBIR, founded 2010) announced a $1.5M NIH SBIR to study Tumor Paint BLZ -100 in patients with soft tissue sarcoma Tumor Paint technology was developed to “light up” tumors during surgery [company website, Oct 13, 14]
Blaze Bioscience (Seattle, WA; no SBIR, 14 employees) with $20 million ... using an artificial form of the scorpion’s chlorotoxin to light up cancer cells so doctors can see them during surgery. ... Tumor Paint is still five years away from being a commercial product [Rachel Lerman, Puget Sound Business Journal, Jul 9, 14]
Blaze Bioscience (Seattle, WA; no SBIR) developing solid tumor cancer products, said it raised $9 million in Series B funding, which goes along with the $8.5 million it raised earlier this year. .... to support the clinical development of Blaze’s first Tumor Paint product candidate, BLZ-100, which is designed to assist surgeons in surgical excision of solid tumors by illuminating cancer cells intra-operatively in real time and at high resolution." ..... has now raised $19 million since its founding in 2010 [Ben Miller, Puget Sound Business Journal, Dec 3, 13]
Blaze Bioscience (Seattle, WA; no SBIR, founded 2010) raised $8.5M ... founded to develop and commercialize Tumor Paint technology, which has the potential to fundamentally transform surgical oncology. [company website]
Blend Therapeutics (Watertown, MA) announced its launch as a biotechnology company that aims to focus on so-called “combination medicines.” Company founders include Robert Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology; Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT, and Omid Farokhzad of Harvard Medical School. Their specialties include chemistry and nanomedicine. [Chris Reidy, Boston Globe, Jan 6, 12]
BL Healthcare (Foxboro, MA; two SBIRs) a provider of telemedicine products has bumped its Series A funding round up to $4.9 million, with another $2 million in equity-, debt-, and rights-based financing, an SEC filing showed. [Erin Kutz, xconomy.com, Apr 1, 11]
BL Healthcare (Foxborough, MA; $200K SBIR) developer of electronic technology for health care, has bumped up a previous funding round from $5 million to $6 million, and boosted the amount of that round it has received from $3 million to $5 million, according to federal documents. [Mass High Tech, Mar 25, 11]
Spectrometry technology-maker Block Engineering (Marlborough, MA; one SBIR long ago) reports it has landed $4.4 million from the U.S. government to develop a handheld infrared spectrometer to detect explosive materials. [Mass High Tech, Nov 5, 09]
Bloom Energy (Sunnyvale, CA; no SBIR, founded 2001) a fuel cell technology company, started building a factory in Newark, DE ... plans to hire “hundreds” of people to work in the factory on a 272-acre site owned by the Univ of Delaware [that] used to be a Chrysler assembly plant. [Stephen EF Brown, San Francisco Business Times, Apr 30, 12]
Bloom Energy (Sunnyvale,CA;noSBIR) , has raised about $400 million from investors and spent nearly a decade developing a new variety of solid oxide fuel cell, ... generating electricity at a cost of 8 to 10 cents a kilowatt hour, using natural gas. [Todd Woody, New York Times, Feb 24]
Solar panel technology companyBloo Solar (El Dorado Hills, CA; no SBIR) raised $6.8 million in its latest round of funding ...Launched in 2005, the recent investment brings total investment into the company to more than $20 million. The company last raised $3 million in the fall in its quest to develop next-generation ultra-efficient solar panels. [Mark Anderson, Sacramento Business Journal, Jun 11, 13]
BluDiagnostics (Madison, WI; no SBIR, founded 2015) start-up that helps women with fertility problems, has raised $1.2 million of debt funding from 14 investors ... makes an app, called the BluDiagnostics Fertility Finder, that helps women with fertility problems. It analyzes hormones found in saliva and displays the results.... formed by Katie Brenner, a postdoctoral fellow in biochemistry at the University of Wisconsin-Madison. It raised $600,000 of the money in January, when it said it was trying to raise $800,000. That goal has been amended to $1.2 million, according to the recent filing. [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 4, 16]
A robotics surgery company Blue Belt Holdings (Plymouth, MN; no SBIR) that spun out of Carnegie Mellon University has been acquired by a London-based medical technology giant Smith & Nephew plc for $275 million. ... [buyer] said the deal will help it to secure a leading position in orthopedic robotics-assisted surgery. ... Blue Belt’s portable Navio surgical system provides robotics assistance in partial knee replacement surgery through software and a handheld, robotic device. [Patty Tascarella, Pittsburgh Business Times, Oct 29, 15]
Blue Belt Technologies (Pittsburgh, PA; $1M SBIR) said it has sold its first NavioPFS orthopedic surgical system, reaching a deal with Community Regional Medical Center in Fresno, Calif. ... designed for unicondylar knee replacement and the Fresno medical center is expected to start partial knee surgeries using the NavioPFS system beginning in February. [Paul Gough, Pittsburgh Business Times, Jan 31, 13]
Blue Belt Technologies (Pittsburgh, PA; $1M SBIR) A medical device start-up company in Pittsburgh's East Liberty neighborhood has closed on $2.4 million in private investor-led series A financing. ... a Carnegie Mellon University spin-off, makes surgical instruments for orthopedic and neurosurgery procedures [Pittsburgh Business Journal, Sep 30, 09]
Bluebird bio announced [FDA] has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. [company oress release, Aug 17, 2022] at a price of $2.8 million per patient. [Wall Street Journal]
bluebird bio up 22% [Aug 5, 22]
Regeneron and 2seventy bio (no SBIR) have revealed the candidate spearheading their CAR-T pact. Working with the bluebird bio spinout, Regeneron has selected MUC16 as the target for the first CAR-based solid tumor program. Bluebird and Regeneron began working together on oncology cell therapies in 2018. [Nick Paul Taylor, Fierce Biotech, Jan 11, 22]
bluebird bio down 19% [Nov 8, 21] reported quarterly financials
bluebird bio down 27% [Aug 9, 21] after the company announced new safety issues, and the suspension of its European commercial operations. [Josh Nathan-Kazis, Barron's, Aug 9, 21]
The FDA has lifted a clinical hold placed on bluebird bio’s sickle cell gene therapy in February, making way for the company to get a phase 1/2 trial and phase 3 study of the treatment back on track. [ Amirah Al Idrus, Fierce Biotech, Jun 7, 2021 ]
bluebird bio down 38% [Feb 16, 21] said that it was suspending marketing of its gene therapy Zynteglo, which treats beta thalassemia, and suspending two trials of another gene therapy for sickle cell disease. The suspensions came after a patient who received the sickle cell gene therapy more than five years ago was diagnosed with acute myeloid leukemia. [Barron's Feb 16, 21]
Bluebird Bio, biotech pioneer in the field of gene therapies, plans to split itself in two later this year, spinning off its cancer-drug unit into a new, publicly traded company so it can focus on rare diseases. [Joseph Walker, WSJ, Jan 11, 20]
bluebird bio down 17% [Nov 5, 20]
Bristol Myers Squibb and bluebird bio, announced that the companies received a Refusal to File letter from [FDA] regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. [companies press release, May 12, 20] With its Bristol Myers-partnered CAR-T therapy under FDA review, bluebird bio is getting a $200 million payout. The Big Pharma is forking over the cash to get out of future payments on the treatment outside the U.S. The duo retooled their deal to focus on the impending U.S. rollout of the anti-BCMA treatment, known as idecabtagene vicleucel (ide-cel) or bb2121, according to a statement. [Amirah Al Idrus, Fierce Biotech, May 11, 20]
Bluebird Bio, which just won approval of Zynteglo in Europe two weeks ago, announced the latest price tag [$1.8M] for a gene therapy, a treatment meant to provide a long-lasting effect with a single dose, developed for the rare blood disease beta thalassemia, [Frank Vinluan, xconomy.com, Jun 14, 19]
Bluebird Bio said that the European Commission’s regulatory nod for its therapy, Zynteglo, is a conditional approval, meaning the decision was made with less data than typically required for new drugs. [Frank Vinluan, xconomy.com, Jun 3. 19]
Bluebird Bio paid Gritstone Oncology $20 million upfront, plus a $10 million equity investment, to cement a partnership that will use Gritstone’s artificial intelligence technology to find tumor targets for new cancer immunotherapies. [Ben Fidler, xconomy.com, Aug 24, 18]
Biocept (San Diego CA; one SBIR, market cap $16M) down 11% [Jul 17, 18]
bluebird bio and Regeneron Pharmaceuticals (no SBIR) announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite®platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides, and bluebird bio will contribute its field-leading expertise in gene transfer and cell therapy. [joint companies press release, Aug 6, 18]
Regeneron Pharmaceuticals [develops antibody drugs] and Bluebird Bio [gene and cell therapy specialist] have struck a wide-ranging partnership to broaden the reach of their respective cancer immunotherapy work, inking a deal to develop multiple cell therapies together. [Ben Fidler, xconomy.com, Aug 6, 18]
bluebird bio down 10% [Jun 22, 18]
Bluebird bio has added two targets and up to €417 million ($500 million) in milestones to its T-cell receptor (TCR) collaboration with Medigene. The expanded deal tasks Medigene with applying its TCR technology platform to additional target antigens of interest to Bluebird. [Nick Paul Taylor, Fierce Biotech, May 14, 18]
An experimental treatment for the inherited blood disorder allowed 15 out of 22 participants to stop blood transfusions entirely. The other seven patients, most suffering from a severe form of the disease, now need transfusions less often. Long-lasting cure: Doctors followed patients for up to three and a half years, and the treatment, made by Bluebird Bio, didn’t appear to wear off during that time. [MIT Tech Rvw, Apr 19, 18]
Bluebird bio has pulled the trigger on an option to co-develop and co-promote the anti-BCMA CAR-T treatment, bb2121, with Celgene in the U.S. The move comes two years after Celgene forked over $10 million to exclusively license the therapy. The pair entered a global research pact in 2013 to discover, develop and commercialize novel cancer treatments. [Amirah Al Idrus, Fierce Biotech, Mar 28, 18]
bluebird bio up 11% [Jan 22, 18]
Patients with highly advanced multiple myeloma have seen spectacular results with Bluebird Bio and Celgene’s CAR-T therapy bb2121; the disease was pushed into remission in more than half of those treated. The 21-patient study showed an 86% overall response rate to the therapy, which mobilizes the immune system to attack cancer cells expressing the B-cell maturation antigen (BCMA). [Fierce Biotech, Dec 11, 17]
bluebird bio up 18% [Dec 11, 17] announced updated data from the ongoing HGB-205 clinical study of its LentiGlobin gene therapy product candidate in patients with severe sickle cell disease (SCD) and transfusion-dependent -thalassemia (TDT). [company press release, Dec11, 17]
The New York Times reported that gene therapy companies are struggling to find supplies of viral vectors, a crucial component of the cutting-edge drugs. Bluebird Bio (Cambridge, MA; no SBIR) announced it has bought its own virus-making facility in Durham, NC. [Frank Vinluan, xconomy.com, Dec 1, 17]
bluebird bio announced that four oral and seven poster presentations will feature data from bluebird programs during the 59th Annual Meeting of the American Society for Hematology (ASH). The data will highlight bluebird's advancement of its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD), and its bb2121 product candidate in patients with relapsed/refractory multiple myeloma. [company press release, Nov 1, 17]
A single dose of Bluebird Bio’s gene therapy for cerebral adrenoleukodystrophy (cALD) stabilized the disease in 15 of 17 patients over more than two years of follow-up. The interim results from the phase 2/3 trial—which have been published in the New England Journal of Medicine—suggest that Bluebird’s Lenti-D (elivaldogene tavalentivec) therapy could be the first alternative to stem cell transplantation using cells donated by another person for children with CALD, who typically die before the age of 10. ... Other companies working on new therapies for ALD include NeuroVia (backed by Sanofi Genzyme and Novartis’ venture arms), which recently raised $14 million in a series A round to fund its small-molecule NV1205 candidate; Minoryx Therapeutics (Spain), which has a PPAR gamma agonist MIN-102 in phase 1/2 testing, and MedDay Pharma (France), which has said it expects to report phase 2b/3 results with its biotin-based MD1003 candidate by the end of this year. [Phil Taylor, FierceBiotech, Oct 5, 17]
bluebird bio up 10% [Sep 28, 17]
blueird bio up 11% [Aug 31, 17]
bluebird bio up 10% [Aug 30, 17]
bluebird bio up 11% [Jun 7,17]
bluebird bio down 11% [Dec 7, 16]
bluebirdbio up 10% [Nov 14, 16]
bluebird bio up 14% [Nov 9, 16]
bluebird bio down 11% [Nov 3, 16]
bluebird bio down 13% [Oct 14, 16]
Bluebird Bio will work with Germany’s Medigene to develop T cell-based immunotherapy products for cancer. Bluebird paid Medigene $15 million up front, and could shell out over $1 billion total if a variety of milestones are hit. [xconomy.com, Sep 30, 16]
bluebird bio up 11% [Sep 15, 16]
bluebird bio up 10% [Sep 12, 16]
Avrobio (Cambridge, MA; no SBIR) raised $25 million. Along with Bluebird Bio and U.K. startup Orchard Therapeutics, Avrobio is one of the few companies advancing an “ex vivo” gene therapy approach, which involves harvesting a patient’s own stem cells outside the body. [Ben Fidler, xcomomy.com, Aug 5. 16]
bluebird bio up 11% [Jul 27, 16]
Bluebird Bio unveiled the first data from patients taking [gene] therapy, known as Lenti-D. And the results, while early and in just a handful of patients, are promising. .... At the end of March, none of the 17 patients in its trial had any new major disabilities. [Ben Fidler, xconomy.com, Apr 20, 16]
bluebird bio up 13% [Apr 6, 16]
bluebird bio down 11% [Mar 23,16]
bluebird bio up 13% [Feb 16, 16]
bluebird bio up 11% [Feb 1, 16]
bluebird bio up 12% [Jan 12, 16]
bluebird bio down 19% [Jan 11, 16]
bluebird bio down 38% [Dec 7, 15] after the gene-therapy company disclosed disappointing clinical trial data in patients with sickle cell disease. [Charley Grant, Wall Street Journal, Dec 7, 15]
The bar has been high for Bluebird Bio’s experimental gene therapy LentiGlobin, which up until last week had essentially had a 100 percent success rate—albeit in a small sample size—in eliminating the need for chronic blood transfusions in beta-thalassemia patients. But new data cast some doubt on LentiGlobin’s effectiveness in some of the folks with the most severe form of the disease, sinking Bluebird’s shares about 18 percent. [Ben Fidler, xconomy.com, Nov 19, 15]
Bluebird Bio has helped catalyze gene therapy’s recent renaissance with snippets of human data that hint of a long-lasting, perhaps even one-time fix for a crippling blood disorder known as beta-thalassemia. However, the company released data today that dampen the hopes for a long-term fix for some of the folks with the most severe form the rare disease. ... [CEO Nick] Leschly acknowledges that this is a learning exercise for Bluebird. Up to this point, Bluebird had essentially had a 100 percent success rate—albeit in a small sample size—of eliminating the need for chronic blood transfusions in beta-thalassemia patients, a major milestone for gene therapy. [Ben Fidler, xconomy.com, Nov 5, 15]
bluebird bio down 22% [Nov 5, 15]
bluebird bio up 11% [Nov 3, 15]
bluebird bio down 13% [Sep 28,15]
bluebird bio down 10% [Sep 25, 15]
bluebird bio down 10% [Sep 21, 15]
bluebird bio down 10% [Aug 10, 15]
bluebird bio up 12% [Mar 5, 15]
Hopes that fledgling companies will repeat and extend upon those advances [by Bristol-Myers-Squibb] are behind the recent share-price gains in Juno Therapeutics, Kite Pharma and bluebird bio. Their treatments, which take a different approach than Bristol-Myers’s, haven’t yet reached the market. .... Shares of Juno, which is developing therapies for leukemias and lymphomas, ended Friday’s trading at $45.52, following a December initial public offering at $24. Kite Pharma has soared to $62.80 from $28 since the beginning of October. Bluebird bio, driven more by advances by gene-therapy drugs than in immunotherapy, has climbed to $93.32 from $39 since early December. [Gregory Zuckerman and Ron Winslow, Wall Street Journal, Feb 22, 15]
bluebird bio down 10% [Jan 15, 15]
bluebird Bio (no SBIR) up 72% [Dec 9, 14] Four patients with a lethal blood disorder were able to forgo life-sustaining blood transfusions within 90 days after they were treated with a technique to replace the defective gene responsible for their disease, researchers said. .... the latest to show promise for the field of gene therapy, and for a treatment being developed by bluebird bio [Ron Winslow, Wall Street Journal, Dec 9, 14]
bluebird bio up 10% [Jul 18, 14]
Precision Genome Engineering (Seattle, WA; no SBIR) or Pregenen, has been purchased by Bluebird bio ... Former Pregenen shareholders are also eligible to receive up to $135 million if certain clinical and commercial milestones are achieved. ... Pregenen is a recognized leader in the development and reprogramming of novel Homing Endonuclease and MegaTAL based enzymes that provide a highly specific and efficient way to silence, edit, or insert genetic components,” said Pregenen co-founder Dr. Andrew Scharenberg, in a statement. [Ben Miller, Puget Sound Business Journal, Jul 1, 14]
bluebird bio up 11% [Jun 20, 14] provided a small, yet encouraging glimpse into its potential. Bluebird reported data from two beta-thalassemia patients dosed with its gene therapy, Lenti-Globin. Both of them were able to kick the chronic blood transfusions they’ve been getting most of their lives in a matter of weeks, and at least in the short term (3.5 months and 6.5 months respectively), their responses have held up. Bluebird’s shares have soared about 40 percent this week as a result. [Ben Fidler, xconomy.com, Jun 20, 14]
bluebird bio up 32% [Jun 16, 14]
bluebird bio down 15% [May 21, 14]
bluebird bio up 27% [May 14, 14]
Bluebird bio, one of Celgene’s small partner firms, which Third Rock also financed, is working on a treatment for sickle-cell disease that inserts into the patient’s blood cells a properly functioning version of the faulty gene that causes the inherited ailment. [The Economist, Feb 15, 14]
bluebird bio up 10% [Feb 10, 14]
bluebird bio up 14% [Jul 2, 13] from IPO price
bluebird bio up 58% [Jun 19, 13]
bluebird bio announced the formation of a global collaboration with Celgene to discover, develop, and commercialize gene therapies for oncology treatments. .... include an upfront payment and up to $225 million per product in potential option fees and clinical and regulatory milestones,” bluebird bio said in a press release. “Bluebird bio also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the United States in exchange for a reduction of milestones. [Boston Globe, Mar 21, 13]
Bluebird Bio (Cambridge, MA; no SBIR), gene-therapy startup, expects to launch studies next year for two rare genetic diseases: childhood adrenoleukodystrophy, or ALD, an inherited and lethal neurological disorder; and beta thallasemia, which causes the destruction of red blood cells and leads to life-threatening anemia. Its technique involves extracting a patient's own bone-marrow cells, isolating certain stem cells, and delivering the gene therapy before returning the cells to the body. [Ron Winslow, Wall Street Journal, Dec 29, 12]
bluebird bio (Cambridge, MA; no SBIR) said that the California Institute for Regenerative Medicine has approved a $9.3 million award to support the development one of bluebird bio’s gene therapies. ... called LentiGlobin, said the company. LentiGlobin is designed to treat beta-thalassemia, an inherited blood disorder that causes the body to have an inadequate amount of functional hemoglobin. [Boston Globe, Oct 27, 12]
gene-therapy company bluebird bio (Cambridge, MA; $550K SBIR as Genetix Pharma) has added Arch Venture Partners to its roster of backers for its latest round that brought in $30 million in financing ... raised a total of approximately $75 million, the latest being a $35 million round in 2010 ... In March, bluebird bio entered into a deal, worth up to $4.2 million, with the French Muscular Dystrophy Association (AFM). The agreement focused on the development of LentiGlobin, a treatment intended for beta-thalassemia and sickle cell anemia. [Rodney Brown, Mass High Tech, Apr 20, 11]
Bluebird bio, (Cambridge, MA; no SBIR) genetics-focused biotech firm, has entered into a deal, worth up to $4.2 million, with the French Muscular Dystrophy Association (AFM). The agreement focuses on the development of LentiGlobin, a treatment intended for beta-thalassemia and sickle cell anemia. [Michelle Lang, Mass High Tech, Mar 16, 11]
BluDiagnostics (Madison, WI; no SBIR) startup, which is developing a saliva-based fertility test, has raised $600,000 in debt financing as part of a seed funding round, co-founder Katie Brenner confirmed ... will start working to raise its Series A funding round shortly after the seed round’s final close [Jeff Buchanan, xconomy Wisconsin, Jan 19, 16]
As the search for missing airliner Malaysia Airlines Flight 370 continues, equipment from Bluefin Robotics (Quincy, MA; $2M SBIR) will be helping. Last year, Bluefin announced the expansion of its Naval Research Laboratory (NRL) contract to produce a variation of its specialized, Bluefin-21 UUV Knifefish product. [David Harris, Boston Business Journal, Mar 25, 14]
Bluefin Robotics (Quincy, MA; $2M SBIR) designer of Unmanned Underwater Vehicles, or UUVs, said that one of its vehicles recently completed an autonomous run from Boston to New York in 109 operational hours. [Chris Reidy, Boston Globe, Oct 30, 13]
Autonomous underwater vehicle maker Bluefin Robotics (Cambridge, MA; $2M SBIR) received the OK from the U.S. Navy that its subsea lithium battery is safe for use aboard Naval aircraft. [Patricia Resende, Boston Business Journal, Apr 2, 13]
Bluefin Robotics (Cambridge,MA;$2M SBIR) has won a $30 million contract modification to exercise the third option under its deal with the U.S. Navy for an underwater bomb-finding robot. [Rodney Brown, Mass High Tech, Mar 3, 11]
Bluefin Robotics (Cambridge,MA;$2M SBIR) reports it has reeled in a contract for its spray glider autonomous underwater vehicle from Horizon Marine (Marion, MA; one 1991 SBIR). ... In February, the Navy exercised an option on a previously awarded contract, worth a potential $29 million, with Bluefin for its Bluefin-9 mine-detecting AUV. [Jul 08]
Bluefin Robotics (Cambridge, MA; $2M SBIR) reports it has established worldwide distribution agreements for sales and support of its autonomous underwater vehicles, pressure-tolerant subsea lithium polymer batteries and related technologies [Mass High Tech, Nov 15]
Meanwhile, subsdies in Minnesota. The state of Minnesota approved its first five grants worth $2.27 million to manufacturers as part of the new, $24 million Job Creation Fund. The fund hopes to attract scores of companies to Minnesota and to encourage firms here to stay and expand in the state. ... So far, the state has approved grants to Axis Clinicals (Dilworth, MN; no SBIR) ($779,988) an India-based clinical-trials laboratory that decided to open a new $12 million facility in Dilworth with 100 employees. , Heraeus Medical Components (White Bear Township, MN; no SBIR) ($498,100) Heraeus Medical is expected to add 55 workers. It plans to spend $7.8 million to renovate its existing plant, Bluegrass Proteins (Dawson, MN; no SBIR) ($650,000) Kentucky-based Bluegrass Proteins will bring 56 jobs, plans to invest $18.2 million to buy and retrofit the Associated Milk Producers’ raw milk plant, Harmony Enterprises(Harmony, MN; no SBIR) ($215,000), and Valmont Industries(Farmington, MN; no SBIR) ($129,000). an aluminum pole maker with operations in Minnesota, Indiana and Canada... makes waste compactors and recycling balers. Its plans include 14 new hires and a $1.1 million plant expansion. will add 15 workers. Combined, the five companies plan to add 240 jobs in Minnesota. [Dee DePass, Minneapolis Star Tribune, Apr 1, 14]
Bluegrass Vascular Technologies (San Antonio, TX, no SBIR, founded 2010) focused on innovating lifesaving devices and methods for vascular access, announced the enrollment of its first patients in the SAVE-US (Surfacer® System to Facilitate Access in VEnous Occlusions – United States) pivotal trial. [company press release, Jan 18, 18]
Bluegrass Vascular Technologies (San Antonio, TX; no SBIR) that relocated its headquarters from Lexington, Kentucky, to San Antonio in 2014, has entered into a strategic relationship with Merit Medical Systems. ... will give Bluegrass Vascular streamlined distribution of its Surfacer Inside-Out Access Catheter in Europe. [W. Scott Bailey, San Antonio Business Journal, Mar 6, 17]
Bluegrass Vascular (San Antonio, TX; no SBIR, founded 2010) announced that it has received CE Mark approval and is launching limited commercial sale of its Surfacer® Inside-Out® Access Catheter System. The Surfacer System is indicated for obtaining central venous access to facilitate catheter insertion into the central venous system via a novel Inside-Out approach. [company press release, Aug 30, 16] closed $4.5 million in Series A financing in 2014 ... a spin-out from medical technology incubator Therix Medical [company website]
Bluegrass Vascular Technologies (San Antonio, TX; no SBIR, founded 2010 by Therix Medical (no SBIR)) focused on innovating lifesaving devices and methods for vascular access procedures, announced today that its Surfacer® Inside-Out® Access Catheter System was successfully used on a patient facing life-threatening complications from end-stage renal disease. The procedure was performed under Germany’s “compassionate use” program, which grants access to physicians for use of medical devices not yet CE Mark approved in Europe [company press release, Mar 30, 16]
Moving to the money. Medical technology startup Bluegrass Vascular Technologies (now San Antonio, TX; no SBIR) closed on $4.5 million in new investor funding. Targeted Technology Fund II, a San Antonio-based venture capital fund that invests in early-stage life sciences companies, led the Series A investment. As part of the deal, Bluegrass Vascular, which was launched in 2011, will relocate its headquarters from Lexington, Ky., to San Antonio. ..... “The Surfacer System is a propriety system that allows physicians to gain venous access using a novel inside-out approach,” says Alan Dean, senior managing director of Targeted Technology Fund II and director of Bluegrass Vascular. [W. Scott Bailey, San Antonio Business Journal, Jul 31, 14]
Blueprint Medicines (Cambridge, MA; no SBIR, founded 2011) announced that [FDA] has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT is the first precision therapy approved to treat a genomically defined population of patients with GIS [company press release, Jan 9, 20] total funding $240M [crunchbase.com]
Ipsen (France) and Blueprint Medicines (Cambridge, MA; no SBIR) announced Ipsen, through its subsidiary Clementia Pharmaceuticals, and Blueprint Medicines have entered into an exclusive, worldwide license agreement for the development and commercialization of BLU-782, an oral, highly selective investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). [joint companies press release, Oct 16, 19]
Blueprint Medicines (Cambridge, MA; no SBIR) has another deal on its plate that could net it hundreds of millions of dollars. The biotech raised $147 million in [IPO] last year, two months before it received FDA approval to begin clinical trials on its two lead drug candidates in July. Now Blueprint has signed a deal with Roche to apply its drugs, known as kinase inhibitors, to cancer immunotherapy. ... Blueprint agreed to discover, develop, and commercialize up to five small molecules for the pharmaceutical giant, with Roche offering Blueprint $45 million up front. Blueprint can make $215 million more on option fees and milestone payments related to research, preclinical, and clinical development of the drugs. [David Holley, xconomy,.com, Mar 15, 16]
Blueprint Medicines (Cambridge, MA; no SBIR) developing targeted therapies for cancer, said that new investor Fidelity Biosciences joined in the $40 million Series A financing ... to apply fresh scientific understanding to produce a family of kinase inhibitors — drugs that can block the action of “switching points’’ that regulate cell processes and the proliferation of cancerous cells — to combat diseases ranging from melanomas and leukemias to lung and colon cancers. [Chris Reidy, Boston Globe, May 24, 12]
Blueprint Medicines,(Cambridge,MA; no SBIR) early-stage cancer therapeutics firm, has scored a $40 million Series A funding round ... use the funds and its own compound library and Insights-to-Validation platform to develop personalized treatments based on targeted molecular aberrations of cancer. ... co-founded in 2011 by Nick Lydon, Brian Druker, Chris Varma and David Armistead. Lydon and Druker, both scientific advisory board members, co-developed Gleevec, a drug approved for the treatment of chronic myelogenous leukemia. [Michelle Lang, Mass High Tech. Apr 11,11]
Bayer AG and BlueRock Therapeutics (Cambridge, MA; no SBIR) announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform [for] approximately USD 1 billion. [joint compaies press release, Aug 8, 19]
new stem cell therapeutics company, BlueRock Therapeutics (New York, Toronto, and Boston) launched with $225 million from international healthcare giant Bayer and Versant Ventures. .... Using work from Nobel Prize winner Shinya Yamanaka and others, company said one of its first projects aims to repair heart muscle, injured from heart attack, with new cells created from stem cells. [Alex Lash, xconomy.com, Dec 12, 16]
|
||||||
DANIEL ISHAG, an entrepreneur who made tens of millions by selling his online advertising business, is to float a biological company with technology that can cleanse waste water. Bluewater Bio International is aiming to float on the Alternative Investment Market in the next few weeks, valuing the business at about £25m. ... Its technology uses bacteria found naturally in soil to cleanse waste water. It claims to remove 99% of biological contamination in waste water and to be more effective than other nitrogen and phosphate systems. [The Sunday Times, Nov 25]
Blue Water Vaccines (Cincinnati, OH; no SBIR), a developer of a universal flu vaccine, raised a $7 million seed round [Cincy Inno, Aug 8, 19]
Blue Water Vaccines (Cincinnati, OH; no SBIR), developing a universal flu vaccine, announced the completion of an oversubscribed $7M seed round, FINSMES reports. ... basing its work on that which was originally developed by theoretical epidemiologist Sunetra Gupta and virologist Craig Thompson’s team at the University of Oxford in the U.K. [Courtney Gabrielson, CincyInno, Jul 9, 19]
JustRight Surgical, now Bolder Surgical (Louisville, CO; no SBIR, founded in 2010), announced it has secured $27 million. ... provides surgeons right-sized surgical instruments to safely and effectively perform minimally invasive surgery in pediatric patients from neonate to teenager. [company press release, Jan 16, 19]
Bolt Biotherapeutics (Redwood City, CA; no SBIR, founded 2015), a clinical-stagebiotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of theinnateimmune system to treat cancer, announced the closingof an oversubscribed $93.5 million Series C financing. ... has raised more than $170 million since its founding [company press release, Jul 1, 20]
Bolt Biotherapeutics (Redwood City, CA; no SBIR, founded 2015) a biotechnology company focused on unleashing the power of the immune system to achieve anti-tumor immunity in patients, announced the completion of a $54M Series B financing [company press release, Feb 5, 19] founded by Ed Engleman, a professor of pathology and medicine at Stanford Medicine. The company’s drug platform is based on technology licensed from Stanford University. [Frank Vinluan, xconomy.com, Feb 5, 19] total funding $30M [crunchbase.com]
Lab-made leather replacements will soon join vegetable-based meat replacements on store shelves thanks to startups like Bolt Threads, which today announced that it would join companies like Modern Meadow (Brooklyn, NY; two SBIRs) in the quest to bring to market vegetable-based replacements for animal hides. ... Earlier this year, Bolt Threads raised a $123 million financing to expand its business beyond the manufacture of spider silk ... Working with established partner Stella McCartney and using technology licensed from the biomaterials company Ecovative Design, Bolt is bringing Mylo’s mushroom-based leather replacement to the world in a debut of one of McCartney’s Falabella bag designs made from the mushroom material. [Jonathan Shieber, TechCrunch, Apr 16, 18]
Bolt Threads, the startup making spider silk from microbugs, has raised a giant $123 million Series D round of funding. [Sarah Buhr, Techcrunch.com, Jan 3, 18]
Bolt Threads, the biotech company spinning microbes into spider silk, is raising a whopping $106 million in Series D financing. Bolt Threads has been on a meteoric rise since it first told TC about its ambitious endeavor to make spider silk, a material stronger than teflon but softer than a cloud. [techcrunch.com, Nov 9, 17]
Bolt Threads, the biotech company spinning microbes into spider silk, is raising a whopping $106 million in Series D financing. Bolt Threads has been on a meteoric rise since it first told TC about its ambitious endeavor to make spider silk, a material stronger than teflon but softer than a cloud. [Sarah Buhr, techcrunch.com, Nov 9, 17]
Bolt Threads (Emeryville, CA; no SBIR) says it is now poised to use spider silk as nature intended—as a high-strength fiber. David Breslauer, Bolt's co-founder, says company scientists have engineered thousands of recombinant spider silk genes into yeast, in search of the highest performing materials. They have also plowed through a vast amount of trial and error to optimize the conditions for growing and purifying the proteins and spinning them into fibers. “It has been hard,” Breslauer says. But he insists that Bolt Threads has finally succeeded, though he declines to detail the exact procedures. [Robert Service, Science, Oct 20, 17] raised $40M in 2015 and $50M in 2016 [company website]
[a tie] was spun from the same material spiders spin out from their behinds. The difference is this thread was mass-produced from fermented microbial poop instead, and it’s the first product out from materials science startup Bolt Threads (Emeryville, CA; no SBIR). ... Bolt is not the only company using this process to mass produce the silk. Japan-based Spiber also uses a special yeast to make spider silk and plans to produce its first product, a $1,000 silk-spun “Moon Parka” jacket sometime this year. [techcrunch.com, Mar 10, 17]
Biotech startup Bolt Threads (Emeryville, CA; no SBIR) raised $50 million in a Series C round of venture funding, the company announced ... has also inked a deal with [lifestyle brand] Patagonia to begin developing and designing products with these science fiction-esque new threads. [Lora Kolodny, techcrunch.com, May 11, 16]
Bolt Threads (Emeryville, CA; no SBIR) use genetic engineering to make extremely versatile fibers the way spiders can. ... While synthetic fibers made from petroleum tend to be good at one thing, silk can be reëngineered to suit diverse applications. Spiders themselves do this, fine-tuning their silk to make strong structural struts for their webs, sticky spots to capture prey, and a tough line to hang from. ... genetically engineered yeast brew silk proteins that can be spun into fibers. The properties of those fibers can be altered by tinkering with the protein concentration and the temperature, tension, and other aspects of the spinning process. ... says its first products will be in consumer apparel in 2016. Its fibers, which are much finer than natural materials like cotton and stronger than nylon.. [Katherine Bourzac, technologyreview.com, Sep 21, 15]
Bolt Threads (Emeryville, CA; SBIR not allowed for secret firms) emerged from stealth with $32.3 million in Series B funding to make clothing fabrics inspired by spider silk. ... 2009 to create material from proteins similar to that of a spider web and can adjust the properties of the material for strength, stretchiness, softness or comfort. The company plans to partner with athletic apparel companies to put the materials in activewear. .... turn raw ingredients – sugar, water, and yeast – into raw fibers and industry-best performance fabrics.” [Gina Hall, Silicon Valley Business Journal, Jun 4, 15]
Bone Biologics (Burlington, MA; one SBIR in 2005) up 57% [Dec 10, 22]
Stratasys (Eden Prairie, MN; no SBIR) added the maker of a new generation, high-speed aircraft to its roster of aerospace customers. Boom Supersonic (Denver, CO; no SBIR) aviation startup, is deploying Stratasys 3-D printing capabilities to build its new supersonic passenger airplane capable of flying nearly three times as fast as any commercial aircraft on the market, according to a news release from both companies. ... Stratasys generated $672 million in 2016 [Nick Williams, Minneapolis / St. Paul Business Journal, Jun 15, 17]
Boragen (Research Triangle Park, NC; no SBIR) developing a next-generation fungicide, raising $10 million. ... the first startup launched by RTP’s AgTech Accelerator. [David Ranii,Raleigh News & Observer, Apr 11, 17]
agtech startup Boragen (Research Triangle Park, NC; no SBIR) raised $10 million in funding. With that Series A investment round, aims to develop new fungicides that overcome the problem of chemical resistance. It’s the first investment made by AgTech Accelerator, which launched last year to help nurture promising new technologies for the farming sector. [Frank Vinluan, xconomy.com, Mar 6, 17]
Techne Corp (Minneapolis,MN;no SBIR) announced it acquired Boston Biochem (Cambridge, MA; $900K SBIR), a developer of products related to regulatory protein ubiquitin, and its European markets distributor. The deal closed last Friday and the assets were purchased in cash. [Wendy Lee, Minneapolis Star Tribune, Apr 4]
The Massachusetts Life Sciences Center said it has awarded $500,000 grants to three Bay State life sciences companies. "The companies receiving grants are Boston Biochem (Cambridge, MA; $900K SBIR)) Tetragenetics (Cambridge, MA and Ithaca, NY; $1.1M SBIR), and Thermedical (Somerville, MA; no SBIR) the center said in a press release. "Each company will receive $500,000 from the center to match federal small business grant funding that the companies had previously been awarded.... The three companies that are receiving awards have committed to collectively creating 40 new jobs in the Commonwealth by the end of 2011, including six jobs to be relocated from New York." The center is a quasi-public agency with the mission of helping to create jobs in the state's life sciences industry. [Boston Globe, Jun 1, 10]
Boston Biomedical (Norwood, MA; $1.6M SBIR) announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel will be discontinued due to futility. [company press release, Jul 1, 19]
Boston Biomedical (Norwood,MA; $900K SBIR) a five-year-old biotechnology startup, said it has agreed to be acquired by Japanese drug maker Dainippon Sumitomo Pharma [which] will make an upfront payment of $200 million to Boston Biomedical shareholders and later make development milestone payments up to $540 million relating to the compounds being developed by Boston Biomedical, which is working on anticancer drugs.If the drugs eventually are launched, the Japanese buyer will make additional milestone payments totaling as much as $1.9 billion based on meeting sales targets, boosting the potential value of the deal to $2.6 billion. [Robert Weisman, Boston Globe, Mar 1, 12]
Boston Biomedical (Norwood,MA;$900K SBIR) signed a license agreement with Dainippon Sumitomo Pharma Co. Ltd. of Osaka, Japan, for BBI's BBI608 candidate compound for all oncology indications. ... BBI will get a $15 million upfront payment and clinical trial support ... During the option agreement period, Dainippon will pay a maximum of $55 million for part of the development costs of BBI608 and to continue the option. If it exercises the option for Japan, upon successful clinical development and commercialization of BBI608 in Japan, BBI could receive a total maximum of about $100 million, including milestone payments, in addition to running royalties. ... BBI was created in 2007 when Woburn-based ArQule Inc. gave former chief scientific officer and current BBI CEO Li a $5 million research contract to start the spinout company. [Lon Valigra, Mass High Tech, Apr 12, 11]
In a new video, the Atlas robot [by Boston Dynamics (Waltham, MA; $5.4M SBIR)) is seen carrying a tool bag up some scaffolding and then throwing it to a human construction worker who's standing on a simulated construction site. The demonstration requires Atlas to use its sensors and a large variety of capabilities to navigate the site while remaining balanced. [Michael Kan, pcmag.com, Jan 28, 2023]
Hyundai Motor Group and SoftBank Group agreed on main terms of the transaction pursuant to which Hyundai Motor Group will acquire a controlling interest in Boston Dynamics (Waltham, MA; $5.5M SBIR) in a deal that values the mobile robot firm at $1.1 billion. The deal came as Hyundai Motor Group envisions the transformation of human life by combining world-leading robotics technologies with its mobility expertise. Financial terms were not disclosed. [joint companies press release, Dec 11, 20]
Boston Dynamics [Waltham, MA; $5.4M SBIR)’ Spot is patrolling a Singapore park to encourage social distancing. In a new pilot program, a remote operator will control Spot as it patrols around two miles of Singapore’s Bishan-Ang Mo Kio Park. A recorded message encourage social distancing will be broadcast from the robot. [Brian Heater, TechCrunch, May 8, 20] The park is a Lush 153-acre urban park along the banks of a former canal with lawns, walking tracks & playground. [park website] where the daily high is 88F in a stable well organized city-state island where hundreds of ships idle offshore awaiting their turn into the port.
Boston Dynamics (Waltham, MA; $5.3M SBIR, founded 1992) For nine years, the secretive firm — which got its start with U.S. military funding — has unnerved people around the world with YouTube videos of experimental robots resembling animal predators. ... its parent, SoftBank, rebuffed requests seeking information about its work. ... [CEO]Marc Raibert, agreed to a brief interview in late May. Raibert had just demonstrated the machine that will be the company’s first commercial robot in its 26-year history: the dog-like, door-opening SpotMini, which Boston Dynamics plans to sell to businesses as a camera-equipped security guard next year. [Matt O’Brien, San Francisco Chronicle, Jun 7, 18]
Google-owner Alphabet has agreed to sell robotics firm Boston Dynamics (Waltham, MA; $3.2M SBIR) to SoftBank, the Japanese telecommunications and technology company. Terms of the deal remain undisclosed. ... That Alphabet has finally sold its most high-profile robotics subsidiary may signal an end to the company’s passing flirtation with the world of humanoid and industrial robots. .... As part of the SoftBank deal, Alphabet is also selling Schaft, a humanoid robotics company Google acquired as part of its Replicant buying spree back in 2013 and 2014. Schaft was spun out of the JSK Robotics Laboratory within the University of Tokyo. [theverge.com, Jun 9, 17]
Boston Dynamics ($3M SBIR), the manufacturer of many a nightmarish robot, has been testing its mechanical dog, Spot, for package delivery in Boston. [April Glaser, recode.net, Apr 27, 17]
One of the firms [Andy Rubin] persuaded Google to buy [in 2013] is Boston Dynamics (Waltham, MA; $3.4M SBIR), a maker of artificial dogs and other scary-looking mechanical beasts. Its founder, Marc Raibert, is known to cherish his autonomy. That may help explain why Boston Dynamics is now up for sale. An uncertain path to profitability may also play its part in that decision. The firm’s automatons are a hit on YouTube, but internally Alphabet thinks it will take another decade before they can be put to commercial use. [The Economist, Jun 11, 16] Meanwhile, BD has been attracting good military bucks.
Big player checks out. Google parent Alphabet is dismantling its robotics effort after less than three years and aims to sell Boston Dynamics, the legged-robot maker that was the centerpiece of the program, according to people familiar with the matter. The moves reflect internal disagreements about the direction of Boston Dynamics and concerns about Alphabet’s ability to make money from robots as the company increases its scrutiny of costs, said the people familiar with the matter. In addition to Boston Dynamics, Google bought at least six other robotics firms in 2013, combined them into a group dubbed Replicant [recently dissolved] [Jack Nicas, Wall Street Journal, Mar 23, 16]
Boston Dynamics (Waltham, MA; $5.4M SBIR) [robots] picking up boxes and staggering gamely through the woods. Impressive though those feats are, it seems they may no longer fit with Google’s new vision for its robotics research, as Bloomberg is reporting that the subsidiary is to be sold off. [Will Knight, technologyreview.com, Mar 17, 16]
[humanoid robot] Atlas was developed with military funding by Boston Dynamics (Cambridge, MA; $3.6M SBIR), which was among several robotics businesses acquired by Google shortly before the first [DARPA Robotics Challenge] event [December 2013]
Google-owned bot maker Boston Dynamics ($3.4M SBIR) has added another leggy member to its family of fearsome robotic quadrupeds. This one’s called Spot, and its special talent is a killer sense of balance. Even as Boston Dynamics employees repeatedly kick the robot, it manages to stay standing. .... Among the more resilient is Schaft, a humanoid from Japan that blew away the competition in the DARPA Robotics Challenge, a contest where humanoid robots had to tackle an obstacle-course of mock-rescue tasks. [Nidhi Subbaram, BetaBoston Feb 10, 15] BD video of four-legged robot with a note that no robots were harmed. Note DARPA's use of prizes instead of subsidies. The difference, of course, is that prize contestants have an incentive to succeed; the subsidy recipient has an incentive to succeed only enough to keep the sponsor's attention. Which is one contributor to the success of "SBIR mills" in attracting awards.
A phase-changing material developed by robotics firm Boston Dynamics (Waltham, MA; $3.3M SBIR) and MIT researchers could allow a robot to shape-shift much like the T-1000 robot featured in the movie "Terminator 2." .... Boston Dynamics and MIT began developing the material as part of the Chemical Robots program of the Defense Advanced Research Projects Agency (DARPA), which was interested in "squishy" robots that can squeeze through tight spaces and then expand again, according to MIT. [Sara Castellanos, Boston Business Journal, Jun 16, 14]
The Atlas humanoid robot, unveiled last year by Boston Dynamics (Waltham, MA; $3M SBIR, built with DARPA funding), later acquired by Google, is a [too expensive] marvel. .... a million dollars, and consumes around 15 kilowatts of electricity .... [SRI that recently began working on that problem under a contract with DARPA] will be to replace the power-hungry hydraulics that move Atlas’s joints with a smaller number of lighter, more efficient, and cheaper electric components [Tom Simonite, technologyreview.com, April4, 14]
two of the robot-makers acquired recently by Google, Boston Dynamics (Cambridge, MA; $3M SBIR) and Schaft [a spin-out of the University of Tokyo, won the contest], dominated the [DARPA robot] contest [of 16 teams] , giving some sense of why the company was so keen to snap them up. ... The teams that placed second and fourth both used a humanoid robot called Atlas, developed by Boston Dynamics [Will Knight, technologyreview.com, Dec 21, 13]
Google has acquired Boston Dynamics (Waltham, MA; $3.2M SBIR) , a maker of military robots which can run, walk and imitate other human and animal movements. .... Founded in 1992, Boston Dynamics has secured government contracts including a $10 million contract in September from the Pentagon, to advance the LS3 (Legged Squad Support Systems) program. The company was first awarded a $32 million federal contract in 2010 to design and develop the robot, and began a two-year field test in 2012. [Kyle Aslpach, Boston Business Journal, Dec 16, 13]
Boston Dynamics (Waltham, MA; $3.2M SBIR) got a $10 million contract from the Pentagon to advance the Legged Squad Support Systems (LS3) program. .... advancing a legged robot that can carry gear for personnel through rugged terrain all while interpreting verbal and visual commands, according to the company. .....first awarded a $32 million federal contract in 2010 to design and develop the robot. [Patricia Resende, Boston Business Journal, Sep 20, 13]
A prototype built by Boston Dynamics (Waltham, MA; $3.3M SBIR) reached a speed of 18 miles per hour, a new record for legged robots, the company said today. The previous record was 13.1 miles per hour, set at MIT in 1989, according to Boston Dynamics. [Boston Globe, Mar 5, 12]
Boston Dynamics (Waltham,MA;$2.4M SBIR) reports it has landed $32 million from [DARPA] to develop a Big Dog-like robot to carry supplies for U.S. Marines. [Mass High Tech, Feb 2, 10]
The BigDog four-legged robot made by Boston Dynamics (Waltham, MA; $2.5M SBIR) set a new autonomous distance record for legged robots last year by traveling 12.8 miles without human intervention. And the Defense Department-funded robot recently spent some time undergoing tests at Ft. Benning, Ga., according to a video from the Ft. Benning news site the Benning Report. [Mass High Tech, Feb 27, 09]
Boston Dynamics (Cambridge, MA; $2.5M SBIR) got a $10M DARPA contract for the development of a dog-like robot - run, maneuver and jump to avoid obstacles- with a shot at $40M in follow-on Navy contracts. [Mass High Tech, Aug 3] The company calls itself the leading provider of human simulation software, tools, and solutions
Robo-tuna.
Boston Engineering
(Waltham, MA;
$1.8M SBIR, founded 1995, 70 employees ) announced
it received a $200,000 [state] grant to help commercialize its
fish-like underwater robot that could be used by the U.S. military for
inspecting ships, securing ports, and identifying contraband.
.... has raised more than $4 million for the development and
commercialization of its Unmanned Underwater Vehicle technology, said
Mark Smithers, co-founder and chief technology officer ....
part
of a START Stage II Grant, a $6 million initiative funded by the
Patrick administration and Boston-based venture capital firm
MassVentures to help growing companies commercialize their technologies
[Sara Castellanos, Boston Business Journal, Jun 27, 14]
Boston Engineering (Waltham, MA; four Phase 1 SBIRs) landed [yet another Phase 1 SBIR] to develop a robotic platform to catch, service, refuel and relaunch unmanned aerial vehicles, or UAVs. The Waltham engineering services company and researchers at Georgia Institute of Technology plan to design the “Unmanned Recovery, Service and Launch Automation” system (URSALA) [Mass High Tech, Jul 31, 09]
Boston Metal (Woburn MA; no SBIR) announced that it has raised $20M in a Series A funding round led by Breakthrough Energy Ventures with participation from Prelude Ventures and The Engine [which] accelerates the first industrial-scale deployments of Boston Metal’s molten oxide electrolysis (MOE) technology for the production of ferroalloys. The new funding also supports the continued scale-up of MOE for the production of emissions-free steel.... invented at the lab-scale at MIT and Boston Metal has since scaled the technology over 1,000x. [company press release, Jan 10, 19] Venture Breakhrough is $1-billion Bill Gates-chaired. The idea sounds a lot like a derivative of an earlier MIT spinout Molten Metal advoacated by the then MIT Tech spin-out leader John Preston.
Boston Metal (formally Boston Electrometallurgical, Woburn, MA; one SBIR) received a [$2M DOE] award to help commercialize molten oxide electrolysis production of primary iron and steel and a separate $150K SBIR for increasing efficiency of vanadium production. ... An electrolysis cell is a closed circuit, like a battery, but instead of producing electrical energy, it consumes electrical energy to produce a target metal or alloy by reducing [removing oxygen] a molten metal oxide, Boston Metal previously received a $2,279,027 award from DOE to develop a one-step molten oxide electrolysis process for producing titanium [Ti] metal directly from its oxide [Denis Paiste, MIT Materials Research Laboratory, Aug 29,18] ... has raised $13M to date [James Temple, MIT Tech Rvw, September 24, 2018]
Boston Micromachines (Cambridge, MA; $4.5M SBIR) specializing in deformable mirrors, said that one of its products is currently deployed in a telescope at the Palomar Observatory in California [Chris Reidy, Boston Globe, Sep 24, 12]
Optics systems maker Boston Micromachines (Cambridge, MA; six Phase II SBIRs in ten years) has landed a NASA Phase 2 SBIR to support NASA’s Exoplanet Exploration program .... will construct a 2048 actutor that can handle the harsh environments and correct what space telescope optics cannot. [Patricia Resende, Mass High Tech, May 7, 12]
Boston Micromachines (Watertown, MA; $3M SBIR) reports it has landed [another] $200,000 NASA [SBIR] to develop optics technology .. to develop a driver with a minimum hundred-fold reduction in power consumption and a tenfold reduction in size, while maintaining a high level of precision and decreasing costs. [Mass High Tech, Jan 7, 10]
Boston Micromachines ($2M SBIR)has paired with California-based Thorlabs (no SBIR) to develop a new Adaptive Optics (AO) toolkit aimed at making such technologies easier and cheaper for researchers, according to executives [Mass High Tech, Jan 21]
Boston Micromachines (Watertown MA) got a $600,000 Phase 2 SBIR from NASA. No record of prior SBIRs. [Mass High Tech, Nov 1, 06]
Boston-Power (Westborough, MA; $200K SBIR, founded 2005) maker of lithium-ion batteries, has raised $20 million in debt funding, according to a recent regulatory filing. ... Last December, Boston-Power said it received $290 million in financial backing to boost its manufacturing presence in China. [Sara Castellanos, Boston Business Journal, Feb 2, 15]
The Wall Street Journal reports that Boston-Power (no SBIR), a developer of advanced lithium ion battery technology, is raising $250 million from private investors. .... tied in part to Tesla’s plans to build a large battery factory. ... raised about $125 million in 2011, shedding some top executives and moving most of its operations to China. [Curt Woodward, xconomy.com, Jun 13, 14]
Boston Power redeploying. announcing today that it has raised $125 million. The deal, which brings Boston-Power’s total funding pot to more than $316 million, has some serious implications for the company’s place in Massachusetts ... What’s staying in Massachusetts, in addition to [Chair] Lampe-Onnerud, are the R&D, designing, and fine-tuning of the company’s battery cells. All of these operations will take place in the Westborough office, while China-based teams will focus on developing the battery technology for customer applications. Boston-Power will be reducing its roughly 80-person workforce in the Bay State by about 35 percent, as those functions shift abroad, says Lampe-Onnerud. [Erin Kutz, xconomy.com, Sep 19, 11]
Boston-Power has added $6.4 million to its previously announced Series E round of $60 million, according to a regulatory filing. [Mass High Tech, Aug 4, 10]
Boston-Power won a new round of venture capital worth $60 million, which will help the company to grow its operations in Massachusetts [Kyle Alspach, Mass High Tech, Jun 25, 10]
Boston-Power has joined a coalition of Swedish automotive and technology organizations to commercialize high performance electric cars based on Saab Automobile AB designs. The group has received the equivalent of $12 million in funding from the Swedish Energy Agency to advance the development of the ZE Saab 9-3, an electric version of the carmaker’s sedan [Jackie Noblett, Mass High Tech, Dec 15, 09]
Boston-Power said that its Sonata battery will ship with the new HP Pavilion dv8 Entertainment Notebook PC. [Boston Globe, Oct 15, 09]
Money Talks. A post on Scott Kirsner's Innovation Economy blog on Boston.com notes that A123 Systems spent far more [$500K] on lobbying than Boston-Power did [$30K]. [Boston Globe, Aug, 7, 09] Boston-Power apparently still could win future federal funding. It is in the running for a $100 million grant from the Department of Defense, to be announced later this year. [Innovation Economy blog]
Boston-Power reports it has raised $55 million in new funding, which the Westborough-based company says it will use to ramp up manufacturing, sales, marketing, and research and development efforts for its Sonata Lithium-ion batteries. ... This Series D round brings Boston-Power’s total funding to $125 million since it was founded in 2005 [Mass High Tech, Jan 14, 09]
next-generation lithium-ion battery [company website] Boston-Power (Westborough, MA; no SBIR) raised an additional $45M in funding from VC firms ... previously raised $24.7M. [Wall Street Journal, Jan 3] Frost & Sullivan 2007 technology innovation of the year award
Boston Therapeutics (Manchester, NH; no SBIR), a developer of diabetes therapeutics, announced that it has secured its first purchase order for distribution of the dietary supplement Sugardown in Italy. [DC Dennison, Boston Globe, Dec 30, 11] A public company ... a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. [Thestreet.com]
Over the last half-year, Google has quietly acquired seven technology companies in an effort to create a new generation of robots. .... not something aimed at consumers. Instead, the company’s expected targets are in manufacturing .... Among the companies are Schaft, a small team of Japanese roboticists who recently left Tokyo University to develop a humanoid robot, and Industrial Perception (Palo Alto, CA; no SBIR), a start-up here that has developed computer vision systems and robot arms for loading and unloading trucks. Also acquired were Meka (San Francisco, CA; no SBIR) and Redwood Robotics (San Francisco, CA; no SBIR), makers of humanoid robots and robot arms, and Bot & Dolly (San Francisco, CA; no SBIR), a maker of robotic camera systems that were recently used to create special effects in the movie “Gravity.” A related firm, Autofuss (San Francisco, CA; no SBIR), which focuses on advertising and design, and Holomni (Mountain View, CA, no SBIR) a small design firm that makes high-tech wheels. The seven companies are capable of creating technologies needed to build a mobile, dexterous robot. Mr. Rubin said he was pursuing additional acquisitions. [John Markoff, New York Times, Dec 4, 13] Note that all the US companies live around San Francisco Bay with the hotbed of innovative venture capital. And none needed SBIR to attract major investment.
NASA will test energized structures devised by Boundless ( Boulder, CO) wherein part of the spacecraft structure is a battery. At least some of the development came from MDA Phase 2 SBIR. Why, do you suppose, did NASA never fund an SBIR for the technology? Too much risk? If not to take technical risks, what does NASA do with its SBIR? Add incremental bricks to its temple of knowledge?
Boundless Bio (San Diego, CA; SBIR does not do stealth) came out of stealth mode with an announcement that it had raised a $46.4 million Series A financing round to fund the development of cancer drugs targeting tumors that have what’s known as extrachromosomal DNA. [Sarah de Crescenzo, xconomy.com, Sep 19, 19]
BoXZY (Pittsburgh, PA; no SBIR) is launching a Kickstarter to raise funds for manufacturing and scaling up production. [CEO] Johnson said they have set a goal of $50,000 for the campaign but have a stretch goal of $600,000. ... In addition to 3-D printing, the [consumer desktop 3-D printing system] also functions as a CNC milling and laser cutting robot. [Justine Coyne, Pittsburgh Business Times, Mar 6, 15]
The FDA rejected Braeburn Pharmaceuticals’ (Princeton, NJ; no SBIR) buprenorphine injection for treating opioid addiction. Princeton, NJ-based Braeburn did not explain why the FDA rejected its drug, but said no new clinical trials are needed. [Alex Lash, xconomy.com, Jan 25, 18]
BrainCells (San Diego, CA; no SBIR) said it will acquire an experimental drug that failed as a treatment for Alzheimer’s disease but has shown promise for treating depression and other disorders that affect mental cognition. London-based Proximagen Group will receive up to $51 million if BrainCells reaches certain milestones in the development of sabcomeline. ... employs about 30 people, uses technology developed by its founders to test experimental compounds and molecules for their ability to trigger the growth of neural stem cells that improve psychiatric and neurological disorders. [Keith Darce, signonsandiego, Aug 6, 10]
Braingu (Grand Rapids, MI; $1.6M SBIR) received a five-year, $125 million contract to support a cloud-based command and control environment for the U.S. Air Force’s Advanced Battle Management System. The SBIR Phase III award [not SBIR money] will include the provision of DevSecOps as a service to the Department of Defense Platform One at multiple security classification levels, DOD said. [Kacey Roberts, govconwire.com, June 9, 2023]
BrainScope (Bethesda, MD; no SBIR) has landed a new federal clearance, verifying its technology's ability to detect and assess concussions, BBJ reports. The startup makes a portable medical device that can quickly assess traumatic brain injuries, which affect millions of Americans annually. BrainScope previously was awarded more than $30M in DoD research contracts and is backed by more than $16M in venture funding. [Kieran McQuilkin, DCInno, Jan 3, 19]
BrainScope (Bethesda, MD; no SBIR) announced that it has been awarded a research contract by (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and concussion products. [company press release, Sep 7, 18] previously awarded more than $27 million in [DOD] research contracts. [Morgan Eichensehr, Baltimore Business Journal, Sep 4, 18]
BrainScope (Bethesda, MD; no SBIR) the medical neurotechnology company which created the first FDA-cleared handheld medical device for assessment of the full spectrum of traumatic brain injury, announced it has completed a $16 million equity financing [to] to support the commercial launch of its flagship BrainScope One medical device. [company press release, Aug 30, 17]
BrainScope got the [FDA] green light to promote the Ahead 300, a device to evaluate traumatic brain injuries. It employs a smartphone connected to a custom sensor to track and examine a patient's brain injuries. The device is financed in part by Steve Cases' Revolution venture fund and also received $500,000 in a competition from General Electric and the NFL. [Washington Business Journal, Sep 29, 16]
Brainscope (Bethesda, MD; no SBIR) picked up a $500K from the NFL in 2015 to advance its non-invasive brain function measuring technology. [DC InnoBeat, Sep 14, 16]
Even if an assessment test on the sideline of a football or soccer field deems you to be concussion-free after a blow to the head, that doesn’t necessarily mean you didn’t suffer one, says Michael Singer, CEO of BrainScope (Bethesda, MD) that has developed a new technology for detecting signs of a concussion in a person’s brain waves and has raised approximately $70 million from investors including the U.S. Department of Defense and the NFL. There is no objective way to detect or assess a concussion, technically known as a mild traumatic brain injury, and BrainScope is trying to change that. [Mike Orcutt, technologyreview.com, Jun 9, 16]
BrainScope recently took home the Emerging Life Science Firm of the Year prize at the 28th annual award banquet. The firm has developed technology to spot concussions in athletes, soldiers and others who've suffered head trauma. Last year, BrainScope won $500,000 after coming in as one of six finalists in the General Electric NFL Head Health Challenge. [Bethesda Magazine, May 17, 16]
BrainScope (Bethesda, MD; no SBIR) whose devices will help on-site assessment of traumatic brain injuries, has received $12 million from government contracts. The Maryland Venture Fund has invested a total of $900,000 in the company. The funds are raised by InvestMaryland, a public-private partnership between the state and venture capital firms [Jeff Clabaugh, Washington Business Journal, Aug 5, 14]
The Maryland Technology Development Corp. (Tedco) has invested $1.1 million in 14 state startups.The grants were made through the organization's Technology Commercialization Fund. ... toward advancing the each company's technology and product commercialization efforts. Common Curriculum LLC, Diagnostic Biochips Inc. and Firejack Inc. were each awarded $100,000. • Authentik Solutions LLC; Brain Sentry LLC; Clear Guide Medical LLC; ConverGene LLC; Cordex Systems LLC; Pregmama LLC; SameGrain, Inc; TimberRock Energy Solutions, Inc. and Vasoptic Medical, Inc. each received $75,000. • Magpie Sensing LLC was awarded $74,990 • Weinberg Medical Physics LLC received $60,000 [Baltimore Business Journal, Jul 19, 13]
Brainstorm Cell Therapeutics (Hackensack, NJ and Israel; no SBIR) up 29% [Dec 29, 17] This past year was an extraordinary success for BrainStorm Cell Therapeutics. A key accomplishment was the enrollment of the first US patients in the Phase 3 clinical trial of NurOwn(R) for the treatment of amyotrophic lateral sclerosis (ALS) [CEO letter, Dec 29, 17]
Brain Tunnelgenix Technologies (Hamden, CT; no SBIR) that has developed a non-invasive way to measure body temperature, has raised $250,000 of a planned $6 million funding round, according to federal documents. [Mass High Tech, Apr 19, 10]
BrainXell (Madison, WI; $3.5M SBIR) raised a $13 million Series A round last month for a $59 million post-money valuation. [Teddy Nykiel, WiscInno, October 15, 2021]
BrainXell (Madison, WI; no SBIR) spun out of human stem cell research performed at the university. BrainXell, which was launched in 2015 and made its first sale earlier this year, turns stem cells into neurons in its laboratory, then sells those cells to other scientists, some of whom are working to develop new drugs. [Jeff Buchanan, xconomy.com, Nov 8, 16]
Bra-Ket Science, a stealthy research firm in Austin [TX}, reported raising $1.8M in equity funding out of a $3.1M offering. The company’s sparse website says it’s working on a new approach to creating “practical, room-temperature qubit storage.” [Brent Wistrom, AustinInno, July 1, 20
Globus Medical entered into an agreement to buy Branch Medical Group (Eaglesville, PA; no SBIR, founded 2005, 100+ employees) for $52.9 million. ... makes high precision spinal and orthopedic medical devices. ... generated sales of $23.3 million and earnings of $9.1 million last year. [John George, Philadelphia Business Journal, Feb 26, 15]
Brashear, a big old little company with at least two recent MDA Phase 2 SBIRs is being bought by biggie L-3 Communications for $36M hard cash. The abstracts for the two MDA awards suggests the $1.4M went for relatively advanced engineering of militarily useful mirrors. The press release describes Brashear as a leading developer and supplier of complex electro-optical systems for military and international customers, as well as prime aerospace contractors. In operation for over 120 years, the company designs and manufactures electro optical systems including, laser ranging and tracking systems, test range instrumentation, telescope systems, naval fire control systems and laser beam directors. Hardly the struggling entrepreneur that needs a nursery stage boost to jump start a new technology.
The Department of Energy will award $128M to support 75 research projects that seek to advance the development of solar technologies. Most money went to academic and large businessses. Several awards went to former SBIR winners: Energy Materials (Norcross GA one SBIR) won a $4M Solar project award to create new methods to deposit layers of material to make the cell, develop a high-speed process ; Leading Edge Crystal Technologies (Gloucester, MA; one SBIR) won $2.5M to develop a floating-silicon method for producing high-quality single crystalline wafers ; Sunvapor (Livermore, CA ; one SBIR) won $2.5M to show how using enormous tanks that normally store liquefied petroleum gas can be used to accumulate and store solar-generated steam ; Brayton Energy (Hampton,NH; $3M SBIR) won $700K to partner w Oak Ridge Lab to examine examine creep behavior—the tendency to deform under mechanical stress—in thin-sheet nickel alloys; Ceramic Tubular Products (Lynchburg, VA; $3.2M SBIR) won $1.9M to develop silicon carbide composite receiver tubes for molten chloride salt and liquid sodium receivers; Echogen Power Systems, (Akron, OH; $300K SBIR) won $4.4M to develop a large-scale, low-cost, single-shaft compressor for supercritical carbon dioxide (sCO2) power cycles; Osazda Energy (Albuquerque, NM; one SBIR) won $1M to develop a cost-effective metal paste that strengthens the metal connections in solar cells; Scion Plasma (East Lansing, MI; $200K SBIR) won $1M to develop a tool that rapidly deposits transparent conductive oxide onto heterojunction silicon with intrinsic thin layer (HIT) solar cells; Swift Coat (Peoria, AZ; one SBIR) won $1M to make and scale multilayer, anti-reflective and anti-soiling coatings for solar glass [Jane Edwards, govconwire, Nov 7, 19]
Brayton Energy (Hampton, NH; one SBIR) will receive up to $1.6 million [from DOE's SunShot Incubator program] for a project to build and test a new solar receiver that uses supercritical carbon dioxide as the heat transfer fluid [Don Seiffert, Mass High Tech, Jun 14, 12]
Breathe Technologies (San Ramon, CA; no SBIR) raised $23 million in venture funding and got Food and Drug Administration clearance for a mobile system to help people with respiratory disorders breathe. [SEF Brown and Ron Leuty, San Francisco Business Times, May 18]
Breethe (Baltimore, MD; no SBIR) reported a [$3M]funding round that included 22 investors. [Morgan Eichensehr, Baltimore Business Journal, Dec 28, 17] a product development-stage company spun out of the University of Maryland, Baltimore in 2014 to develop and commercialize the world's first wearable artificial lung [company website]
UMd. Biopark startup Breethe (Baltimore MD; no SBIR)'s artificial lung technology is intended to improve quality of life for patients living with lung disease and respiratory failure, ... looks to raise $3.6 million [Morgan Eichensehr, Baltimore Business Journal, Sep 14, 17]
Breonics (Albany, NY; $500K SBIR), a biomedical company, could become the first technology company to move into the new Vista Technology Park in Bethlehem. [Michael deMasi, The Business Review (Albany), Mar13, 13]
Breonics (Otisville, NY; $500K SBIR) received a $2.9 million NIH grant ... working on technology designed to increase the number of viable kidneys for transplantation ... founded in 1996. It designs products to improve the system for organ transplants. The firm has patents for methods it has has developed for storing organs prior to transplantation that could increase the donor pool [Business Review (Albany), Sep 1, 10]
Bren-Tronics (Commack, NY; $1M SBIR), Inventus Power (no SBIR), Navitas Systems (Woodridge, IL; $1.6M SBIR) government solutions group and Ultralife (Newark, NY; $200K SBIR) have secured spots on a potential nine-year, $1.25 billion contract for a lightweight wearable battery being developed under the Army's Tactical Power Generation Program [Christine Thropp, govconwire.ccom. May 13, 21]
BreviTest Technologies (Houston, TX; no SBIR) received a grant of just under $240,000 from the NIH to help develop the company’s “rapid robotic analyzer” into a curbside saliva test for cannabis intoxication. This test would be used by law enforcement in traffic stops, among other scenarios. [Angela Shah, xconomy.com, April 18, 16]
Brewer Science (Rolla, MO; $6M SBIR) that produces advanced materials used in electronics, has won a $10 million judgment stemming from an intellectual property theft case. Brewer Science president and founder Terry Brewer said a former employee, Hai Xuan, and his wife used company equipment designs and other trade secrets of Brewer Science to form Best Tools LLC, and then partnered with Chinese manufacturer Jiangyin Jiatu Technical Co. and others to manufacture and distribute equipment that competed directly with Brewer Science. [Brian Feldt Reporter, St. Louis Business Journal, Sep 22, 15]
Brewer Science (Rolla, MO; $5.7M SBIR over 30 years, founded 1981) founder and CEO Terry Brewer was presented the Kathryn C. Hach Award for Entrepreneurial Success on Tuesday by the American Chemical Society. Brewer was recognized for his innovation in developing microelectronic products used in many of today’s electronics. In addition, the award recognizes Brewer’s leadership in building the entrepreneurial community. [Vince Brennan, St. Louis Business Journal, Mar 25, 15]
Terry Brewer and Brewer Science (Rolla, MO; $5.7M SBIR from SBIR's first year 1983, founded 1981) received a SEMI Award for North America. Brewer was recognized for revolutionizing optical lithography with anti-reflective coatings. developed and commercialized anti-reflective coating materials that were instrumental in the industry's progress in at least three different technologies — g-line to 248 nm to 193 nm lithography, and now to extreme ultraviolet (EUV) and directed self-assembly (DSA) technology. ... SEMI is the global industry association serving the manufacturing supply chain for the micro- and nano-electronics industries. [Joe Dwyer, St. Louis Business Journal, Jan 20, 15]
Brewer Science (Rolla, MO; $6M SBIR 1983-2009) that produces advanced materials used in electronics, has completed construction on its new 25,000-square-foot manufacturing building. .... will enable the company to bring on 65 new high-tech jobs. It’s the eighth time the company has expanded in Missouri. [Brian Feldt, St. Louis Business Journal, May 7, 14]
Brewer Science, (Rolla, MO; $6M SBIR from 1983 (first year of SBIR) to 2008) that produces advanced materials used in electronics, is set to break ground today on a new 25,000-square-foot manufacturing facility in Rolla. ... could be eligible for up to $1.1 million in incentives under the Quality Jobs program, which gives companies tax breaks for creating new high-paying jobs with benefits. [St Louis Business Journal, Apr 30, 13]
Brewer Science (Rolla, MO) won an ATP grant to develop Contact Planarization for IC manufacturers to flatten the layers produced in making an integrated circuit chip. Brewer says the dominant method to achieve such planarization in use today is chemical mechanical planarization (CMP), expensive, but also wasteful of materials, energy and environmental resources. Contact Planarization will facilitate true independence from feature size and density effects. also a reduction in cost of ownership as well as environmental impact, a smaller clean room footprint, improved throughput and planarization performance. .. it will cost one half what CMP costs to process a wafer. If trends in wafer production continue, at an annual growth rate of 10%, the savings could reach nearly half a billion dollars ($470M) per year by the end of 2003 and close in on $1B shortly thereafter. The CPT has been licensed from Agere Systems. Brewer has had about $5M in SBIR Phase 2s from BMDO, AF, and NSF, although the chances of BMDO's getting any more BMDO funding for such indirect technology will have to wait for another BMDO change of attitude toward innovation.
Vical (San Diego, CA; $13M SBIR, founded 1987) stockholders late last month OK’d a reverse merger with Brickell Biotech (NASDAQ: BBI). ... was developing treatments for life-threatening infectious diseases, including antiviral and antifungal compounds, announced in June that it planned to become part of Brickell (Boulder, CO; no SBIR) developing drugs for skin diseases. [Sarah de Crescenzo, xconomy.com, Sep 10, 19]
Bridgelux (Livermore, CA; no SBIR) which raised $60 million this summer and then cut 53 jobs in the fall, raised $15 million more. ... seeks ways to make more efficient lights using LEDs. It hopes to have a product on sale in 2013. [Steven EF Brown, San Francisco Business Times, Oct 25, 11]
Also for ARPA-E Bridger Photonics (Bozeman, MT; $14M SBIR) for $2.6M was developing an aerial-deployable LiDAR system capable of simultaneous, rapid, and precise 3D topography and methane concentration measurements [in which it] leveraged its previous expertise in LiDAR mapping, originally developed for the [DOD]. [arpa-e.energy.gov report, May 7, 18]
Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M; A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.
Bright View Technologies (Durham, NC; no? SBIR, founded 2002) (SBA can boast of its snappy new website but cannot keep the gate open) which designs and manufactures components for LED and fluorescent lights, has added a half-dozen workers over the past year and is continuing to hire. ... as a [VC]-backed startup; it has been a subsidiary of Tredegar (Richmond, VA) since it was acquired in 2010. [David Ranii, Raleigh News & Observer, May 27, 15]
Bright View Technologies (Morrisville, NC; no SBIR) has raised $4 million to boost the manufacturing and marketing of its first products.The -based company, founded in 2003 using technology licensed from Duke University, began shipping its first product -- a component for LED lighting fixtures -- at the end of last year. .... 45-employee company ... has raised $34 million in financing. [David Ranii, Raleigh News & Observer, Apr 23, 09]
Bright View (Morrisville, NC; no SBIR) that has devoted five years to developing a line of components used in TV screens and computer monitors has raised $11 to launch its first products. ... co-founded in 2003 by Ed Fadel and David Reed, based on technology licensed from Duke University. ... To date the company has raised $30 million in financing. [David Ranii, Raleigh News & Observer, Jun 15, 08]
Tech start-ups victimized. The price of the Brilliant (no SBIR)'s 'smart home' controller went up $50 even before it went on sale. The three-year old company joined the race to create intelligent home devices last week. .. The White House’s latest round of threatened tariffs on imports from China — where the device is manufactured — led the company to push the price up to $299 at the last minute. ... Hardware entrepreneurs say new levies on Chinese imports of up to 25 percent could be the "death knell" for their inventions. [Richard Waters, Financial Times, Sep 12, 18] Hear the cheers of the real-estate mogul's "base" every time he asserts another imaginary fact.
Applied Technology Associates (Albuquerque, NM; $39M SBIR) announced it's joining the formation of BlueHalo, a leading provider of advanced engineering solutions and technology to the national security community. BlueHalo was formed through the combination of AEgis Technologies (Albuquerque, NM; $22M SBIR), including its previously integrated acquisitions Excivity (Birmingham, AL; no SBIR) and EMRC Heli (no SBIR) , and its recently announced acquisition of Brilligent Solutions (Fairborn, OH; one SBIR). [ATA press release, Oct 29, 20]
Australia, Canada, Germany. Korea, Japan, UK, Israel, Italy, Poland. Not a world tour: the places where Brimrose Corp of America has reps for its acousto-optic products that started with a BMDO SBIR in 1986. Add Austria, Belgium, Brazil, Denmark, Finland, Malaysia, Holland, Norway, Saudi Arabia, Sweden, and Taiwan for the spectroscopic products. With that lineup, founder Ron Rosemeier must know a lot about airplanes.
New and Improved Bleaches With the Luminar 2000 by Brimrose Corp of America bleach makers can (and at least one is) control hypochlorite concentration during manufacture. Hypochlorite carries the oxygen that does the bleaching. The 2000 derived from Acousto-Optic Tunable Filters developed for SDIO (remember?) as anti-missile discriminators in the nose of interceptors. The AOTFs though have made a nice commercial living for both fast-exploiting Brimrose and Ciencia (East Hartford, CT). For hypochlorite inspection, see the Application Note by Brimrose.
The Texas Medical Center, the largest medical complex in the world, announced the TMC Venture Fund, a $25 million initiative designed to support technologies and early-stage companies to flourish in Houston’s health care ecosystem and further the TMC’s mission to advance health, education and research. Its awardees for 2017: Alleviant Medical (Houston, TX, founded 2017) developing a novel minimally-invasive device to treat congestive heart failure; Briteseed (Chicago, IL; no SBIR, founded 2012) commercializing a new class of smart surgical tools that have artificial-vision assistance; CNSDose (Australia, founded 2015, raised $1M) uses advanced genetic technology to fast-track finding the right antidepressant and dose; Noninvasix (Galveston, TX; no SBIR, founded 2007) developing a patient monitor to directly, accurately and noninvasively measure brain oxygenation in premature babies in the neonatal intensive care unit. [TMC press release, Nov 8, 17]
Fast Track Surgery Funded
by grant money
from
DARPA's telemedicine program, closed a first-round private placement in
July 97 from private investors and Seaflower Associates. Total capital
raised $1.1M. Prerevenue. Says The Red Herring about Brock
Rogers Surgical (Waltham, MA). The DARPA money was a Fast
Track
SBIR for a two-armed robot for surgery with lots of fancy software.
Wonderful story for seven-employee firm? Did the government just
substitute for market financing and do nothing more than lower the cost
of capital (not a legitimate government function)? Don't expect any
SBIR advocate or beneficiary to admit it even if it's true. They think
any government money is good. One competitor is MicroDexterity
Systems which got NASA and NIH funding. A third competitor Intuitive
Surgical Systems had to go to bed without a government bone.
Data security startup Bromium (Cupertino, CA; no SBIR) said it has raised $40 million in Series C funding to spread use of its "micro virtual machine technology." ... has now raised more than $75 million since it was founded in 2010 .... focuses on securing laptops and desktop computers when they access the Internet, isolating Web pages, attachments and files that might contain malware in its micro virtual machines. A single computer can run hundreds of these virtual machines without the user noticing any difference in performance, Banga said. [Cromwell Schubarth, Silicon Valley Business Journal, Oct 23, 13]
Brooks Automation (Chelmsford, MA; no SBIR) has closed on a purchase of Nexus Biosystems (Poway, CA; no SBIR) in a cash deal worth $79 million. ... Nexus makes automated compound and sample management solutions for life sciences companies [Rodney Brown, Mass High Tech, Jul 26, 11]
DHS gave Bruker Daltonics (no DHS SBIRs), a subsidiary of Bruker BioSciences ($436M in 2006 revenue) a $1.3 M a Phase 3, three-year research contract for its chemical detection technology. [Mass High Tech, Sep 14]
Buffalo BioLabs (Buffalo, NY; $300K SBIR) is targeting investors to raise $500,000, which it would use to research animal testing models and hire a salesperson. .... 28-person preclinical drug testing company since it broke off from Cleveland BioLabs LLC in October 2013 ... performs early-stage and advanced preclinical research studies for clients in a way that's more timely and cost-effective than what might be possible at their own facilities. [David Bertola, Buffalo Business First, Dec 16, 15]
medical device start-up Burl Concepts (San Diego, CA;no SBIR), which has developed a portable ultrasound device to detect strokes in the field, said that it has raised $3 million in a second round of funding. The new capital brings the total amount raised by the company to $7.5 million. [San Diego Union Tribune, Oct 4, 16]
Applied Biomolecular Technologies (Athens, OH; no SBIR, founded 2006) is owned by three former Battelle biotech researchers and an entrepreneur pursuing a private path to getting research out of academic laboratories and into the marketplace. ... One of their newest subsidiaries, Lattice Biotech LLC (no SBIR), is trying to raise $5 million to advance technology it licensed from Nationwide Children’s Hospital to make antibodies that weaken protective films around infectious bacterial colonies. But that’s just one of a half-dozen biotech ventures it’s developing ... [also own] Burr Oak Therapeutics LLC (no SBIR), whose product is under wraps for now. In February 2014 it acquired and expanded an Athens company it renamed Binding Protein Technologies LLC (formerly Athens Research ($1M SBIR). ... Last month Applied Bio Ventures invested in but did not acquire a fellow commercialization engine, Brainstage (Carnegie, PA; no SBIR), which itself has six biotech companies in its portfolio. [Carrie Ghose, Columbus Business First, Apr 1, 15]